Enzymatic assembly of carbon–carbon bonds via iron-catalysed sp^3 C–H functionalization by Zhang, Ruijie K. et al.
Letter
https://doi.org/10.1038/s41586-018-0808-5
Enzymatic assembly of carbon–carbon bonds via 
iron-catalysed sp3 C–H functionalization
ruijie K. Zhang1, Kai Chen1, Xiongyi Huang1, Lena Wohlschlager1,2, Hans renata1,3 & Frances H. Arnold1*
1Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, USA. 2Present address: Institute of Food Technology, University of Natural Resources and Life 
Sciences, Vienna, Austria. 3Present address: Department of Chemistry, The Scripps Research Institute, Jupiter, FL, USA. *e-mail: frances@cheme.caltech.edu
N A T U R E | www.nature.com/nature
SUPPLEMENTARY INFORMATION
https://doi.org/10.1038/s41586-018-0808-5
In the format provided by the authors and unedited.
© 2019 Springer Nature Limited. All rights reserved.
 
 
 
 
1 
Supplementary Information 
  
Enzymatic assembly of carbon–carbon bonds via  
iron-catalysed sp3 C–H functionalization 
 
Ruijie K. Zhang1, Kai Chen1, Xiongyi Huang1, Lena Wohlschlager1,2, Hans Renata1,3, and 
Frances H. Arnold1* 
 
1Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, 
CA, USA. 
2Present address: Institute of Food Technology, University of Natural Resources and Life 
Sciences, Vienna, Austria. 
3Present address: Department of Chemistry, The Scripps Research Institute, Jupiter, FL, USA. 
*e-mail: frances@cheme.caltech.edu 
 
 
This PDF file includes: 
I. General methods 2–6 
II. Supplementary Figs. 1–11 and Supplementary Tables 1–5 7–20 
III. Screening of enzymes for C–H alkylation activity 21–24 
IV. Directed evolution of C–H alkylation enzymes 25–30 
V.  Nucleotide and amino acid sequences 31–35 
VI. Substrate synthesis and characterization 36–43 
VII. Synthesis and characterization of reference compounds 44–53 
VIII. Small scale enzymatic reactions and product calibration curves 54–65 
IX. Enzymatic C–H alkylation reactions on preparative scale 66–76 
X. Syntheses of (+)-lyngbic acid and (+)-cuspareine 77–81 
XI. Determination of enantioselectivity 82–106 
XII. NMR Spectra 107–156 
XIII. Supplemental References 157–160 
 
 
 
 
 
2 
I. General methods 
(A) General. Unless otherwise noted, all chemicals and reagents were obtained from 
commercial suppliers (Sigma-Aldrich, VWR, Alfa Aesar, Combi-Blocks) and used without further 
purification. Silica gel chromatography was carried out using AMD Silica Gel 60, 230-400 mesh. 
1H and 13C NMR spectra were recorded on a Varian Inova 300 MHz, Varian Inova 500 MHz, or 
Bruker Prodigy 400 MHz instrument in CDCl3 and are referenced to residual protio solvent signals. 
Data for 1H NMR are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sext = sextet, m = multiplet, dd = doublet of doublets, 
dt = doublet of triplets, ddd = doublet of doublet of doublets), coupling constant (Hz), integration. 
Sonication was performed using a Qsonica Q500 sonicator. High-resolution mass spectra were 
obtained at the California Institute of Technology Mass Spectral Facility. Synthetic reactions were 
monitored by thin layer chromatography (TLC, Merck 60 gel plates) using a UV-lamp or an 
appropriate TLC stain for visualization.  
E. coli cells were grown using Luria-Bertani medium (LB) or Hyperbroth (AthenaES) (HB) 
with 0.1 mg/mL ampicillin (LBamp or HBamp). Primer sequences are available upon request. T5 
exonuclease, Phusion polymerase, and Taq ligase were purchased from New England Biolabs 
(NEB, Ipswich, MA). M9-N minimal medium (abbreviated as M9-N buffer; pH 7.4) was used as 
a buffering system for whole cells and lysates, unless otherwise specified. M9-N buffer was used 
without a nitrogen source; it contains 47.7 mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM NaCl, 2.0 
mM MgSO4, and 0.1 mM CaCl2.  
(B) Chromatography. Analytical reversed-phase high-performance liquid 
chromatography (HPLC) was carried out using an Agilent 1200 series instrument and a Kromasil 
100 C18 column (4.6 × 50 mm, 5 µm) or an Eclipse XDB C18 column (4.6 x 150 mm, 3 µm) with 
water and acetonitrile as the mobile phase. Analytical chiral HPLC was conducted using either an 
Agilent 1200 series instrument with n-hexane and isopropanol as the mobile phase or JACSO 2000 
series supercritical fluid chromatography (SFC) system with supercritical CO2 and isopropanol as 
the mobile phase. Enantiomers were separated using one of the following chiral columns: 
Chiralpak AD-H, Chiralpak IC (4.6 mm × 25 cm), Chiralcel OB-H (4.6 mm × 25 cm), Chiralcel 
OD-H (4.6 mm × 25 cm), Chiralcel OJ-H (4.6 mm × 25 cm).  Gas chromatography (GC) analysis 
was carried out using an Agilent 7820A or Shimadzu GC-17A GC system, both equipped with an 
FID detector and with a J&W HP-5 column (30 m × 0.32 mm, 0.25 µm film). Chiral GC was 
conducted using either an Agilent 7820A instrument (FID) and an Agilent CycloSil-B column (30 
m × 0.32 mm, 0.25 µm film) or an Agilent 6850 GC (FID) with a Chiraldex G-TA column (30 m 
× 0.25 mm, 0.12 µm film). Gas chromatography-mass spectrometry (GC-MS) analyses were 
carried out using a Shimadzu GCMS-QP2010SE system and J&W HP-5ms column (30 m × 0.25 
mm, 0.25 µm film). 
 (C) Cloning and site-saturation mutagenesis. pET22b(+) was used as a cloning and 
expression vector for all enzymes described in this study. All enzymes described in this study were 
expressed with a C-terminal 6xHis-tag. Site-saturation mutagenesis was performed using the “22c-
trick” method1. The PCR products were digested with DpnI, gel purified, and ligated using Gibson 
MixTM (ref. 2). The ligation mixture was used to directly transform electrocompetent E. coli strain 
E. cloni BL21(DE3) cells (Lucigen).  
(D) Expression of P450 and P411 variants in 96-well plates.  Single colonies from LBamp 
agar plates were picked using sterile toothpicks and cultured in deep-well 96-well plates containing 
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LBamp (300 µL/well) at 37 ºC, 220 rpm shaking, and 80% relative humidity overnight. After, HBamp 
(1000 µL/well) in a deep-well 96-well plate was inoculated with an aliquot (50 µL/ well) of these 
overnight cultures and allowed to shake for 3 hours at 37 ºC, 220 rpm, and 80% relative humidity. 
The plates were cooled on ice for 30 minutes and the cultures were induced with 0.5 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) and 1.0 mM 5-aminolevulinic acid (final concentrations). 
Expression was conducted at 20 ºC, 150 rpm for 16–20 hours.  
(E) Reaction screening in 96-well plate format. E. coli (E. cloni BL21(DE3)) cells in 
deep-well 96-well plates were pelleted (3,000 × g, 5 min, RT) and resuspended in M9-N buffer 
(20 µL/well) by gentle vortexing. A GOX oxygen depletion system was added (20 µL/well of a 
stock solution containing 14,000 U/mL catalase and 1,000 U/mL glucose oxidase in 0.1 M 
potassium phosphate buffer, pH 8.0) and the 96-well plate was transferred into an anaerobic 
chamber. In the anaerobic chamber, argon-sparged reaction buffer (50 mM glucose in M9-N or 33 
mM glucose in M9-N, 300 µL/well) was added, followed by alkane substrate (10 µL/well, 400 
mM in EtOH) and ethyl diazoacetate (10 µL/well, 400 mM in EtOH). In some cases, the substrates 
and reaction buffer were mixed together prior to addition to the plate.  The plate was sealed with 
an aluminum foil and shaken at room temperature and 500 rpm in the anaerobic chamber. After 
5–20 hours, the seal was removed and the reactions were worked up following the appropriate 
method below. 
Product formation screening using GC and GC-MS. After 5–20 hours, a solution of 0.4 
mM 1,3,5-trimethoxybenzene (internal standard) in a mixed solvent system (cyclohexane/ ethyl 
acetate = 1:1, 510 µL) was added. The plate was tightly sealed with a reusable silicone mat, 
vortexed (15 s × 3) and centrifuged (3,000 × g, 5 min) to completely separate the organic and 
aqueous layers. The organic layers (180 µL/well) were transferred to 300 µL vial inserts, which 
were then placed in 2 mL vials and analyzed by GC. 
Product formation screening using HPLC. After 5–20 hours, the reaction mixtures, or an 
aliquot thereof (150 µL/well), were quenched by the addition of an equal or greater volume of 
acetonitrile (400 µL/well or 150–200 µL/well). This step is kept consistent within each round of 
directed evolution. The plate containing the resulting mixture was tightly sealed with a reusable 
silicone mat, vortexed (15 s × 3) and centrifuged (3,000 × g, 5 min) to pellet the cells. The 
supernatant was filtered through an AcroPrep 96-well filter plate (0.2 µm) into a shallow-well plate 
and analyzed by reverse-phase HPLC.  
Enantioselectivity screening. After 5–24 hours, mixed solvent (cyclohexane/ ethyl acetate 
= 1:1, 250–500 µL/ well) was added to the reaction mixtures or aliquots thereof (250 µL). The 
plate containing the resulting mixture was tightly sealed with a reusable silicone mat, vortexed (15 
s × 3) and centrifuged (3,000 × g, 5 min) to completely separate the organic and aqueous layers. 
When smaller volumes of mixed solvent were used for the extraction (< 400 µL), the extraction 
mixture was transferred to a 1.6 mL Eppendorf tube, vortexed (15 s × 3), and centrifuged (20,000 
× g, 1 min). The organic layers (180 µL/well) were transferred to 300 µL vial inserts, which were 
then placed in 2 mL vials and analyzed by chiral HPLC (IC column, 2% i-PrOH in n-hexane).  
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(F) Expression of P411 variants. E. coli (E. cloni BL21(DE3)) cells carrying plasmid 
encoding the appropriate P411 variant were grown overnight in 5 mL LBamp. Preculture (2 mL) 
was used to inoculate 48 mL of HBamp in a 125 mL Erlenmeyer flask; this culture was incubated 
at 37 ºC, 230 rpm for 2.5 hours. The culture was then cooled on ice (20–30 min) and induced with 
0.5 mM IPTG and 1.0 mM 5-aminolevulinic acid (final concentrations). Expression was conducted 
at 20 ºC, 130 rpm, for 16–18 hours. Following, E. coli cells were pelleted by centrifugation (2,600 
× g, 10 min, 4 ºC or 3,000 × g, 5 min, 4 ºC). Media was removed and the resulting cell pellet was 
resuspended in M9-N buffer to OD600 = 60. An aliquot of this cell suspension (3 mL) was taken to 
determine P411 concentration using the hemochrome assay after lysis by sonication. When 
applicable, remaining cell suspension was further diluted with M9-N buffer to the OD600 used for 
the biotransformation (described in (H)) and the concentration of P411 protein in the 
biotransformation was calculated accordingly. 
(G) Hemochrome assay for the determination of heme protein concentration. E. coli 
cells expressing heme protein and resuspended in M9-N buffer were lysed by sonication using a 
Qsonica Q500 sonicator equipped with a microtip (2 mins, 1 second on, 1 second off, 25% 
amplitude); samples were kept on wet ice for this process. The resulting lysed solution was 
centrifuged (20,000 × g, 10 min, 4 °C) to remove cell debris. The supernatant (clarified lysate) was 
separated from the pellet and kept on ice until use. In a falcon tube, a solution of 0.2 M NaOH, 
40% (v/v) pyridine, 0.5 mM K3Fe(CN)6 was prepared (pyridine-NaOH-K3Fe(CN)6 solution). 
Separately, a solution of 0.5 M Na2S2O4 (sodium dithionite) was prepared in 0.1 M NaOH. To an 
Eppendorf tube containing 500 µL of clarified lysate in M9-N buffer was added 500 µL of the 
pyridine-NaOH-K3Fe(CN)6 solution, mixed, and transferred to a cuvette; the UV-Vis spectrum of 
the oxidized FeIII state was recorded immediately. To the cuvette was then added 10 µL of the 
sodium dithionite solution. The cuvette was sealed with parafilm and the UV-Vis spectrum of the 
reduced FeII state was recorded immediately. A cuvette containing 500 µL of M9-N, 100 µL 1 M 
NaOH, 200 µL pyridine, and 200 µL water (complete mixture without protein and K3Fe(CN)6) 
was used as a reference for all absorbance measurements. Concentrations of cytochromes P450, 
cytochromes P411, and globins were determined using a published extinction coefficient for heme 
b, ε556(reduced)-540(oxidized) = 23.98 mM-1cm-1 (ref. 3).  Cytochrome c concentration was measured 
using a modified procedure, reported previously4.  
(H) Biotransformations using whole E. coli cells. Suspensions of E. coli (E. cloni 
BL21(DE3)) cells expressing the appropriate heme protein variant in M9-N buffer (typically OD600 
= 30) were degassed by bubbling with argon in sealed vials for at least 40 minutes; the cells were 
kept on ice during this time. Separately, a solution of D-glucose (250 mM in M9-N) was degassed 
by sparging with argon for at least 30 minutes. All solutions were then transferred into an anaerobic 
chamber for reaction set up. To a 2 mL vial were added a GOX oxygen depletion solution (20 µL 
of stock solution containing 14,000 U/mL catalase and 1,000 U/mL glucose oxidase in 0.1 M 
potassium phosphate buffer, pH 8.0), D-glucose (40 µL of 250 mM stock solution in M9-N buffer), 
degassed suspension of E. coli expressing P411 (typically OD600 = 30, 320 µL), alkane substrate 
(10 µL of 400 mM stock solution in EtOH), and diazo compound (10 µL of 400 mM stock solution 
in EtOH) in the listed order. Final reaction volume was 400 µL; final concentrations were 10 mM 
alkane substrate, 10 mM diazo compound, and 25 mM D-glucose. Note: reaction performed with 
E. coli cells resuspended to OD600 = 30 indicates that 320 µL of OD600 = 30 cells were added, and 
likewise for other reaction OD600 descriptions. The vials were sealed, removed from the anaerobic 
chamber, and shaken at room temperature and 500 rpm for 18 hours. A modified procedure was 
used for reactions conducted at 4 °C. Reactions were set up in the same manner, except kept on 
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ice. Reactions were shaken in a cold room (4 °C) and 500 rpm for 18 hours. The reactions were 
worked up and analyzed by HPLC or GC as appropriate; the reaction workup procedures are 
outlined in detail in Section VIII. Preparative scale enzymatic reactions were performed using a 
different procedure which is described in detail in Section IX. The expression of heme protein was 
measured using the hemochrome assay (Section I (G)), and the concentration of heme protein in 
the biotransformation was calculated accordingly. 
  (I) Enzymatic reactions using clarified E. coli lysate. Lysates for biocatalytic reactions 
were prepared as follows: E. coli (E. cloni BL21(DE3)) cells expressing the appropriate heme 
protein variant were resuspended in M9-N buffer and adjusted to OD600 = 60. The cell suspension, 
in 3 mL portions, was lysed by sonication using a Qsonica Q500 sonicator equipped with a 
microtip (2 mins, 1 second on, 1 second off, 25% amplitude); samples were kept on wet ice for 
this process. The resulting lysed solution was centrifuged (20,000 × g, 10 min, 4 °C) to remove 
cell debris. Protein concentration of the supernatant (clarified lysate) was determined using the 
hemochrome assay (see Section I (G)); the protein concentration in lysate was adjusted to the 
desired amount by addition of M9-N buffer. Lysate was placed in a sealed vial and the headspace 
of the vial was purged with a stream of argon for at least 40 minutes. The lysate was kept on ice 
during all parts of this procedure. Separately, D-glucose solution (500 mM in M9-N buffer) and 
Na2S2O4 (20 mM in M9-N) were degassed by bubbling the solutions with argon for at least 40 
minutes. All solutions were then transferred into an anaerobic chamber for reaction set up. To a 2 
mL vial were added a GOX oxygen depletion solution (20 µL of stock solution containing 14,000 
U/mL catalase and 1,000 U/mL glucose oxidase in 0.1 M potassium phosphate buffer, pH 8.0), D-
glucose (20 µL of 500 mM stock solution in M9-N buffer), lysate (320 µL), Na2S2O4 (20 µL of 20 
mM solution in M9-N), alkane substrate (10 µL of 400 mM stock solution in EtOH), and ethyl 
diazoacetate (10 µL of 400 mM stock solution in EtOH) in the listed order. Final reaction volume 
was 400 µL; final concentrations were typically 2.0 µM heme protein, 1 mM Na2S2O4, 10 mM 
alkane substrate, 10 mM ethyl diazoacetate, and 25 mM D-glucose. The vials were sealed, removed 
from the anaerobic chamber, and shaken at room temperature and 500 rpm for 18 hours. Reactions 
were analyzed following the same methods as described for biotransformations using whole E. 
coli cells (see Section VIII).  
(J) Protein purification. E. coli (E. cloni BL21(DE3)) cells carrying plasmid encoding a 
P411 variant were grown overnight in 19 mL LBamp (37 ºC, 250 rpm). HBamp (450 mL) in a 1 liter 
flask was inoculated with 19 mL of the preculture and shaken for 2.5 hours at 37 °C and 220 rpm. 
Cultures were cooled on ice (30 min) and induced with 0.5 mM IPTG and 1.0 mM 5-
aminolevulinic acid (final concentrations). Expression was conducted at 22 °C, 130 rpm, for 16–
20 hours. Cultures were then centrifuged (5,000 × g, 10 min, 4 ºC) and the cell pellets frozen at     
-20 ºC. For purification, frozen cells from two such cultures were resuspended in His-trap buffer 
A (25 mM tris, 100 mM NaCl, 20 mM imidazole, pH 7.5, 4 mL/g of cell wet weight), loaded with 
hemin (1 mg/g wet cell weight) and powdered DNaseI, and lysed by sonication. To pellet cell 
debris, lysates were centrifuged (20,000 × g, 20 min, 4 °C). The protein containing a C-terminal 
6xHis-tag was purified with a nickel NTA column (1 mL HisTrap HP, GE Healthcare, Piscataway, 
NJ) using an AKTA purified FPLC system (GE healthcare). Proteins were eluted on a linear 
gradient from His-trap buffer A to His-trap buffer B (25 mM tris, 300 mM imidazole, 100 mM 
NaCl, pH 7.5) over 10 column volumes. Fractions containing the desired heme protein were 
combined, concentrated, and subjected to three exchanges of phosphate buffer (0.1 M potassium 
phosphate, pH 8.0) using centrifugal filters (10 kDa molecular weight cut-off, Amicon Ultra, 
Merck Millipore) to remove excess salt and imidazole. Concentrated proteins were aliquoted, 
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flash-frozen on powdered dry ice, and stored at -80 ºC.  
(K) Enzymatic reactions using purified heme protein. A solution of NADPH or Na2S2O4 
in phosphate buffer (0.1 M potassium phosphate, pH 8.0) was degassed by sparging with argon for 
at least 30 minutes (reaction solution). Separately, a solution of D-glucose (250 mM in 0.1 M 
potassium phosphate, pH 8.0) was also degassed in the same manner. Crimp vials (2 mL) were 
each charged with the GOX oxygen depletion system (20 µL of a stock solution containing 14,000 
U/mL catalase and 1,000 U/mL glucose oxidase in 0.1 M potassium phosphate, pH 8.0). After 
degassing was complete, all solutions, 2 mL crimp vials, and purified protein (in 0.1 M potassium 
phosphate, pH 8.0), kept on ice, were brought into the anaerobic chamber. D-Glucose (40 µL of 
250 mM solution), reaction buffer containing reductant (300 µL, reductant is either NADPH or 
Na2S2O4), and purified protein (20 µL) were added to the 2 mL vial.  The mixture was shaken for 
5 min to ensure even distribution of the proteins; then, reaction vials were charged with alkane 
substrate (10 µL of 400 mM stock solution in EtOH) and ethyl diazoacetate (10 µL of 400 mM 
stock solution in EtOH). Final reaction volume was 400 µL. Final concentrations were 10 mM 
alkane substrate, 10 mM ethyl diazoacetate, and 25 mM D-glucose; concentrations of protein and 
reductant are variable and described with the individual experiment. The vials were sealed, 
removed from the anaerobic chamber, and shaken at room temperature and 500 rpm for 18 hours. 
The reactions were quenched by the addition of acetonitrile (400 µL) and internal standard (10 µL). 
This mixture was then transferred to a microcentrifuge tube and centrifuged (20,000 × g, 10 min). 
The supernatant was transferred to a vial and analyzed by HPLC. 
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II. Supplementary Figs. 1–11 and Supplementary Tables 1–5  
 
 
 
Supplementary Fig. 1. Evolutionary lineage from P-4 (A82L) to P411-CHF evaluated for C–H 
alkylation of 4-ethylanisole (1i). 
Notes: Standard reaction conditions: clarified lysate of E. coli expressing the indicated heme 
protein variant (see Section IV), 10 mM substrate 1i, 10 mM ethyl diazoacetate (2), 1 mM 
Na2S2O4. Reactions with generations 1, 2, and 3 variants employed 4.0 µM heme protein; all other 
reactions used 2.0 µM heme protein. Bars represent mean TTN values averaged over four reactions 
(performed from two independent cell cultures, each used for duplicate reactions); each TTN data 
point is shown as a grey dot. Enantioselectivity results are represented by green diamonds. See 
Supplementary Table 13 in Section IV for the data presented here. TTN, total turnover number; 
RT, room temperature. 
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P411-gen6 variant TTN to 3a 
Full-length (P411-gen6) 59 
∆FAD (P411-gen6b) 98 
Heme domain only 73 (100†) 
Supplementary Fig. 2. Truncation of a full-length P411 protein delivers active C–H alkylation 
enzymes. 
Notes: a, Domain architecture of cytochrome P450BM3. For its native monooxygenase activity, the 
FMN and FAD domains, collectively called the reductase domain, are responsible for delivering 
the necessary reducing equivalents from NADPH to the heme domain.  The end of the FMN 
domain and the fragment of the polypeptide chain included in the ∆FAD complex were chosen 
based on a report by S. Govindaraj and T. L. Poulos5. b, Systematic truncation of the P411-gen6 
full-length protein was performed to deliver P411-gen6b (P411∆FAD-gen6, amino acids 1–664) 
and P411-gen6 heme-domain only (amino acids 1–463). Under the stated reaction conditions, both 
P411-gen6b (∆FAD) and the heme domain only protein delivered 3a with higher total turnover 
compared with the full-length protein. Standard reaction conditions: lysate of E. coli with 2.0 µM 
heme protein, 10 mM 1a, 10 mM 2, and 1 mM Na2S2O4 (unless otherwise indicated). TTN results 
are an average of at least duplicate reactions. RT, room temperature; TTN, total turnover number. 
See Section IV for more information on P411-gen6 and P411-gen6b. †5 mM dithionite was used 
in these reactions. 
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Supplementary Fig. 3. Structural visualization of amino acids mutated during directed evolution 
of P-4 (A82L) to P411-CHF. 
Notes: The structure of P-4 (A82L) (heme domain) was modeled using the crystal structure of a 
related P411 variant (PDB 5UCW), which contains two additional mutations. Considering only 
the changes incurred in the heme domain, the following mutations were accumulated in going from 
P-4 (A82L) to P411-CHF: N70E, A74P, A78L, M177L, F263Y, H266V, A330Y, T436L, S438T 
(shown as blue spheres, residues 327 and 437 were not included in this analysis because P-4 
(A82L) and P411-CHF contain the same amino acid residues at those positions). Most of the 
mutations are at positions that line the distal heme pocket and all of the mutated residues are within 
15 Å of the iron atom in the heme cofactor.  
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Supplementary Fig. 4. Structural visualization of amino acid differences between P450BM3 wild-
type and P411-CHF. 
Notes: The structure of P450BM3 wild-type (heme domain) was modeled using the crystal structure 
of H. M. Girvan et al. (PDB 2IJ2).  Comparing only the heme domains of the two proteins, the 
following 23 amino acids are changed in P411-CHF relative to P450BM3 wild-type: N70E, A74P, 
V78L, A82L, F87A, P142S, T175I, M177L, A184V, S226R, H236Q, E252G, I263Y, H266V, 
T268G, A290V, A328V, A330Y, L353V, I366V, C400S, T436L, E442K (shown as green 
spheres). Overall, 5% of the amino acids in the heme domain of P450BM3 have been substituted in 
P411-CHF.   
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Supplementary Fig. 5. Kinetic isotope effect of C–H alkylation catalyzed by P411-CHF. 
Notes: Data points represent an average of duplicate measurements; error bars represent one 
standard deviation. Data collected at the 10-minute time point using substrate 1a-d2 were excluded 
due to non-linear behavior. Detailed experimental methods are described below. 
Independent rate experiments with P411-CHF show an intermolecular kinetic isotope 
effect (KIE, kH/kD) of 5.1. This suggests that C–H insertion is rate-determining and could possibly 
involve a linear transition state6. In contrast, kinetic isotope effects for rhodium catalysts with 
carboxylate ligands are significantly less (KIE = 1.55–3.2)7,8; this has been invoked as evidence to 
support a widely accepted three-centered transition state for C–H insertion with these systems9. 
The difference in KIE between P411-CHF and the rhodium-carboxylate catalysts suggests that 
these systems may have different transitions states or different mechanisms for the C–H insertion 
step. Since the nature of the C–H insertion step could influence the substrate and product profiles 
of the catalyst, this is one strong motivation to develop diverse systems for this chemistry.  
Determination of initial rates. Initial rates were measured from independent reactions set 
up in parallel using clarified lysate of E. coli cells overexpressing P411-CHF. The concentration 
of P411-CHF was normalized to be 2.0 µM in each reaction. A modified version of the procedure 
for reactions with lysate (Section I (I)) was followed. The modification is as follows: after 
combining all components of the reaction mixture except the alkane and diazo substrates, the 2 
mL reaction vial was allowed to shake in the anaerobic chamber at 500 rpm for at least 10 minutes 
to ensure even mixing. Reaction vials were then charged with alkane substrate (10 µL, 400 mM in 
EtOH) and ethyl diazoacetate (10 µL, 400 mM in EtOH) and shaken at 500 rpm, room temp. Final 
concentrations were 2.0 µM P411-CHF, 1 mM Na2S2O4, 10 mM alkane substrate, 10 mM ethyl 
diazoacetate, and 25 mM D-glucose. Reactions were set up in duplicate and quenched at the 
indicated time points by addition of acetonitrile (400 µL) and internal standard (10 µL, 60 mM 
ethyl phenoxyacetate in MeCN). This mixture was then removed from the anaerobic chamber, 
kH/kD = 5.1
P411-CHF
or
OMe
H H
MeO
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D D
MeO
OMe
D/H
MeO
CO2Et
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transferred to a microcentrifuge tube, and centrifuged (20,000 × g, 10 minutes). The supernatant 
was transferred to a vial and analyzed by HPLC (see Section VIII). Turnover number was 
calculated by dividing the concentration of product (mM) by concentration of P411-CHF (0.002 
mM). 
 
 
Supplementary Fig. 6. Product profiles for the reaction of 4-allylanisole (1m) and ethyl 
diazoacetate (2) with P411-CHF and with P-I263F. 
Notes: Representative GC traces of reactions performed with P411-CHF (top), P-I263F (middle), 
or a vector control (bottom) in E. coli cells. Reactions were performed with 10 mM substrate 1m 
and 10 mM 2, following the general procedure detailed in Section I (H).  Vector control indicates 
that E. coli harboring pET22b(+) encoding a protein that does not contain a transition metal 
cofactor (halohydrin dehalogenase, UniProt ID: Q93D82) was employed in the reaction.  
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Supplementary Fig. 7. P411-CHF catalyzes C–H alkylation of 1h with ethyl diazoacetate (2). 
Notes: Representative GC traces of reactions performed with P411-CHF (top), P-I263F (middle), 
or a vector control (bottom) in E. coli cells. Reactions were performed as in Supplementary Fig. 
6, with substrates 1h and 2.  
While P411-CHF was able to access C–H alkylation product 3h (930 TTN to 3h, 1:1 
3h:3h’) in the presence of a reactive Si–H bond, reaction with E. coli harboring P-I263F only 
afforded Si–H insertion product 3h’. Additionally, compound 3h’ was also observed in vector 
control reactions employing whole E. coli cells. Neither 3h nor 3h’ were detected in a control 
reaction where 1h and 2 were combined in M9-N buffer in the absence of cells. See Section VIII 
for detailed analysis of product concentrations.  
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Supplementary Fig. 8. Enzymatic reaction of P411-CHF with substrate 4e and ethyl diazoacetate 
(2) produces cyclopropene 5e’ as a side product.  
Notes: Representative GC trace of a reaction performed using P411-CHF in E. coli cells (top) with 
10 mM substrate 4e and 10 mM ethyl diazoacetate (2), following the general procedure detailed 
in Section I (H). Also shown are GC traces for reference compounds 5e (middle) and 5e’ (bottom), 
used for the identification of P411-CHF synthesized products.  
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Supplementary Fig. 9. Enzymatic C–H alkylation of 4,N,N-trimethylaniline (7a) with P411-CHF 
is selective for the α-amino position. 
Notes: Representative GC-MS trace of a reaction performed using P411-CHF in E. coli cells (top) 
with 10 mM substrate 7a and 10 mM ethyl diazoacetate (2), following the general procedure 
detailed in Section I (H). Also shown is a trace for reference compound 8a’ (bottom), which is not 
observed in the reaction with P411-CHF.  This demonstrates that P411-CHF has exquisite 
selectivity for the alkylation of α-amino C–H bond in the presence of primary benzylic C–H bonds. 
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Supplementary Fig. 10. Product profile of P411-CHF catalyzed C–H alkylation of 4-ethyl-N,N-
dimethylaniline (7b) with ethyl diazoacetate (2).  
Notes: Representative HPLC trace of a reaction performed using P411-CHF in E. coli cells (top) 
with 10 mM substrate 7b and 10 mM ethyl diazoacetate (2), following the general procedure 
detailed in Section I (H). Also shown is a trace for reference compound 8b’ (bottom), which was 
identified as a minor side product in the P411-CHF catalyzed reaction. Major product 8b was 
assigned by performing a preparative scale enzymatic reaction (see Section IX) and isolation and 
characterization of the major product.  
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Supplementary Fig. 11. Additional diazo substrates tested for C–H alkylation with P411-CHF 
and P411-gen5. ‘+’ indicates product was detected; N. D., not detected. #Other products derived 
from compound 7a were also observed by GC-MS. 
Notes: Reactions were performed using E coli cells expressing P411-CHF (resuspended to OD600 
= 59) or P411-gen5 (resuspended to OD600 = 49) with 10 mM coupling partner 7a and 10 mM 
diazo compound. Product formation was analyzed by GC-MS only. The identity of the product 
was not confirmed by comparison with chemically synthesized reference compounds or through 
isolation and characterization. These preliminary results are noteworthy, but should not be used 
alone for drawing conclusions.  
Diazo compounds 9a, 9b, and 9c, for the formation of products 10a, 10b, and 10c, were 
also investigated with P411-CHF (+, +, +, respective preliminary results) and P411-gen5 (+, N. 
D., +). Additional variants were tested for these transformations and subsequent preparative scale 
reactions for product isolation and characterization were pursued; these results are described in 
Fig. 4c.   
Because P411-CHF and its related variants are fully genetically encoded and can be readily 
optimized by directed evolution, these enzymes can serve as starting points for the evolution of 
future variants.  Some of these future variants will certainly surpass P411-CHF in C–H alkylation 
activity with alternative diazo reagents. 
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Supplementary Table 1. Initial results for C–H alkylation of p-methoxybenzyl methyl ether 
(1a) with ethyl diazoacetate (2) catalyzed by heme proteins and control reactions.  
 
 
Catalyst Catalyst concentration TTN to 3a 
P-4 (A82L) (in E. coli cells, OD600 = 29) 4.0 µM 13 
R. marinus NOD (Y32G) (in E. coli cells, 
OD600 = 30) 
11.6 µM 7 (12†) 
Vector control (in E. coli cells, OD600 = 40)*, ξ N. A.  n. d. 
Hemin 400 µM n. d.†, # 
Hemin + BSA 400 µM (hemin),  
0.6 mg/mL (BSA) 
n. d.†, #  
Notes: Reactions performed with 10 mM 1a and 10 mM 2; results are the average of duplicate reactions. 
BSA, bovine serum albumin; TTN, total turnover number; n. d., not detected. OD600 value refers to that of 
the resuspension used for the reaction. †These reactions contain 1 mM Na2S2O4, used as reductant. *Vector 
control indicates that E. coli harboring pET22b(+) encoding a protein which does not have a transition 
metal cofactor (halohydrin dehalogenase, UniProt ID: Q93D82) was employed in the reaction. ξReaction 
time was 24 h. #For reactions with hemin ± BSA, a 0.5 mM solution of hemin (± BSA, 0.75 mg/mL) in M9-
N (320 µL) was used instead of a cell suspension; no D-glucose was added to these reactions. 
 
Supplementary Table 2. Initial results for C–H alkylation of 4-ethylanisole (1i) with ethyl 
diazoacetate (2) catalyzed by heme proteins and control reactions.  
 
 
Catalyst Catalyst concentration TTN to 3i 
P-4 (A82L) (in E. coli cells, OD600 = 21) 4.0 µM 3 
R. marinus NOD (Y32G) (in E. coli cells, 
OD600 = 30) 
11.6 µM < 1 (2†) 
Vector control (in E. coli cells, OD600 = 40)*,
 ξ N. A.  n. d.
  
Hemin 400 µM n. d.†, # 
Hemin + BSA 400 µM (hemin),  
0.6 mg/mL (BSA) 
n. d.†, #  
Notes: Reactions performed with 10 mM 1i and 10 mM 2; results are the average of duplicate reactions. 
Other notes are the same as in Supplementary Table 1.  
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Supplementary Table 3. P411-gen9, an evolved P411∆FAD C–H alkylation enzyme, is active 
in whole E. coli cells, in clarified E. coli lysate, and as a purified protein.  
 
 
Form [P411], µM Exogenous reductant TTN to 3a 
 whole E. coli cells 
(OD600 = 15–17) 
2.0 µM None 900 
Lysate 2.0 µM Na2S2O4, 1 mM 940 
Purified protein 11.9 µM Na2S2O4, 1 mM 150 
Purified protein 11.9 µM Na2S2O4, 5 mM 210 
Purified protein 10.0 µM–11.9 µM NADPH, 10 mM 250 
Notes: Reactions were performed with 10 mM 1a and 10 mM 2 for 18–20 hours at room temperature, 
following the procedures detailed in Section I (H, I, and K). Results are the average of at least two 
reactions. See Section IV for more information on P411-gen9.  
 These experiments demonstrate that C–H alkylation can be catalyzed using an evolved 
P411∆FAD enzyme in whole E. coli cells, in clarified E. coli lysate, and as a purified protein. The 
results using purified P411-gen9 are preliminary and the TTN values should be interpreted with 
caution as no studies regarding the effect of purification conditions on the activity of the enzyme 
nor studies to optimize the reaction conditions were pursued. 
 
Supplementary Table 4. Enzymatic C–H alkylation reactions performed using E. coli cells 
harboring P411-CHF under non-standard conditions. 
 
 
Conditions TTN to 3a e.r. 
Anaerobic, full system, room temp. 2150 96.7 : 3.3 
Anaerobic, full system, 4 °C 2090 98.0 : 2.0 
Anaerobic, no GOX, room temp. 2100 96.7 : 3.3 
Anaerobic, no GOX, no D-glucose, room temp. 1770 96.7 : 3.3 
Aerobic, no GOX, no D-glucose, room temp. 30 not measured 
Notes: Standard reaction conditions are E. coli cells expressing P411-CHF (resuspended to OD600 = 
30) with 10 mM 1a and 10 mM ethyl diazoacetate (2). Reactions were allowed to proceed at the 
indicated temperature for 18 h. For reactions without the GOX oxygen depletion solution, 20 µL of 
M9-N buffer was added instead; for reactions without D-glucose, 40 µL of M9-N buffer was added. 
The aerobic reaction was set up under air, without prior degassing of cells or reagents with argon. 
Results are the average of duplicate reactions. 
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Supplementary Table 5. Reaction progress analysis of enantioselectivity. 
 
 
Time Relative amount of 8c formed† e.r. 
15 min 0.045 83.6 : 16.4 
30 min 0.062 83.2 : 16.8 
1 h 0.093 83.5 : 16.5 
20 h 1 83.9 : 16.1 
18 h (isolated) ξ not applicable  82.8 : 17.2 
Notes: Standard reaction conditions are E. coli cells expressing P411-CHF (resuspended to OD600 
= 30) with 10 mM 7c and 10 mM ethyl diazoacetate (2), following the general procedure detailed 
in Section I (H). Reactions were quenched after the indicated time by the addition of cyclohexane 
(500 μL) and internal standard (10 μL of 40 mM ethyl benzoate). The mixture was transferred to 
a 1.5 mL microcentrifuge tube, vortexed (10 seconds, 3 times), and centrifuged (20,000 × g, 5 
minutes) to completely separate the organic and aqueous layers. The organic layer was taken for 
chiral HPLC analysis (see Section XI). †This refers to the ratio of the HPLC peak areas for 8c 
(sum of enantiomers) over internal standard in a reaction quenched at the indicated time to that of 
a reaction quenched at 20 h. ξProduct was isolated after an enzymatic reaction for 18 h; preparative 
scale reaction conditions were employed and full details are provided in Section IX.  
 This experiment demonstrates that enantioselectivity of enzymatic C–H alkylation does 
not change with time and substrate conversion. While it is possible that the protein is altered during 
the course of the reaction10, this does not affect the enantioselectivity of the product.  
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III. Screening of enzymes for C–H alkylation activity  
Testing diverse heme proteins for reaction discovery 
A composite plate of 40 heme proteins and their variants from various organisms were 
screened for formation of product 3a from substrates 1a and 2. These proteins were cloned and 
used in other studies, including carbene Si–H insertion4 and alkene cyclopropanation 11 , 12 . 
Expression of these proteins followed the procedures as described by the prior studies and testing 
for initial activity was carried out with whole E. coli cells. The general procedure for reaction 
screening in 96-well plate format (Section I (E)) was employed and the reactions were analyzed 
by GC-MS. Note: Since this was an initial test, proper expression of the indicated proteins was not 
verified. Consequently, negative results should be interpreted with caution. From this experiment, 
it was observed that R. marinus NOD (Y32G) had a low level of C–H alkylation activity 
(Supplementary Table 6).  
In addition, eight diverse heme proteins, including R. marinus NOD (Y32G), were chosen 
and tested for C–H alkylation activity using substrates 1a and 2 following the general procedure 
for small scale enzymatic reactions using whole E. coli cells (Section I (H)) (Supplementary Table 
7). Product formation by variant R. marinus NOD (Y32G) was characterized by HPLC (see 
Section VIII). Other reactions were analyzed by GC-MS for formation of product 3a and the 
expression of all proteins were measured using the hemochrome assay. Conditions with no 
exogenous reductant as well as with the addition of 1 mM Na2S2O4 (final concentration) were 
tested. 
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Supplementary Table 6. Preliminary experiments with heme proteins. 
 
UniProt 
ID 
Organism Annotation Abbrev. 
name 
No. of 
variants 
Ref. Formation 
of 3a 
B3FQS5 Rhodothermus 
marinus 
Cytochrome c Rma cyt 
c 
9 4 n. d. 
P15452 Hydrogenobacter 
thermophilus 
Cytochrome c-
552 
Hth cyt c 2 4 n. d. 
P00080 Rhodopila 
globiformis 
Cytochrome c2 - 2 4 n. d. 
D0MGT2 Rhodothermus 
marinus 
Nitric oxide 
dioxygenase 
Rma 
NOD 
10 11 detected† 
P02185 Physeter catodon 
(Sperm whale) 
Myoglobin Mb 1 11* n. d. 
B3DUZ7 Methylacidiphilum 
infernorum  
Hemoglobin-like 
flavoprotein 
HGG# 2 11* n. d. 
O66586 Aquifex aeolicus Thermoglobin - 1 11 n. d. 
G7VHJ7 
 
Pyrobaculum 
ferrireducens 
Protoglobin 
 
- 1 11 n. d. 
Q0PB48 Campylobacter 
jejuni 
Truncated 
hemoglobin 
- 1 11 n. d. 
Q9YFF4 Aeropyrum pernix Protoglobin - 10 11 n. d. 
O31607 Bacillus subtilis Truncated 
hemoglobin 
- 1 12 n. d. 
Notes: Reactions performed with 10 mM 1a and 10 mM 2. No., number; Abbrev., abbreviated; 
Ref., reference.; n. d., not detected. †Small amount of 3a was detected in the reaction with variant 
R. marinus NOD (Y32G). No product 3a was detected in the reaction mixtures of other R. marinus 
NOD variants. *While these heme proteins were not reported in this reference, the expression 
conditions employed for these variants followed those given in the reference. #This protein is 
abbreviated as Hell’s Gate Globin (HGG) on the basis of a prior literature report which uses this 
name13.  
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Supplementary Table 7. Heme proteins tested for C–H alkylation activity. 
 
UniProt 
ID 
Organism Annotation Abbrev. 
Name 
Mutation(s) 
from WT 
Formation 
of 3a 
P14779 
 
Bacillus 
megaterium 
 
cytochrome 
P450/NADPH-
P450 reductase 
P450BM3 none* 
 
 
n. d. 
Q55080 
 
Sulfolobus 
acidocaldarius 
Cytochrome 
P450 
CYP119 none* n. d. 
D0MGT2 Rhodothermus 
marinus 
Nitric oxide 
dioxygenase 
Rma 
NOD 
Y32G+, * 7 TTN† 
(12 TTNξ) 
B3DUZ7 
 
Methylacidiphilum 
infernorum 
Hemoglobin-like 
flavoprotein 
HGG none+, * n. d. 
P02185 Physeter catodon 
(Sperm whale) 
Myoglobin Mb H64V V68A 
D122N+, * 
n. d. 
B3FQS5 Rhodothermus 
marinus 
Cytochrome c Rma cyt c none+, # n. d. 
B3FQS5 Rhodothermus 
marinus 
Cytochrome c Rma cyt c V75T 
M100D 
M103E+, # 
n. d. 
P15452 Hydrogenobacter 
thermophilus 
Cytochrome c Hth cyt c none+, # n. d. 
Notes: Heme proteins were tested in whole E. coli cells (OD600 = 30) both with and without the 
addition of 1 mM Na2S2O4 (final concentration). Reactions were performed with 10 mM 1a and 
10 mM 2; results are the average of at least duplicate reactions. Abbrev., abbreviated; WT, wild-
type; n. d., not detected; TTN, total turnover number. †This data is also included in Supplementary 
Table 1. ξReaction includes 1 mM Na2S2O4. +These variants are also included in Supplementary 
Table 6. *These proteins were expressed following the procedure of A. M. Knight et al.11. 
#Cytochrome c variants were expressed following the procedure of S. B. J. Kan et al.4.  
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Screening previously engineered cytochrome P450BM3 variants 
 A composite plate of 36 cytochrome P450BM3 variants from lineages engineered for non-
natural reactions including C–H amination14, olefin aziridination15, and olefin cyclopropanation16a 
was screened for C–H alkylation activity using substrates 1a and 2. Variants of cytochrome 
P450BM3 in which the axial cysteine ligand is replaced with serine are termed cytochrome P41116b. 
The general procedure for reaction screening in 96-well plate format (Section I (E)) was employed 
and the reactions were analyzed by HPLC. Most variants showed no activity (17 variants) or trace 
activity (15 variants) for 3a formation. The four highest performing variants, all which contain an 
axial cysteine-to-serine mutation (P411), are shown in Supplementary Table 8. While P-4 (A82L) 
was chosen as the parent protein for the directed evolution of a C–H alkylation enzyme, the 
information gained from this experiment was used to guide the first several rounds of evolution. 
 
Supplementary Table 8. Engineered cytochrome P411 variants show promiscuous C–H 
alkylation activity. 
 
Name Mutations from P450BM3 WT Relative amount 
of 3a formed† 
P-4 (A82L) V78A, A82L, F87A, P142S, T175I, A184V, 
S226R, H236Q, E252G, I263F, T268G, A290V, 
A328V, L353V, I366V, C400S, T438S, E442K  
1 
P-4 (A82L A78V 
F263Y) 
A82L, F87A, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263Y, T268G, A290V, 
A328V, L353V, I366V, C400S, T438S, E442K 
1.4 
P-4 (A82L A78V 
F263L) 
A82L, F87A, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263L, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, E442K 
0.5 
P-4 (A82L A78V 
F263L E267D) 
(a.k.a. P411CHA) 
A82L, F87A, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263L, E267D, T268G, A290V, 
A328V, L353V, I366V, C400S, T438S, E442K 
0.7 
Notes: Reactions were performed with 10 mM 1a and 10 mM 2 following the general procedure 
for reaction screening in 96-well plate format (Section I (E)). Results are the average of duplicate 
reactions. All variants are reported in ref. 14. †This refers to the ratio of the HPLC peak area for 
3a in reactions with the indicated variant to that in reactions with P-4 (A82L).  
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IV. Directed evolution of C–H alkylation enzymes 
Construction of site-saturation libraries 
Site-saturation libraries were generated employing the “22c-trick” method1 and screened 
in one 96-well plate; double site-saturation libraries were generated using the same method to 
target two different sites and these were screened in three 96-well plates. Following the general 
screening in 96-well plate procedure (Section I (E)), variants which exhibited higher formation of 
C–H alkylation product (3a or 3i) or improved enantioselectivity for product 3a were identified. 
A summary of the amino acid residues targeted for mutagenesis is presented in Supplementary 
Table 9, as well as the beneficial mutation(s) selected for each round of mutagenesis. The locations 
of the selected beneficial mutations are displayed on a structural model of the P411 enzyme 
(Section II, Supplementary Fig. 3).  
 Variants which were identified to show higher activity and/ or enantioselectivity during 
screening were streaked out on LBamp agar plates. A single colony was selected, sequenced, and 
the TTN measured for both products 3a and 3i using clarified lysate of E. coli cells overexpressing 
the desired protein (unless otherwise indicated, the concentration of P411 variant was normalized 
such that each reaction contained 2.0 µM enzyme, general procedure Section I (I)). Enantiomeric 
ratios of the enzymatic products produced by P411-gen6 and further evolved variants were also 
characterized. The results are summarized in Supplementary Tables 12 and 13.  
 
Supplementary Table 9. Summary of directed evolution for C–H alkylation. 
Round Parent Diversification strategy† Screening substrate 
(selection criteria) 
Changes 
made* 
1 P-4 (A82L) Individual variants identified as 
active for C–H amination14 
4-ethylanisole (1i) 
(activity) 
F263Y 
2 P-4 (A82L F263Y) Site-saturation mutagenesis 
A78X 
4-ethylanisole (1i) 
(activity) 
A78L 
3 P-4 (A82L F263Y 
A78L) 
Site-saturation mutagenesis 
T327X 
4-ethylanisole (1i) 
(activity) 
T327I 
4 P411-gen4 
(P-4 (A82L F263Y 
A78L T327I)) 
Site-saturation mutagenesis 
A74X, E267X 
4-ethylanisole (1i) 
(activity) 
A74G 
5 P411-gen5 
(P411-gen4  
(A74G)) 
Site-saturation mutagenesis 
A328X, H92X, R255X, A264X, 
H100X, F393X, L437X 
p-methoxybenzyl 
methyl ether (1a) 
(activity) 
L437Q 
6 P411-gen6 
(P411-gen5 
(L437Q)) 
Protein truncations: 
full-length P411,  
∆FAD domain, 
heme-domain only 
p-methoxybenzyl 
methyl ether (1a) 
 (activity) 
∆FAD 
domain 
6b P411-gen6b Site-saturation mutagenesis p-methoxybenzyl S438T 
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(P411∆FAD-gen6) A78X, F87X, I263X, T438X methyl ether (1a) 
 (activity) 
7 P411-gen7 
(P411-gen6b  
(S438T)) 
Site-saturation mutagenesisψ 
A330X, F331X, T436X, A82X, 
L181X, L188X 
p-methoxybenzyl 
methyl ether (1a) 
 (activity) 
T436L 
8 P411-gen8 
(P411-gen7  
(T436L))  
Site-saturation mutagenesis 
D63X, F162X, M177X, V178X, 
L439X 
4-ethylanisole (1i) 
(activity) 
M177L 
9 P411-gen9 
(P411-gen8 
(M177L)) 
Site-saturation mutagenesis 
F87X, E267X, M118X, L437X, 
H266X, S332X, T260X, T365X 
4-ethylanisole (1i) 
(activity) 
H266V 
10 P411-gen10 
(P411-gen9 
(H266V)) 
 
Site-saturation mutagenesis 
N70X, T88X, H171X, H361X, 
P329X, T269X, L75X, L52X 
4-ethylanisole (1i) 
(activity) 
& 
p-methoxybenzyl 
methyl ether (1a) 
 (enantioselectivity) 
N70E 
11 P411-gen11 
(P411-gen10 
(N70E)) 
Site-saturation mutagenesis 
L71X, S72X, F261X, G265X, 
L86X, I401X, A330X, C400X 
p-methoxybenzyl 
methyl ether (1a) 
(activity & 
enantioselectivity) 
A330Y 
12 P411-gen12 
(P411-gen11 
(A330Y)) 
Double site-saturation 
mutagenesis 
P329X-F331X#, A328X-F331X#,  
T327X-T268X, A74X-L437X 
p-methoxybenzyl 
methyl ether (1a) 
(activity & 
enantioselectivity) 
I327T 
13a P411-gen13 
(P411-gen12  
(I327T)) 
Double site-saturation 
mutagenesis 
L181X-L437X, V178X-E267X, 
M118X-I401X 
p-methoxybenzyl 
methyl ether (1a) 
(activity & 
enantioselectivity 
None 
13b P411-gen13 
(P411-gen12 
(I327T)) 
Testing previously identified 
beneficial and neutral mutationsξ. 
p-methoxybenzyl 
methyl ether (1a) 
(activity & 
enantioselectivity 
G74P, 
Q437L 
14 P411-CHF 
(P411-gen13  
(G74P Q437L)) 
N. A. N. A. N. A. 
Notes: Some residues were saturated more than once, in different parents. Gen, generation; N. A., 
not applicable. †Residues for site-saturation mutagenesis libraries are listed relative to the amino 
acid at that position in wild-type P450BM3. *Beneficial mutations are listed relative to the amino 
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acid at that position in the parent protein. ψRandom mutagenesis by error-prone PCR on this parent 
enzyme and screening for C–H alkylation activity was also performed (unpublished results). 
However, no mutations from this study were carried forward to the next enzyme generation; the 
F162L mutation, identified in this context, was included in the diversification strategy of round 
13b. #Only NDT libraries were constructed and screened for this double-site saturation experiment. 
ξSelect mutations identified from previous rounds of mutagenesis and screening were introduced 
in various combinations to P411-gen13. Twenty-seven variants were attempted and screened.  
Supplementary Table 10. Mutations and truncations relative to P450BM3 wild-type for the P411 
variants described in Supplementary Table 9.  
Gen. Name Mutations relative to P450BM3 WT Domain 
composition† 
1 P-4 (A82L) V78A, A82L, F87A, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263F, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, E442K 
Full-length 
2 P-4 (A82L F263Y) V78A, A82L, F87A, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263Y, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, E442K 
Full-length 
3 P-4 (A82L F263Y 
A78L) 
V78L, A82L, F87A, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263Y, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, E442K 
Full-length 
4 P411-gen4 
(P-4 (A82L F263Y 
A78L T327I)) 
V78L, A82L, F87A, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263Y, T268G, A290V, T327I, 
A328V, L353V, I366V, C400S, T438S, E442K 
Full-length 
5 P411-gen5 
(P411-gen4 
(A74G)) 
A74G, V78L, A82L, F87A, P142S, T175I, A184V, 
S226R, H236Q, E252G, I263Y, T268G, A290V, 
T327I, A328V, L353V, I366V, C400S, T438S, E442K 
Full-length 
6 P411-gen6 
(P411-gen5  
(L437Q)) 
A74G, V78L, A82L, F87A, P142S, T175I, A184V, 
S226R, H236Q, E252G, I263Y, T268G, A290V, 
T327I, A328V, L353V, I366V, C400S, L437Q, 
T438S, E442K 
Full-length 
6b P411-gen6b 
(P411∆FAD–gen6) 
A74G, V78L, A82L, F87A, P142S, T175I, A184V, 
S226R, H236Q, E252G, I263Y, T268G, A290V, 
T327I, A328V, L353V, I366V, C400S, L437Q, 
T438S, E442K 
∆FAD domain 
7 P411-gen7 
(P411-gen6b 
(S438T)) 
A74G, V78L, A82L, F87A, P142S, T175I, A184V, 
S226R, H236Q, E252G, I263Y, T268G, A290V, 
T327I, A328V, L353V, I366V, C400S, L437Q, E442K 
∆FAD domain 
8 P411-gen8 
(P411-gen7 
(T436L)) 
A74G, V78L, A82L, F87A, P142S, T175I, A184V, 
S226R, H236Q, E252G, I263Y, T268G, A290V, 
T327I, A328V, L353V, I366V, C400S, T436L, 
L437Q, E442K 
∆FAD domain 
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9 P411-gen9 
(P411-gen8 
(M177L)) 
A74G, V78L, A82L, F87A, P142S, T175I, M177L, 
A184V, S226R, H236Q, E252G, I263Y, T268G, 
A290V, T327I, A328V, L353V, I366V, C400S, 
T436L, L437Q, E442K 
∆FAD domain 
10 P411-gen10 
(P411-gen9 
(H266V)) 
 
A74G, V78L, A82L, F87A, P142S, T175I, M177L, 
A184V, S226R, H236Q, E252G, I263Y, H266V, 
T268G, A290V, T327I, A328V, L353V, I366V, 
C400S, T436L, L437Q, E442K 
∆FAD domain 
11 P411-gen11 
(P411-gen10 
(N70E)) 
N70E, A74G, V78L, A82L, F87A, P142S, T175I, 
M177L, A184V, S226R, H236Q, E252G, I263Y, 
H266V, T268G, A290V, T327I, A328V, L353V, 
I366V, C400S, T436L, L437Q, E442K 
∆FAD domain 
12 P411-gen12 
(P411-gen11 
(A330Y)) 
N70E, A74G, V78L, A82L, F87A, P142S, T175I, 
M177L, A184V, S226R, H236Q, E252G, I263Y, 
H266V, T268G, A290V, T327I, A328V, A330Y, 
L353V, I366V, C400S, T436L, L437Q, E442K 
∆FAD domain 
13 P411-gen13 
(P411-gen12 
(I327T)) 
N70E, A74G, V78L, A82L, F87A, P142S, T175I, 
M177L, A184V, S226R, H236Q, E252G, I263Y, 
H266V, T268G, A290V, A328V, A330Y, L353V, 
I366V, C400S, T436L, L437Q, E442K 
∆FAD domain 
14 P411-CHF 
(P411-gen13 
(G74P Q437L)) 
N70E, A74P, V78L, A82L, F87A, P142S, T175I, 
M177L, A184V, S226R, H236Q, E252G, I263Y, 
H266V, T268G, A290V, A328V, A330Y, L353V, 
I366V, C400S, T436L, E442K 
∆FAD domain 
†Full-length cytochrome P411 variants contain amino acids 1–1048. Cytochrome P411 variants 
containing the FAD truncation (∆FAD domain) contain amino acids 1–664.  
 
Supplementary Table 11. Other P411 variants described in this study. 
Name Mutations from P450BM3 WT Reference 
P-I263F V78A, F87V, P142S, T175I, A184V, S226R, 
H236Q, E252G, I263F, T268A, A290V, L353V, 
I366V, C400S, T438S, E442K   
17 
P411-IY (T327I) N70E, A74G, V78L, A82L, F87A, M118S, 
P142S, F162L, T175I, M177L, A184V, S226R, 
H236Q, E252G, I263Y, H266V, T268G, 
A290V, T327I, A328V, A330Y, L353V, I366V, 
C400S, I401L, T436L, L437Q, E442K 
N. A. † 
†N. A., not applicable. The parent of this variant, P411-IY, was made for round 13b of directed 
evolution (see Supplementary Table 9). The P411-IY (T327I) variant, which contains an additional 
T327I mutation, was identified in the context of a separate carbene transfer project (Chen, K., 
Zhou, A. Z. & Arnold, F. H., unpublished results). 
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Supplementary Table 12. Enzymatic C–H alkylation data presented in Fig. 2b.  
 
 
Variant [P411], µM TTN ± SD e.r. 
P-4 (A82L) 4.0 14 ± 2 N. A. 
P-4 (A82L F263Y) 4.0 29 ± 1 N. A. 
P-4 (A82L F263Y A78L) 4.0 23 ± 5 N. A. 
P411-gen4 2.0 48 ± 3 N. A. 
P411-gen5 2.0 68 ± 3 N. A. 
P411-gen6 2.0 59 ± 4 rac 
P411-gen6b 2.0 98 ± 2 rac 
P411-gen7 2.0 200 ± 4 55.0 : 45.0 
P411-gen8 2.0 560 ± 50 59.4 : 40.6 
P411-gen9 2.0 940 ± 30 64.7 : 35.3 
P411-gen10 2.0 1480 ± 50 68.1 : 31.9 
P411-gen11 2.0 1240 ± 30 77.9 : 22.1 
P411-gen12 2.0 1490 ± 40 88.5 : 11.5 
P411-gen13 2.0 1960 ± 40 94.0 : 6.0 
P411-CHF 2.0 2020 ± 40 96.7 : 3.3 
Notes: Reactions were performed using clarified E. coli lysate with 10 mM 1a and 10 mM 2, 
following the general procedure detailed in Section I (I). Each reported TTN is the average over 
four reactions (performed from two independent cell cultures, each used for duplicate reactions). 
TTN, total turnover number, refers to TTN to 3a; SD, standard deviation; N. A., not applicable, 
indicates that this value was not measured; rac, racemic. Parts of this data are also included in 
Supplementary Fig. 2 and Supplementary Table 3. 
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Supplementary Table 13. Enzymatic C–H alkylation data presented in Supplementary Fig. 1.  
 
 
Variant [P411], µM TTN ± SD e.r. 
P-4 (A82L) 4.0 2 ± 0 N. A. 
P-4 (A82L F263Y) 4.0 4 ± 0 N. A. 
P-4 (A82L F263Y A78L) 4.0 7 ± 2 N. A. 
P411-gen4 2.0 13 ± 1 N. A. 
P411-gen5 2.0 14 ± 0 N. A. 
P411-gen6 2.0 12 ± 1 N. A. 
P411-gen6b 2.0 18 ± 1 N. A. 
P411-gen7 2.0 34 ± 1 N. A. 
P411-gen8 2.0 130 ± 20 67.7 : 32.3 
P411-gen9 2.0 260 ± 20 71.9 : 28.1 
P411-gen10 2.0 510 ± 30 76.9 : 23.1 
P411-gen11 2.0 450 ± 10 83.0 : 17.0 
P411-gen12 2.0 630 ± 20 92.0 : 8.0 
P411-gen13 2.0 500 ± 30 96.9 : 3.1 
P411-CHF 2.0 440 ± 30 98.0 : 2.0 
Notes: Reactions were performed using clarified E. coli lysate with 10 mM 1i and 10 mM 2, 
following the general procedure detailed in Section I (I). Each reported TTN is the average over 
four reactions (performed from two independent cell cultures, each used for duplicate reactions). 
TTN, total turnover number, refers to TTN to 3i; SD, standard deviation; N. A., not applicable, 
indicates that this value was not measured.  
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V.  Nucleotide and amino acid sequences 
All heme proteins disclosed below were cloned into a pET22b(+) vector and contain a C-
terminal 6xHis-tag. 
DNA and amino acid sequence of P-4 (A82L), a previously reported cytochrome P411 
variant14 which was used as the starting point for directed evolution: 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACACAGATAA
ACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAA
CGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACTTAAGTCAA
GCGCTGAAATTTGCACGTGATTTTCTTGGAGACGGGTTAGCCACAAGCTGGACGCATGAAAAAAATTGGAAAAA
AGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCG
CCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGT
TTAACGCTTGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCC
ATTTATTATAAGTATGGTCCGTGCACTGGATGAAGTAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAG
CTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCA
GATCGCAAAGCAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCAGAAACGGG
TGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTTATTTGCGGGACACGAAGGTACAAGTG
GTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGTAGCAGAAGAAGCAGCA
CGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAACGA
AGCGCTGCGCTTATGGCCAACTGTGCCTGCGTTTTCCCTATATGCAAAAGAAGATACGGTGCTTGGAGGAGAAT
ATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGATTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGAC
GATGTGGAGGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGG
AAACGGTCAGCGTGCGTCTATCGGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAA
AACACTTTGACTTTGAAGATCATACAAACTACGAGCTCGATATTAAAGAAACTTTAAGCTTAAAACCTAAAGGC
TTTGTGGTAAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAA
AAAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGGGTACCG
CTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGTCGCAACGCTTGAT
TCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCTTATAACGGTCATCCGCCTGA
TAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATGAAGTAAAAGGCGTTCGCTACTCCGTAT
TTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCT
AAAGGGGCAGAAAACATCGCTGACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATG
GCGTGAACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTA
CTCTTTCACTTCAATTTGTCGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGAAC
GTCGTAGCAAGCAAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCGACATCTTGAAATTGAACTTCCAAA
AGAAGCTTCTTATCAAGAAGGAGATCATTTAGGTGTTATTCCTCGCAACTATGAAGGAATAGTAAACCGTGTAA
CAGCAAGGTTCGGCCTAGATGCATCACAGCAAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCTCATTTGCCA
CTCGCTAAAACAGTATCCGTAGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTGTTACGCGCACGCAGCT
TCGCGCAATGGCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGAAGCCTTGCTTGAAAAGCAAGCCT
ACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTGCTTGAAAAATACCCGGCGTGTGAAATGAAA
TTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCCCGCGCTATTACTCGATTTCTTCATCACCTCGTGTCGA
TGAAAAACAAGCAAGCATCACGGTCAGCGTTGTCTCAGGAGAAGCGTGGAGCGGATATGGAGAATATAAAGGAA
TTGCGTCGAACTATCTTGCCGAGCTGCAAGAAGGAGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAA
TTTACGCTGCCAAAAGACCCTGAAACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGG
CTTTGTGCAGGCGCGCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCC
GTTCACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACGCTTCAT
ACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAACAAGACGGCAAGAAATT
GATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGGAAGCCAAATGGCACCTGCCGTTGAAG
CAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTGAGTGAAGCAGACGCTCGCTTATGGCTGCAGCAGCTA
GAAGAAAAAGGCCGATACGCAAAAGACGTGTGGGCTGGGCTCGAGCACCACCACCACCACCACTGA 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKNLSQ
ALKFARDFLGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVSEDMTR
LTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRALDEVMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIA
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DRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIRYQIITFLFAGHEGTSGLLSFALYFLVKNPHVLQKVAEEAA
RVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTVPAFSLYAKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGD
DVEEFRPERFENPSAIPQHAFKPFGNGQRASIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLSLKPKG
FVVKAKSKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLD
SHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAA
KGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTN
VVASKELQQPGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLAHLP
LAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMK
FSEFIALLPSIRPRYYSISSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSE
FTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIITLH
TAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQMAPAVEATLMKSYADVHQVSEADARLWLQQL
EEKGRYAKDVWAGLEHHHHHH. 
 
DNA and amino acid sequence of P411-gen5, which was employed for the synthesis of 
key intermediate (+)-8f in the total synthesis of (+)-cuspareine: 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACACAGATAA
ACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAA
CGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACTTAAGTCAA
GGTCTGAAATTTCTGCGTGATTTTCTTGGAGACGGGTTAGCCACAAGCTGGACGCATGAAAAAAATTGGAAAAA
AGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCG
CCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGT
TTAACGCTTGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCC
ATTTATTATAAGTATGGTCCGTGCACTGGATGAAGTAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAG
CTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCA
GATCGCAAAGCAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCAGAAACGGG
TGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTTATATGCGGGACACGAAGGTACAAGTG
GTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGTAGCAGAAGAAGCAGCA
CGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAACGA
AGCGCTGCGCTTATGGCCAATTGTGCCTGCGTTTTCCCTATATGCAAAAGAAGATACGGTGCTTGGAGGAGAAT
ATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGATTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGAC
GATGTGGAGGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGG
AAACGGTCAGCGTGCGTCTATCGGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAA
AACACTTTGACTTTGAAGATCATACAAACTACGAGCTCGATATTAAAGAAACTTTAAGCTTAAAACCTAAAGGC
TTTGTGGTAAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAA
AAAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGGGTACCG
CTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGTCGCAACGCTTGAT
TCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCTTATAACGGTCATCCGCCTGA
TAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATGAAGTAAAAGGCGTTCGCTACTCCGTAT
TTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCT
AAAGGGGCAGAAAACATCGCTGACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATG
GCGTGAACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTA
CTCTTTCACTTCAATTTGTCGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGAAC
GTCGTAGCAAGCAAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCGACATCTTGAAATTGAACTTCCAAA
AGAAGCTTCTTATCAAGAAGGAGATCATTTAGGTGTTATTCCTCGCAACTATGAAGGAATAGTAAACCGTGTAA
CAGCAAGGTTCGGCCTAGATGCATCACAGCAAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCTCATTTGCCA
CTCGCTAAAACAGTATCCGTAGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTGTTACGCGCACGCAGCT
TCGCGCAATGGCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGAAGCCTTGCTTGAAAAGCAAGCCT
ACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTGCTTGAAAAATACCCGGCGTGTGAAATGAAA
TTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCCCGCGCTATTACTCGATTTCTTCATCACCTCGTGTCGA
TGAAAAACAAGCAAGCATCACGGTCAGCGTTGTCTCAGGAGAAGCGTGGAGCGGATATGGAGAATATAAAGGAA
TTGCGTCGAACTATCTTGCCGAGCTGCAAGAAGGAGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAA
TTTACGCTGCCAAAAGACCCTGAAACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGG
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CTTTGTGCAGGCGCGCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCC
GTTCACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACGCTTCAT
ACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAACAAGACGGCAAGAAATT
GATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGGAAGCCAAATGGCACCTGCCGTTGAAG
CAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTGAGTGAAGCAGACGCTCGCTTATGGCTGCAGCAGCTA
GAAGAAAAAGGCCGATACGCAAAAGACGTGTGGGCTGGGCTCGAGCACCACCACCACCACCACTGA 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKNLSQ
GLKFLRDFLGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVSEDMTR
LTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRALDEVMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIA
DRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIRYQIITFLYAGHEGTSGLLSFALYFLVKNPHVLQKVAEEAA
RVLVDPVPSYKQVKQLKYVGMVLNEALRLWPIVPAFSLYAKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGD
DVEEFRPERFENPSAIPQHAFKPFGNGQRASIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLSLKPKG
FVVKAKSKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLD
SHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAA
KGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTN
VVASKELQQPGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLAHLP
LAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMK
FSEFIALLPSIRPRYYSISSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSE
FTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIITLH
TAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQMAPAVEATLMKSYADVHQVSEADARLWLQQL
EEKGRYAKDVWAGLEHHHHHH. 
 
DNA and amino acid sequence of P411-CHF, an evolved C–H alkylation enzyme: 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACACAGATAA
ACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAA
CGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAGAGTTAAGTCAA
CCGCTGAAATTTCTGCGTGATTTTCTTGGAGACGGGTTAGCCACAAGCTGGACGCATGAAAAAAATTGGAAAAA
AGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCG
CCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGT
TTAACGCTTGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCC
ATTTATTATAAGTCTGGTCCGTGCACTGGATGAAGTAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAG
CTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCA
GATCGCAAAGCAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCAGAAACGGG
TGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTTATATGCGGGAGTTGAAGGTACAAGTG
GTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGTAGCAGAAGAAGCAGCA
CGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAACGA
AGCGCTGCGCTTATGGCCAACGGTTCCTTATTTTTCCCTATATGCAAAAGAAGATACGGTGCTTGGAGGAGAAT
ATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGATTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGAC
GATGTGGAGGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGG
AAACGGTCAGCGTGCGTCTATCGGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAA
AACACTTTGACTTTGAAGATCATACAAACTACGAGCTCGATATTAAAGAACTGCTTACGTTAAAACCTAAAGGC
TTTGTGGTAAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAA
AAAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGGGTACCG
CTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGTCGCAACGCTTGAT
TCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCTTATAACGGTCATCCGCCTGA
TAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATGAAGTAAAAGGCGTTCGCTACTCCGTAT
TTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCT
AAAGGGGCAGAAAACATCGCTGACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATG
GCGTGAACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTA
CTCTTTCACTTCAATTTGTCGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGCTC
GAGCACCACCACCACCACCACTGA 
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MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKELSQ
PLKFLRDFLGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVSEDMTR
LTLDTIGLCGFNYRFNSFYRDQPHPFIISLVRALDEVMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIA
DRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIRYQIITFLYAGVEGTSGLLSFALYFLVKNPHVLQKVAEEAA
RVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTVPYFSLYAKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGD
DVEEFRPERFENPSAIPQHAFKPFGNGQRASIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKELLTLKPKG
FVVKAKSKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLD
SHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAA
KGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTL
EHHHHHH. 
 
DNA and amino acid sequence of P411-IY (T327I), a C–H alkylation enzyme derived 
from P411-gen13. 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACACAGATAA
ACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAA
CGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAGAGTTAAGTCAA
GGTCTGAAATTTCTGCGTGATTTTCTTGGAGACGGGTTAGCCACAAGCTGGACGCATGAAAAAAATTGGAAAAA
AGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGCAATGAAAGGCTATCATGCGAGTATGGTCGATATCG
CCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGT
TTAACGCTTGATACAATTGGTCTTTGCGGCTTTAACTATCGCCTTAACAGCTTTTACCGAGATCAGCCTCATCC
ATTTATTATAAGTCTGGTCCGTGCACTGGATGAAGTAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAG
CTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCA
GATCGCAAAGCAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCAGAAACGGG
TGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTTATATGCGGGAGTTGAAGGTACAAGTG
GTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGTAGCAGAAGAAGCAGCA
CGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAACGA
AGCGCTGCGCTTATGGCCAATTGTTCCTTATTTTTCCCTATATGCAAAAGAAGATACGGTGCTTGGAGGAGAAT
ATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGATTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGAC
GATGTGGAGGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGG
AAACGGTCAGCGTGCGTCTCTGGGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAA
AACACTTTGACTTTGAAGATCATACAAACTACGAGCTCGATATTAAAGAACTGCAGACGTTAAAACCTAAAGGC
TTTGTGGTAAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAA
AAAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGGGTACCG
CTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGTCGCAACGCTTGAT
TCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCTTATAACGGTCATCCGCCTGA
TAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATGAAGTAAAAGGCGTTCGCTACTCCGTAT
TTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCT
AAAGGGGCAGAAAACATCGCTGACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATG
GCGTGAACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTA
CTCTTTCACTTCAATTTGTCGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGCTC
GAGCACCACCACCACCACCACTGA 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKELSQ
GLKFLRDFLGDGLATSWTHEKNWKKAHNILLPSFSQQAMKGYHASMVDIAVQLVQKWERLNADEHIEVSEDMTR
LTLDTIGLCGFNYRLNSFYRDQPHPFIISLVRALDEVMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIA
DRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIRYQIITFLYAGVEGTSGLLSFALYFLVKNPHVLQKVAEEAA
RVLVDPVPSYKQVKQLKYVGMVLNEALRLWPIVPYFSLYAKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGD
DVEEFRPERFENPSAIPQHAFKPFGNGQRASLGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKELQTLKPKG
FVVKAKSKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLD
SHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAA
KGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTL
EHHHHHH. 
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DNA and amino acid sequence of R. marinus NOD (Y32G), a heme protein which exhibits 
trace C–H alkylation activity.  
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTGTGCCTGCACTGCAGAAACACTCAGT
CGCTATTAGCGCCACGATGGGTCGGCTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCCTG
AGAGACAGATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAGTATCGACAACCCATCGGCGTTACAG
GCGGCCATCCGCCGCATGGTGCTTTCCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTTGGGA
ATGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGAGACCCTTCTGCAGGCGTGGAAGGAAG
CCTATGATTTTTTAGCTCATTTACTGTCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCAC
CACCACCACCACCACTGA 
MAPTLSEQTRQLVRASVPALQKHSVAISATMGRLLFERYPETRSLFELPERQIHKLASALLAYARSIDNPSALQ
AAIRRMVLSHARAGVQAVHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTKEAQVYAVLAELEH
HHHHH. 
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VI. Substrate Synthesis and Characterization  
Commercially available alkane and diazo substrates were used as received: 1a, 1d, 1f, 1g, 
1i–1k, 1m, 7a, 7c–7f, 9a, 9e, 9f (custom synthesis, Arch Bioscience). Compound 1c was also 
commercial (Combi-Blocks), though the commercial product was used only for synthesis. Ethyl 
diazoacetate (2, Sigma-Aldrich) was concentrated under reduced pressure and its concentration 
relative to residual dichloromethane was determined by 1H NMR. Diazo compounds 9h (ref. 18) 
and 9i (ref. 19) are known and were prepared according to literature procedures. Caution: although 
no safety issues were encountered, diazo compounds are reactive and should be used with caution. 
 
Supplementary Fig. 12. Alkane substrates. This terminology is used to emphasize that the 
reaction reported here acts on a sp3-hybridized C–H bond in the alkane portion of the substrate. 
 
 
Supplementary Fig. 13. Diazo compounds. 
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General Procedure A: Methylation of alcohols 
To a 250 mL round bottom flask was added NaH (60% dispersion in mineral oil, 15–30 
mmol, 1.2–1.5 equiv.). The flask was evacuated and filled with argon (3 times). Anhydrous THF 
(45–80 mL) was added by syringe and the reaction mixture was cooled to 0 °C in an ice bath. 
Alcohol (10–20 mmol, 1.0 equiv.) in THF (5–10 mL) was added dropwise and the reaction mixture 
was allowed to warm to room temperature and stirred for 30 minutes. Following, iodomethane 
(20–40 mmol, 2.0 equiv.) in THF (10 mL) was added and the reaction was stirred at room 
temperature (8–15 hours). The reaction was quenched by the addition of brine (60 mL) or NH4Cl 
(sat. aq., 60 mL) and the phases were separated. The aqueous layer was extracted with diethyl ether 
(3 × 60 mL); the combined organics were washed with aq. sodium thiosulfate (10% w/v, 50 mL, 
when necessary), dried over Na2SO4 and concentrated under reduced pressure. Purification by 
silica column chromatography with hexanes / ethyl acetate or pentane / diethyl ether afforded 
compounds the desired products in 37–99% yield.  
 
1-Methoxy-4-(methoxymethyl-d2)benzene (1a-d2) 
Labeled substrate 1a-d2 was prepared from methyl 4-methoxybenzoate using a two-step 
sequence to 98% deuterium incorporation at the benzylic position. First, to a dry round bottom 
flask, under argon, was added LiAlD4 (0.23 g, 5.5 mmol, 1.1 equiv.) and anhydrous Et2O (10 mL). 
A solution of methyl 4-methoxybenzoate (0.83 g, 5 mmol, 1.0 equiv.) in dry Et2O (5 mL) was 
added dropwise and the reaction was allowed to stir at room temperature for 12 hours. Following, 
the reaction mixture was cooled to 0 °C and diluted with Et2O. The reaction was quenched by the 
addition of 0.2 mL H2O, 0.2 mL NaOH (aq., 1M), and 0.6 mL H2O. The mixture was allowed to 
warm to room temperature and stirred for 15 minutes. MgSO4 was added and the mixture was 
stirred for a further 15 minutes, filtered, and concentrated under reduced pressure. The crude 
product was purified by silica column chromatography with hexanes / ethyl acetate to give (4-
methoxyphenyl)methanol-d2 (0.43 g, 61% yield, 98% deuterium incorporation), with spectral data 
in agreement with literature report20. Methylation of this compound was performed following 
General Procedure A (note: reaction performed on 3.0 mmol scale) to afford 1a-d2 (0.43 g, 61% 
yield, 98% deuterium incorporation).  
1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.5 Hz, 
2H), 3.81 (s, 3H), 3.36 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 159.3, 130.3, 
129.5, 113.9, 73.7 (m, labeled), 57.8, 55.4. HRMS (EI) m/z: 154.0964 (M+˙); 
calc. for C9H10O22H2: 154.0963. 
 
1-(Methoxymethyl)-4-methylbenzene (1b) 
Prepared from p-tolylmethanol using General Procedure A. This compound is 
known in the literature21. 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 8.0 Hz, 2H), 
7.17 (d, J = 7.9 Hz, 2H), 4.43 (s, 2H), 3.37 (s, 3H), 2.35 (s, 3H). 
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1-Bromo-4-(methoxymethyl)benzene (1c) 
Prepared from (4-bromophenyl)methanol using General Procedure A. This 
compound is known21. 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.4 Hz, 2H), 
7.21 (d, J = 8.6 Hz, 2H), 4.41 (s, 2H), 3.38 (s, 3H). 
 
1-(Methoxymethyl)-3-methylbenzene (1e) 
Prepared from m-tolylmethanol using General Procedure A. 1H NMR (400 
MHz, CDCl3) δ 7.28 – 7.21 (m, 1H), 7.19 – 7.08 (m, 3H), 4.43 (s, 2H), 3.40 (s, 
3H), 2.36 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 138.2, 128.6, 128.5, 128.4, 
124.9, 74.9, 58.3, 21.5. HRMS (FAB) m/z: 135.0810 [(M + H+)–H2]; calc. for C9H11O: 135.0810.  
 
(4-(Methoxymethyl)phenyl)dimethylsilane (1h) 
In a 250 mL round bottom flask, under argon, 1-bromo-4-(methoxymethyl)benzene (3.0 g, 
15 mmol, 1.0 equiv.) in anhydrous THF (60 mL) was cooled to -78 °C. A solution of n-butyllithium 
(9 mL, 2.5 M in hexanes, 22.5 mmol, 1.5 equiv.) was added dropwise. The resulting mixture was 
stirred at -78 °C for 2 hours before the dropwise addition of chlorodimethylsilane (2.4 mL, 22.5 
mmol, 1.5 equiv.). The reaction was allowed to warm to room temperature and stirred overnight. 
The reaction mixture was cooled to 0 °C and quenched with NH4Cl (sat. aq., 20 mL). The aqueous 
layer was extracted with diethyl ether (3 × 30 mL); the combined organics were washed with brine 
(30 mL), dried over Na2SO4 and concentrated under reduced pressure. The crude reaction mixture 
was purified by silica column chromatography with hexanes / ethyl acetate to afford 1h (2.14 g, 
79% yield). A second round of purification by silica column chromatography with hexanes / ether 
was performed on a portion of the product.  
1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 8.1 Hz, 
2H), 4.47 (s, 2H), 4.43 (hept, J = 3.7 Hz, 1H), 3.40 (s, 3H), 0.35 (d, J = 3.7 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 139.3, 136.9, 134.3, 127.3, 74.7, 
58.3, -3.6. HRMS (FAB) m/z: 179.0894 [(M + H+)–H2]; calc. for 
C10H15OSi: 179.0892.  
 
1-Ethyl-4-isopropylbenzene (1l) 
The following procedure was modified from the literature22. To a 250 mL round bottom 
flask were added Pd/C (10% Pd on activated charcoal, 486 mg, 20% w/w), 4-
isopropylacetophenone (2.43 g, 15 mmol), and methanol (60 mL). The solution was sparged with 
H2 and stirred under 1 atm H2 for 48 hours; monitoring the mixture by TLC showed that that the 
reaction did not go to completion under these conditions. The crude reaction mixture was filtered 
through a pad of Celite, dried over dried over Na2SO4, and concentrated under reduced pressure. 
Purification by silica column chromatography with hexanes afforded product 1l (218 mg, 1.47 
mmol, 10% yield).  
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1H NMR (500 MHz, CDCl3) δ 7.19 – 7.13 (m, 4H), 2.90 (hept, J = 6.9 Hz, 1H), 
2.65 (q, J = 7.6 Hz, 2H), 1.29 – 1.24 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 
146.2, 141.7, 127.9, 126.5, 33.8, 28.5, 24.2, 15.7. HRMS (FAB) m/z: 149.1327 
(M + H+); calc. for C11H17: 149.1330.  
 
(E)-1-Methoxyoct-2-ene (4a) 
Prepared from (E)-oct-2-en-1-ol using General Procedure A. This compound 
is known in the literature23. 1H NMR (400 MHz, CDCl3) δ 5.70 (dtt, J = 15.6, 
6.6, 1.2 Hz, 1H), 5.54 (dtt, J = 15.3, 6.2, 1.4 Hz, 1H), 3.86 (dq, J = 6.2, 1.0 Hz, 
2H), 3.31 (s, 3H), 2.08 – 1.99 (m, 2H), 1.43 – 1.34 (m, 2H), 1.34 – 1.21 (m, 4H), 
0.88 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 135.2, 126.1, 73.5, 57.8, 32.4, 31.5, 28.9, 
22.7, 14.2. 
 
(E)-1-Methoxyhex-2-ene (4b) 
Prepared from (E)-hex-2-en-1-ol using a modified version of General Procedure A. To a 
100 mL dry round bottom flask, cooled under argon, were added (E)-hex-2-en-1-ol (2.0 g, 20 
mmol, 1.0 equiv.), DMF (35 mL), and iodomethane (5.7 g, 40 mmol, 2.0 equiv.). The resulting 
solution was cooled to 0 °C and NaH (60% dispersion in mineral oil, 960 mg, 24 mmol, 1.2 equiv.) 
was added portion-wise. The mixture was stirred at 0 °C for 30 minutes, then allowed to warm to 
room temperature and stirred for an additional 3 hours. The reaction mixture was cooled to 0 °C, 
quenched with the addition of NH4Cl (sat. aq., 30 mL), and diluted with diethyl ether (50 mL). 
Phases were separated and the aqueous layer was extracted with diethyl ether (3 × 50 mL). The 
combined organics were washed with H2O (2 × 25 mL) and brine (25 mL), dried over Na2SO4, 
and concentrated under reduced pressure (≥ 200 mbar). Purification by silica column 
chromatography with pentane / diethyl ether afforded compound 4b (746 mg, 6.5 mmol, 33% 
yield).  
This compound is known in the literature24. 1H NMR (500 MHz, CDCl3) δ 
5.70 (dtt, J = 15.4, 6.6, 1.2 Hz, 1H), 5.55 (dtt, J = 15.4, 6.3, 1.4 Hz, 1H), 3.87 
(dq, J = 6.3, 1.1 Hz, 2H), 3.32 (s, 3H), 2.06 – 2.00 (m, 2H), 1.42 (app. sext, J = 7.4 Hz, 2H), 0.91 
(t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 134.9, 126.3, 73.4, 57.8, 34.5, 22.4, 13.8. 
 
(E)-7-Bromo-1-methoxyhept-2-ene (4c) 
To a 100 mL flamed dried flask was added Grubbs’ catalyst 2nd generation (85 mg, 1 
mol%). The flask was then evacuated and backfilled with argon for three times. Under argon, a 
dry CH2Cl2 solution containing 6-bromo-1-hexene (1.63 g, 10 mmol, 1.0 equiv.) and 
crotonaldehyde (3.50 g, 50 mmol, 5.0 equiv.) was added to the flask. The mixture was stirred under 
reflux for 20 hours and then cooled to room temperature and filtered through a silica plug. The 
solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (hexanes / ethyl acetate) to give (E)-7-bromohept-2-enal (1.6 g, 84% yield). This 
product was then dissolved in 10 mL dry THF and then added slowly to a suspension of NaBH4 
(375 mg, 10 mmol, 1.0 equiv.) in dry THF (10 mL) at 0 °C. To this reaction mixture, iodine (1.27 
g, 5 mmol, 0.5 equiv.) in 10 mL of THF was slowly added at 0 °C. Reaction was stirred until the 
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aldehyde was fully reduced as indicated by TLC. The reaction was quenched with NH4Cl (sat. 
aq.), the phases were separated, and the aqueous phase was extracted with ethyl acetate (3 × 20 
mL). The combined organic layers were washed with brine and dried over Na2SO4. The solvent 
was removed under reduced pressure and the crude alcohol product was used directly without 
purification. General Procedure A was used for the methylation step and the final product 4c was 
obtained with 50% overall yield (1.03g, 5 mmol).  
This compound is known in the literature25. 1H NMR (400 MHz, CDCl3) δ 5.68 
(dtt, J = 15.3, 6.4, 1.1 Hz, 1H), 5.57 (dtt, J = 15.4, 6.0, 1.2 Hz, 1H), 3.86 (dq, J = 
5.9, 1.0 Hz, 2H), 3.41 (t, J = 6.8 Hz, 2H), 3.32 (s, 3H), 2.14 – 2.05 (m, 2H), 1.92 
– 1.82 (m, 2H), 1.57 – 1.49 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 133.9, 127.0, 
73.3, 57.9, 33.8, 32.3, 31.5, 27.7. HRMS (EI) m/z: 205.0216 (M ‒ H+); calc. for C8H1479BrO: 
205.0228. 
 
(E)-1-(But-1-en-1-yl)-4-methoxybenzene (4d) 
This compound was accessed in a two-step sequence. First, to 
propyltriphenylphosphonium bromide (7.6 g, 19.7 mmol, 1.0 equiv.) suspended in anhydrous THF 
(70 mL) and cooled to 0 °C was added n-butyllithium (2.5 M in hexanes, 7.9 mL, 19.7 mmol, 1.0 
equiv.) dropwise over 10 min to form a bright orange solution. After stirring for 1 hour, 4-
methoxybenzaldehyde (2.7 g, 19.7 mmol, 1.0 equiv.) was added dropwise over 5 min. The reaction 
mixture was allowed to slowly warm to room temperature and stirred at room temperature 
overnight. The reaction mixture was diluted with pentane (50 mL) and the resulting solution was 
washed with HCl (aq., 0.1 M, 50 mL), H2O (50 mL), NaHCO3 (sat. aq., 50 mL), and brine (50 
mL). The organics were dried over sodium sulfate and concentrated under reduced pressure. The 
crude product was purified by silica column chromatography with pentane / diethyl ether to afford 
(E:Z)-4d (2:1 E:Z, 2.50 g, 15.4 mmol, 78% yield).  
 Next, (E:Z)-4d was isomerized following a literature method26. To a dry 25 mL round 
bottom flask, under argon, were added (E:Z)-4d (300 mg, 1.85 mmol), (MeCN)2PdCl2 (235 mg, 
50 mol%), and 4 mL anhydrous dichloromethane. The resulting mixture was stirred at room 
temperature for 24 hours. The crude reaction mixture was filtered through Celite and concentrated 
under reduced pressure. Purification by silica column chromatography using hexanes / diethyl 
ether delivered 4d (> 20:1 E:Z, 279 mg, 1.72 mmol, 93% yield).  
This compound is known in the literature26. 1H NMR (400 MHz, CDCl3) δ 
7.28 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.33 (dt, J = 15.7, 1.6 Hz, 
1H), 6.13 (dt, J = 15.8, 6.5 Hz, 1H), 3.80 (s, 3H), 2.26 – 2.16 (m, 2H), 1.08 
(t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 158.7, 130.9, 130.7, 128.2, 127.1, 114.0, 55.4, 
26.2, 14.0. 
 
1-Methoxyoct-2-yne (4e) 
To a solution of 3-methoxyprop-1-yne (845 µL, 10 mmol, 1.0 equiv.) in anhydrous THF 
(50 mL) at -20 °C, was added n-butyllithium (2 M in THF, 6 mL, 12 mmol, 1.2 equiv.) and HMPA 
(869 µL, 5 mmol, 0.5 equiv.) dropwise over 5 min. The resulting mixture was stirred at -20 °C for 
3 hours before the addition of 1-iodopentane (1.96 mL, 15 mmol, 1.5 equiv.). The reaction was 
allowed to slowly warm to room temperature in 2 hours and stirred for additional 18 hours. The 
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reaction was then quenched by NH4Cl (sat. aq., 20 mL) and H2O (30 mL), and extracted by diethyl 
ether (40 mL × 3). The combined organic layer was washed by H2O (50 mL) and brine (50 mL), 
and then dried over sodium sulfate and concentrated under reduced pressure. The crude product 
was purified by silica column chromatography with pentane / diethyl ether to afford 4e (1.04 g, 
7.4 mmol, 74% yield).  
This compound is known in the literature27. 1H NMR (400 MHz, CDCl3) 
δ 4.07 (t, J = 2.2 Hz, 2H), 3.37 (s, 3H), 2.22 (tt, J = 7.2, 2.2 Hz, 2H), 1.56 
– 1.47 (m, 2H), 1.41 – 1.26 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 87.4, 75.8, 60.4, 57.5, 31.2, 28.5, 22.3, 18.9, 14.1. HRMS (EI) m/z: 139.1128 
[(M – H•)+]; calc. for C9H15O: 139.1123. 
 
4-Ethyl-N,N-dimethylaniline (7b) 
4-Ethylaniline (0.605 g, 5 mmol, 1.0 equiv.) and formaldehyde (1.8 mL, 50 mmol, 10.0 
equiv.) were mixed in acetic acid (30 mL). The solution was stirred for 30 min at 0 °C before 
portionwise addition of NaBH3CN (1.57 g, 25 mmol, 5.0 equiv.). After the reaction was stirred 
overnight, NaOH (aq., 2M) was used to neutralize the reaction at 0 °C until pH 8-10. The crude 
product was extracted with diethyl ether (30 mL × 3). The combined organic layer was washed 
with H2O (50 mL) and brine (50 mL), and then dried over sodium sulfate and concentrated under 
reduced pressure. The crude product was purified by silica column chromatography with hexanes 
/ ethyl acetate to afford 7b (635 mg, 4.25 mmol, 85% yield).  
This compound is known in the literature28. 1H NMR (400 MHz, CDCl3) δ 
7.09 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 8.7 Hz, 2H), 2.92 (s, 6H), 2.57 (q, J = 7.6 
Hz, 2H), 1.21 (t, J = 7.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 149.1, 132.8, 
128.5, 113.3, 41.2, 27.9, 16.1. 
 
3-Diazodihydrofuran-2(3H)-one (9b) 
The preparation of the title compound 9b followed a modified procedure reported by 
Sattely et al29. Sodium azide (4.83 g, 74.3 mmol, 4 equiv.), sodium hydroxide (80 mL 
of 2 M in water, 160 mmol), tetrabutylammonium bromide (60.0 mg, 0.190 mmol, 
0.01 equiv.), and hexane (80 mL) were combined in a 500-mL flask with magnetic stir 
bar open to the air and cooled to 0 °C. With vigorous stirring, triflic anhydride (6.20 mL, 37.1 
mmol, 2 equiv.) was added dropwise. After 15 min, a solution of 2-acetyl-butyrolactone (2.00 mL, 
18.6 mmol) in acetonitrile (70 mL) was poured into the vessel through a funnel, followed by an 
additional 10 mL of acetonitrile to complete the transfer. The initially colorless reaction mixture 
immediately turned yellow. After stirring for 20 min at 0 °C, the mixture was diluted with ice 
water (50 mL) and chilled EtOAc (50 mL) and transferred to a separatory funnel. After phase 
separation and removal of the organic fraction, the aqueous layer was washed with chilled EtOAc 
(50 mL × 5). The combined organic layer was dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The resulting crude product was purified by silica column chromatography with 
hexanes / ethyl acetate as eluents. The yellow-colored fractions were concentrated to afford the 
product as a bright yellow crystalline solid (1.2‒1.6 g, 60‒75% yield). Spectral data are consistent 
with Sattely et al29.   
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2-Diazo-N-methoxy-N-methylacetamide (9c) 
4-Methylbenzenesulfonohydrazide (9.31 g, 50 mmol, 1.0 equiv.) was dissolved in aqueous 
hydrochloric acid (2 M, 30 mL) and warmed to 50 °C (solution 1). 2-Oxoacetic acid (7.40 g of 
50% in water, 50 mmol, 1.0 equiv.) was dissolved in water (100 mL) and heated to 50 °C (solution 
2). Pre-warmed solution 1 was slowly transferred to solution 2. The reaction mixture was then 
stirred at 60 °C for 4 h until all the hydrozone product crashed out. The mixture was cooled to 0 
°C and kept for 2 h. The product 2-(2-tosylhydrazineylidene)acetic acid (9.88 g, 82% yield) was 
collected by filtration, washed with hexane: ethyl acetate (10:1) and dried under vaccum. 
2-(2-Tosylhydrazineylidene)acetic acid (4.84 g, 20 mmol, 1.0 equiv.) was dissolved in dry 
dichloromethane (30 mL). Thionyl chloride (16 mL) and N,N-dimethyl formaldehyde (3 drops, 
cat.) were added to the solution. The reaction mixture was stirred at room temperature for 1 h and 
then heated to reflux (~ 50 °C) for 5 h until the starting material was completely dissolved and the 
reaction turned clear and light yellow. After the reaction was cooled to room temperature, organic 
solvent and the excess thionyl chloride was removed under reduced pressure. The resulting mixture 
(solid) was then dissolved in dry dichloromethane (20 mL) and used for the next step. 
N,O-Dimethylhydroxylamine hydrochloride (3.91 g, 40 mmol, 2.0 equiv.) and triethylamine 
(11.2 mL, 80 mmol, 4.0 equiv.) were mixed in dry dichloromethane (80 mL) and stirred for 30 
min. The solution of acyl chloride was added dropwise over 20 min to the reaction mixture at 0 
°C. The reaction was then stirred at room temperature for 5 h before water (80 mL) was added to 
quench the reaction. The liquid phases were transferred to a separatory funnel, and the aqueous 
phase was extracted with dichloromethane (50 mL× 4). The combined organic phase was washed 
with water (40 mL) and brine (40 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The resulting crude product was purified by silica column chromatography with hexanes 
/ ethyl acetate to afford 9c as a yellow liquid (0.82 g, 32% yield).  
This compound is known in the literature30. 1H NMR (400 MHz, CDCl3) δ 5.33 (s, 
1H), 3.66 (s, 3H), 3.19 (s, 3H). 
 
 
1-Diazopropan-2-one (9d) 
The preparation of the title compound 9d followed a modified procedure reported by 
Zhang et al31. To a solution of acetylacetone (3.4 mL, 33.0 mmol, 1.10 equiv.) and 
triethylamine (5.04 mL, 36.4 mmol, 1.21 equiv.) in dry acetonitrile (25 mL), a solution 
of p-acetamidobenzenesulfonyl azide (7.20 g, 30.0 mmol, 1.0 equiv.) in dry 
acetonitrile (25 mL) was added dropwise. The reaction mixture was stirred at room temperature 
for 4 h. Then, the solvent was removed under reduced pressure and the resulting mixture was then 
purified by silica column chromatography with hexanes / ethyl acetate to give 3-diazopentane-2,4-
dione (3.65 g, 96% yield) as a pale yellow liquid. 
3-Diazopentane-2,4-dione (1.89 g, 15 mmol, 1.0 equiv.) was dissolved in diethyl ether (25 
mL). An aqueous solution (25 mL) of NaOH (3.00 g, 75 mmol, 5.0 equiv.) was added dropwise 
over 10 min to the ether layer with vigorous stirring at 0 °C. The reaction mixture turned dark 
brown within 20 min and was then stirred at room temperature for 4 h. The liquid phases were 
transferred to a separatory funnel, and the aqueous phase was extracted with diethyl ether (30 mL 
× 5). The combined organic phase was dried over Na2SO4, filtered, and concentrated under reduced 
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pressure (T = 24 °C, P ≥ 20 kPa) to give product 9d as a volatile yellow liquid (0.892 g, 71% 
yield). Spectral data is consistent with Zhang et al31. 
 
Ethyl 2-diazobutanoate (9g) 
The preparation of the title compound 9g followed a modified procedure reported 
by Huang et al32.  To a solution of ethyl 2-ethylacetoacetate (3.16 g, 20.0 mmol, 
1.0 equiv.) and p-acetamidobenzenesulfonyl azide (7.21 g, 30.0 mmol, 1.5 equiv.) 
in dry acetonitrile (50 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 
4.5 mL, 30.0 mmol, 1.5 equiv.) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 1 h 
and at room temperature for 2 h. Water (50 mL) was added to quench the reaction. Acetonitrile 
was removed under reduced pressure (T = 24 °C, P ≥ 20 kPa). The mixture was extracted with 
diethyl ether (25 mL × 4). The combined ether layer extract was washed with water (30 mL) and 
brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure (T = 24 °C, 
P ≥ 30 kPa). The crude product was purified by silica column chromatography with hexanes / ethyl 
acetate to give product 9g as a volatile yellow liquid (2.40 g, 84% yield). Spectral data is consistent 
with Huang et al32.  
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VII. Synthesis and characterization of reference compounds  
Racemic reference compounds corresponding to enzymatic products and side-products 
were prepared according to the following procedures. Reference compounds are characterized 
below.  
 
General Procedure B: Aldol reaction and methylation synthetic sequence 
In a dry 100 or 250 mL round bottom flask, under argon, a solution of diisopropylamine 
(6–24 mmol, 1.1–1.2 equiv.) in THF (15–30 mL) was cooled to 0 °C (General Procedure B-1) 
or -78 °C (General Procedure B-2). n-Butyllithium (6–25 mmol, 1.1–1.2 equiv., 1.6 or 2.5 M in 
hexanes) was added dropwise and the resulting mixture was stirred at the appropriate temperature 
for 15-30 min. The mixture was cooled to -78 °C and kept at this temperature for the remainder of 
the reaction. Ethyl acetate (14–28 mmol, 1.4 equiv., General Procedure B-1 or 6–10 mmol, 1.0 
equiv., General Procedure B-2) was added dropwise and the mixture was stirred for an additional 
30-45 min. Then, aldehyde (10–20 mmol, 1.0 equiv., General Procedure B-1 or 9–11 mmol, 1.1–
1.5 equiv., General Procedure B-2) as a solution in THF (15–30 mL, General Procedure B-1) 
or neat (General Procedure B-2) was added slowly and the solution was stirred for a further 0.5–
3 hours. The reaction mixture was quenched at -78 °C by the addition of NH4Cl (sat. aq., 10–30 
mL) and allowed to thaw to room temperature. For General Procedure B-1 only, HCl (1 M aq., 
1.5–3.0 mL) was also added. Phases were separated and the aqueous phase was extracted with 
ethyl acetate or diethyl ether (3 × 20–30 mL). The combined organics were washed with NH4Cl 
(sat. aq., 2 × 10–15 mL), brine (10 mL), dried over Na2SO4 and concentrated under reduced 
pressure. Purification by silica column chromatography with hexanes / ethyl acetate afforded the 
desired aldol adducts in 56–95% yield.  
In the appropriate reaction vessel, aldol adduct (3–4 mmol, 1.0 equiv.), Ag2O (9–10 mmol, 
2.5–3.0 equiv.), and solvent (10–15 mL) were combined, followed by iodomethane (40–60 mmol, 
10–15 equiv., General Procedure B-1 or 9 mmol, 3.0 equiv., General Procedure B-2). The 
reaction was then stirred at the specified temperature for 24–48 hours, with additional equivalents 
of iodomethane (10–20 mmol, 2.5–5 equiv., General Procedure B-1) added as necessary. For 
General Procedure B-1, the reaction was performed in a vial equipped with a pressure release 
cap, toluene was employed as the solvent, and the reaction mixture was stirred at 70 °C. For 
General Procedure B-2, diethyl ether was employed as solvent and the reaction mixture was 
stirred at room temperature; the reaction vessel was covered in aluminum foil to protect its contents 
from light. The crude mixture was filtered through a pad of Celite and concentrated under reduced 
pressure. Purification was performed by silica column chromatography with hexanes / ethyl 
acetate; if necessary, a second purification by reverse phase chromatography was performed 
(Biotage Isolera equipped with Biotage SNAP Ultra C18 column, water / acetonitrile eluent 
system). The desired products were obtained in 25–57% yield. 
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General Procedure C: Horner-Wadsworth-Emmons reaction and Pd/C alkene reduction 
synthetic sequence  
In a dry round bottom flask, under argon, NaH (60% dispersion in mineral oil, 7.4–12 
mmol, 1.1–2.0 equiv.) in anhydrous THF (8–23 mL) was cooled to 0 °C. Triethyl 
phosphonoacetate (7.4–18 mmol, 1.1–3.0 equiv.) was added dropwise and the mixture was allowed 
to warm to room temperature and stirred for 1 hour. Ketone (5–6.7 mmol, 1.0 equiv.) in THF (2–
4 mL) was added and the reaction was stirred at room temperature for 12–18 hours (for the 
preparation of 3j and 3l) or heated to reflux (for the preparation of 3i, 3k, 8a’, and 8b’). The 
reaction was quenched with NH4Cl (sat. aq., 20 mL). Phases were separated and the aqueous layer 
was extracted with ethyl acetate (3 × 30 mL). The combined organics were washed with brine (10–
20 mL), dried over Na2SO4, and concentrated under reduced pressure. When necessary, the crude 
product was purified by silica column chromatography with hexanes / ethyl acetate to afforded the 
desired alkene compounds in 23% to quantitative yield.  
To a round bottom flask were added Pd/C (10% Pd on activated charcoal, 24–30% w/w of 
alkene), methanol (5–6 mL), and alkene (1.2–2.3 mmol). H2 was bubbled through the solution for 
~30 minutes. The reaction was stirred at room temperature under 1 atm H2 until complete reduction 
of the alkene was observed by TLC (typically 3–8 hours). The crude product was filtered through 
a pad of Celite and concentrated under reduced pressure. Purification by silica column 
chromatography with hexanes / ethyl acetate afforded the desired products in quantitative yield.  
 
Ethyl 3-methoxy-3-(4-methoxyphenyl)propanoate (3a) 
This compound was prepared from 4-methoxybenzaldehyde using General 
Procedure B-1.  1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 2H), 6.89 
(d, J = 8.8 Hz, 2H), 4.58 (dd, J = 9.0, 4.9 Hz, 1H), 4.14 (qd, J = 7.1, 1.2 Hz, 
2H), 3.81 (s, 3H), 3.19 (s, 3H), 2.80 (dd, J = 15.2, 9.0 Hz, 1H), 2.55 (dd, J = 
15.2, 4.9 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H). Spectral data are in agreement with that for the 
enzymatic product (see Section IX).   
 
Ethyl 3-methoxy-3-(p-tolyl)propanoate (3b) 
This compound was prepared from 4-methylbenzaldehyde using General 
Procedure B-1. 1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 8.0 Hz, 2H), 7.16 
(d, J = 7.9 Hz, 2H), 4.60 (dd, J = 9.2, 4.7 Hz, 1H), 4.14 (qd, J = 7.1, 1.2 Hz, 
2H), 3.21 (s, 3H), 2.79 (dd, J = 15.3, 9.2 Hz, 1H), 2.55 (dd, J = 15.3, 4.7 Hz, 
1H), 2.35 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
171.2, 137.9, 137.6, 129.4, 126.7, 80.0, 60.7, 56.9, 43.7, 21.3, 14.3. HRMS (FAB) m/z: 221.1169 
[(M + H+)–H2]; calc. for C13H17O3: 221.1178 
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Ethyl 3-(4-bromophenyl)-3-methoxypropanoate (3c) 
This compound was prepared from 4-bromobenzaldehyde using General 
Procedure B-1. 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.4 Hz, 2H), 7.22 
(d, J = 8.3 Hz, 2H), 4.59 (dd, J = 8.9, 5.0 Hz, 1H), 4.14 (qd, J = 7.1, 0.7 Hz, 
2H), 3.21 (s, 3H), 2.77 (dd, J = 15.4, 8.9 Hz, 1H), 2.53 (dd, J = 15.4, 5.0 Hz, 
1H), 1.23 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.8, 139.8, 
131.9, 128.5, 122.0, 79.6, 60.8, 57.1, 43.5, 14.3. HRMS (FAB) m/z: 287.0282 (M + H+); calc. for 
C12H1679BrO3: 287.0283 
 
Ethyl 3-methoxy-3-(4-(trifluoromethyl)phenyl)propanoate (3d) 
This compound was prepared from 4-(trifluoromethyl)benzaldehyde using 
General Procedure B-1. 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.0 Hz, 
2H), 7.46 (d, J = 8.2 Hz, 2H), 4.70 (dd, J = 8.8, 4.9 Hz, 1H), 4.15 (qd, J = 
7.2, 0.7 Hz, 2H), 3.24 (s, 3H), 2.79 (dd, J = 15.5, 8.9 Hz, 1H), 2.56 (dd, J = 
15.4, 4.9 Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H).  13C NMR (101 MHz, CDCl3) δ 
170.7, 145.0, 130.4 (q, J = 32.4 Hz), 127.1, 125.7 (q, J = 3.8 Hz), 124.2 (q, J = 272.1 Hz), 79.7, 
60.9, 57.3, 43.5, 14.3. HRMS (FAB) m/z: 277.1041 (M + H+); calc. for C13H16F3O3: 277.1052 
 
Ethyl 3-methoxy-3-(m-tolyl)propanoate (3e) 
 This compound was prepared from 3-methylbenzaldehyde using General 
Procedure B-1. 1H NMR (400 MHz, CDCl3) δ 7.27 – 7.21 (m, 1H), 7.16 – 
7.08 (m, 3H), 4.60 (dd, J = 9.2, 4.6 Hz, 1H), 4.15 (qd, J = 7.1, 1.3 Hz, 2H), 
3.22 (s, 3H), 2.79 (dd, J = 15.3, 9.3 Hz, 1H), 2.56 (dd, J = 15.3, 4.6 Hz, 1H), 
2.36 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 171.2, 140.7, 138.3, 128.9, 
128.6, 127.4, 123.8, 80.2, 60.7, 57.0, 43.7, 21.6, 14.3. HRMS (FAB) m/z: 223.1338 (M + H+); 
calc. for C13H19O3: 223.1334. 
 
Ethyl 2-(1,3-dihydroisobenzofuran-1-yl)acetate (3f) 
This compound was prepared by the method of U. S. Dakarapu et al.33. To a flame-dried 
Schlenk flask under argon was added [Ir(coe)2Cl]2 (5 mg, 0.0056 mmol, 0.11 mol%), phthalide 
(671 mg, 5 mmol, 1.0 equiv.), anhydrous dichloromethane (1.6 mL), and H2SiEt2 (1.3 mL, 10 
mmol, 2 equiv.). The reaction mixture was stirred for 14 hours at room temperature. The reaction 
mixture was concentrated under reduced pressure to afford the crude silyl acetal, which was used 
without purification.  
 In a dry round bottom flask, the crude silyl acetal (5 mmol, 1.0 equiv.) was combined with 
THF (5 mL) and the resulting mixture cooled to 0 °C. To the mixture were added triethyl 
phosphonoacetate (1.23 g, 5.5 mmol, 1.1 equiv.) and KOSiMe3 (713 mg, 5 mmol, 1.0 equiv.) in 
THF (7.5 mL). The reaction was allowed to warm to room temperature and stirred for 1.5 hours. 
The reaction was quenched with the addition of NH4Cl (sat. aq., 12 mL) and the aqueous phase 
was extracted with diethyl ether (3 × 15 mL). The combined organics were washed with brine (15 
mL), dried over Na2SO4, and concentrated under reduced pressure. Purification by silica column 
chromatography with hexanes / ethyl acetate afforded desired product 3f with impurities (667 mg, 
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3.2 mmol, 65% yield). A portion of the product was taken for a second purification by reverse 
phase chromatography (Biotage Isolera equipped with Biotage SNAP Ultra C18 column, water / 
acetonitrile eluent system).  
Spectral data are in agreement with literature report33. 1H NMR (400 MHz, 
CDCl3) δ 7.33 – 7.26 (m, 2H), 7.25 – 7.16 (m, 2H), 5.71 – 5.63 (m, 1H), 5.19 – 
5.13 (m, 1H), 5.11 – 5.04 (m, 1H), 4.20 (q, J = 7.1 Hz, 2H), 2.80 (dd, J = 15.6, 
4.9 Hz, 1H), 2.73 (dd, J = 15.6, 7.9 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 171.0, 140.8, 139.3, 128.0, 127.6, 121.3, 121.2, 80.5, 72.9, 60.8, 41.8, 14.3. 
 
Ethyl 2-(isochroman-1-yl)acetate (3g) 
This compound was prepared by the method of R. E. TenBrink et al.34. To a 100 mL dry 
round bottom flask, under argon, were added 2-phenylethanol (1.47 g, 12 mmol, 1.0 equiv.), ethyl 
3,3-diethoxypropionate (90% technical grade, 2.51 g, 13.2 mmol, 1.1 equiv.), and anhydrous 
dichloromethane (5 mL). The resulting mixture was cooled to 0 °C and TiCl4 (1 M in 
dichloromethane, 26.4 mL, 26.4 mmol, 2.2 equiv.) was added slowly. The reaction was stirred for 
2 hours at 0 °C and a second portion of ethyl 3,3-diethoxypropionate (90% technical grade, 0.12 
g, 0.6 mmol, 0.05 equiv.) was added. The reaction was stirred for an additional 2 hours at 0 °C.  
The mixture was poured into ice cold HCl (aq., 1 M, 20 mL) and the aqueous phase was extracted 
with dichloromethane (2 x 20 mL). The combined organics were washed with brine (30 mL), dried 
over Na2SO4, and concentrated under reduced pressure. Purification by silica column 
chromatography with hexanes / ethyl acetate afforded desired product 3g with minor impurities 
(2.59 g, ~11.8 mmol, ~98% yield). A portion of the product was taken for a second purification by 
reverse phase chromatography (Biotage Isolera equipped with Biotage SNAP Ultra C18 column, 
water / acetonitrile eluent system).  
Spectral data are in agreement with literature report34. 1H NMR (400 MHz, 
CDCl3) δ 7.22 – 7.15 (m, 2H), 7.15 – 7.09 (m, 1H), 7.08 – 7.02 (m, 1H), 5.25 (dd, 
J = 9.6, 3.5 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 4.13 (ddd, J = 11.4, 5.2, 4.2 Hz, 
1H), 3.82 (ddd, J = 11.4, 9.0, 3.9 Hz, 1H), 3.04 – 2.93 (m, 1H), 2.88 (dd, J = 15.2, 
3.6 Hz, 1H), 2.80 – 2.68 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 171.4, 
136.9, 134.1, 129.2, 126.8, 126.4, 124.6, 73.1, 63.2, 60.8, 41.9, 28.9, 14.3. 
 
Ethyl 3-(4-(dimethylsilyl)phenyl)-3-methoxypropanoate (3h) 
This compound was prepared from ethyl 3-(4-bromophenyl)-3-methoxypropanoate (3c). 
The following procedure was modified from the literature35.  To a 25 mL round bottom flask was 
added Mg turnings* (48 mg, 2.0 mmol, 2.0 equiv.), flame dried, and cooled under positive argon 
pressure. (*Mg turnings were prepared by washing with 0.1 M HCl, sonication, then washing with 
H2O and acetone.) THF (3 mL), LiCl (64 mg, 1.5 mmol, 1.5 equiv.), and Me2SiHCl (170 mg, 1.8 
mmol, 1.8 equiv.) were added and the resulting mixture was stirred for 30 minutes at room 
temperature under positive argon pressure. Aryl bromide 3c (287 mg, 1.0 mmol, 1.0 equiv.) was 
added dropwise via syringe and the reaction was stirred for an additional 2 hours. The crude 
reaction mixture was filtered through a pad of Celite and concentrated under reduced pressure. 
Purification by silica column chromatography with hexanes / ethyl acetate afforded desired 
O
CO2Et
O
CO2Et
 
 
 
 
48 
product 3h (145 mg, 0.54 mmol, 54% yield). 
1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 7.9 Hz, 
2H), 4.63 (dd, J = 9.3, 4.5 Hz, 1H), 4.42 (hept, J = 3.8 Hz, 1H), 4.15 (qd, J = 
7.1, 1.6 Hz, 2H), 3.23 (s, 3H), 2.79 (dd, J = 15.3, 9.3 Hz, 1H), 2.56 (dd, J = 
15.3, 4.5 Hz, 1H), 1.24 (t, J = 7.2 Hz, 3H), 0.35 (d, J = 3.8 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 171.1, 141.8, 137.4, 134.4, 126.2, 80.2, 60.7, 57.1, 43.7, 
14.3, -3.6. HRMS (FAB) m/z: 265.1253 [(M + H+)–H2]; calc. for C14H21SiO3: 265.1260. 
 
Ethyl 2-((4-(methoxymethyl)phenyl)dimethylsilyl)acetate (3h’) 
This compound was prepared by rhodium-catalyzed Si–H insertion. To a dry 50 mL round 
bottom flask, under argon, was added (4-(methoxymethyl)phenyl)dimethylsilane (1h) (541 mg, 3 
mmol, 1.0 equiv.), Rh2(OAc)4 (13.3 mg, ~1 mol%), and anhydrous dichloromethane (12 mL). The 
mixture was cooled to -78 °C, after which ethyl diazoacetate (393 mg, 3.0 mmol, 1.0 equiv.) in 
dichloromethane (3 mL) was added dropwise to the solution over 2 hours. The reaction was 
allowed to slowly warm to room temperature and stirred for a total of 12 hours. The crude reaction 
mixture was filtered through a pad of Celite and concentrated under reduced pressure. The crude 
mixture was purified by silica column chromatography using hexanes / ethyl acetate to deliver 3h’ 
with impurities. A second purification by silica column chromatography using hexanes / diethyl 
ether/ dichloromethane afforded 3h’ (92.6 mg, 0.35 mmol, 12% yield).  
1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.1 Hz, 
2H), 4.46 (s, 2H), 4.04 (q, J = 7.2 Hz, 2H), 3.39 (s, 3H), 2.11 (s, 2H), 1.16 
(t, J = 7.1 Hz, 3H), 0.40 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 172.7, 
139.7, 136.4, 133.8, 127.2, 74.6, 60.1, 58.3, 26.4, 14.5, -2.6. HRMS (FAB) 
m/z: 265.1260 [(M + H+)–H2]; calc. for C14H21SiO3: 265.1260. 
  
Ethyl 3-(4-methoxyphenyl)butanoate (3i) 
This compound was prepared from 1-(4-methoxyphenyl)ethan-1-one using 
General Procedure C. 1H NMR (500 MHz, CDCl3) δ 7.14 (d, J = 8.5 Hz, 
2H), 6.84 (d, J = 8.7 Hz, 2H), 4.08 (qd, J = 7.2, 1.2 Hz, 2H), 3.79 (s, 3H), 
3.24 (h, J = 7.1 Hz, 1H), 2.57 (dd, J = 14.9, 7.2 Hz, 1H), 2.51 (dd, J = 14.9, 
8.0 Hz, 1H), 1.28 (d, J = 7.0 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H). Spectral data are in agreement with 
that for the enzymatic product (see Section IX).   
 
Ethyl 3-(4-methoxyphenyl)pentanoate (3j) 
 This compound was prepared from 1-(4-methoxyphenyl)propan-1-one using 
General Procedure C. Spectral data are in agreement with literature report36;  
1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.8 Hz, 
2H), 4.03 (qd, J = 7.2, 1.3 Hz, 2H), 3.78 (s, 3H), 2.95 (tdd, J = 9.0, 7.0, 5.3 Hz, 
1H), 2.60 (dd, J = 15.0, 7.0 Hz, 1H), 2.51 (dd, J = 14.9, 8.3 Hz, 1H), 1.68 (ddq, J = 13.3, 7.4, 5.4 
Hz, 1H), 1.56 (ddq, J = 13.5, 9.4, 7.3 Hz, 1H), 1.14 (t, J = 7.1 Hz, 3H), 0.78 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.7, 158.2, 136.1, 128.5, 113.8, 60.3, 55.3, 43.3, 41.9, 29.4, 
14.3, 12.1. 
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Ethyl 3-(4-ethylphenyl)butanoate (3k) 
 This compound was prepared from 1-(4-ethylphenyl)ethan-1-one using 
General Procedure C. 1H NMR (400 MHz, CDCl3) δ 7.14 (app. s, 4H), 4.08 
(q, J = 7.1 Hz, 2H), 3.25 (dp, J = 8.3, 7.0 Hz, 1H), 2.66 – 2.48 (m, 4H), 1.29 
(d, J = 6.9 Hz, 3H), 1.26 – 1.15 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 
172.7, 143.1, 142.3, 128.0, 126.8, 60.4, 43.2, 36.2, 28.5, 22.0, 15.7, 14.3. HRMS (FAB) m/z: 
221.1532 (M + H+); calc. for C14H21O2: 221.1542 
 
Ethyl 3-(4-isopropylphenyl)butanoate (3l) 
This compound was prepared from 1-(4-isopropylphenyl)ethan-1-one using 
General Procedure C. 1H NMR (400 MHz, CDCl3) δ 7.15 (app. s, 4H), 4.08 
(q, J = 7.1 Hz, 2H), 3.25 (dp, J = 8.5, 6.9 Hz, 1H), 2.87 (hept, J = 6.9 Hz, 1H), 
2.60 (dd, J = 14.9, 6.7 Hz, 1H), 2.51 (dd, J = 14.9, 8.4 Hz, 1H), 1.29 (d, J = 
7.0 Hz, 3H), 1.23 (d, J = 6.9 Hz, 6H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 172.7, 147.0, 143.2, 126.8, 126.6, 60.4, 43.3, 36.2, 33.8, 24.2, 21.9, 14.3. HRMS 
(FAB) m/z: 235.1696 (M + H+); calc. for C15H23O2: 235.1698. 
 
Ethyl 3-(4-methoxyphenyl)pent-4-enoate (3m) 
This compound was accessed in a two-step sequence. First, p-methoxycinnamaldehyde 
(811 mg, 5 mmol, 1.0 equiv.) was reduced using NaBH4 (227 mg, 6 mmol, 1.2 equiv.) in methanol 
(15 mL) under standard reaction conditions (0 °C for 2 hours). The reaction mixture was quenched 
with NH4Cl (sat. aq., 10 mL) and diluted with dichloromethane (15 mL). Phases were separated 
and the aqueous layer was extracted with dichloromethane (4 × 15 mL). The combined organics 
were washed with brine (25 mL), dried over Na2SO4, and concentrated under reduced pressure. 
Purification by silica column chromatography with hexanes / ethyl acetate delivered p-
methoxycinnamyl alcohol (752 mg, 4.6 mmol, 92% yield), with spectral data that match literature 
report37.  
 Next, to a 50 mL round bottom flask equipped with short-path condenser were added p-
methoxycinnamyl alcohol (740 mg, 4.5 mmol, 1.0 equiv.), triethyl orthoacetate (7.3 g, 45 mmol, 
10 equiv.), and propionic acid (52 mg, 0.7 mmol, 0.15 equiv.). Following standard Johnson-
Claisen rearrangement conditions, this mixture was heated to 140 °C until complete conversion of 
p-methoxycinnamyl alcohol was observed by TLC (~23 hours). Additional propionic acid (2 × 52 
mg) was added after 6 hours and 9 hours reaction time. The reaction mixture was removed from 
heat, concentrated under reduced pressure, and purified using silica gel chromatography with 
hexanes / ethyl acetate as eluents. A second purification by silica gel chromatography with hexanes 
/ ether afforded 3m (357 mg, 1.6 mmol, 36% yield).  
Spectral data for 3m are in agreement with literature report38. 1H NMR (400 
MHz, CDCl3) δ 7.13 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 5.96 (ddd, 
J = 17.5, 9.9, 6.9 Hz, 1H), 5.09 – 5.05 (m, 1H), 5.03 (dt, J = 5.4, 1.3 Hz, 1H), 
4.07 (qd, J = 7.1, 1.0 Hz, 2H), 3.86 – 3.80 (m, 1H), 3.78 (s, 3H), 2.73 (dd, J 
= 15.0, 8.0 Hz, 1H), 2.65 (dd, J = 15.0, 7.6 Hz, 1H), 1.18 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.1, 158.4, 140.7, 134.6, 128.6, 114.6, 114.0, 60.5, 55.4, 44.9, 
40.6, 14.3. 
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Ethyl 2-(4-methoxybenzyl)cyclopropane-1-carboxylate (3m’) 
  This compound was prepared by rhodium-catalyzed alkene cyclopropanation. To a dry 100 
mL round bottom flask, under argon, were added 4-allylanisole (3.0 g, 20 mmol, 10 equiv.), 
Rh2(OAc)4 (8.8 mg, ~1 mol%), and anhydrous dichloromethane (10 mL). Ethyl diazoacetate (262 
mg, 2 mmol, 1.0 equiv.) in dichloromethane (10 mL) was added over ~8 hours using a syringe 
pump; the reaction mixture was allowed to stir for a total of 20 hours at room temperature. The 
reaction mixture was diluted with diethyl ether (20 mL), filtered through a pad of Celite, and 
concentrated under reduced pressure. Several rounds of purification by silica column 
chromatography with hexanes / ethyl acetate or hexanes / diethyl ether eluent systems afforded 
cis-3m’ and trans-3m’ as individual isomers (combined mass 148.1 mg, 0.632 mmol, 32% yield).  
Spectral data are in agreement with literature report39. Characterization 
data for cis-3m’: 1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 8.7 Hz, 2H), 
6.83 (d, J = 8.8 Hz, 2H), 4.13 (q, J = 7.2 Hz, 2H), 3.79 (s, 3H), 2.86 (dd, 
J = 14.9, 6.9 Hz, 1H), 2.77 (dd, J = 15.0, 7.6 Hz, 1H), 1.77 (ddd, J = 8.8, 7.6, 5.9 Hz, 1H), 1.56 – 
1.44 (m, 1H), 1.24 (t, J = 7.1 Hz, 3H), 1.14 – 1.06 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 173.1, 
158.0, 133.7, 129.3, 113.9, 60.5, 55.4, 32.1, 23.1, 18.7, 14.5, 13.7. Characterization data for trans-
3m’: 1H NMR (400 MHz, CDCl3) δ 7.12 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 4.11 (qd, J 
= 7.1, 1.1 Hz, 2H), 3.79 (s, 3H), 2.71 (dd, J = 14.7, 6.3 Hz, 1H), 2.52 (dd, J = 14.8, 7.1 Hz, 1H), 
1.65 (ddtd, J = 8.7, 7.1, 6.4, 4.1 Hz, 1H), 1.52 – 1.46 (m, 1H), 1.27 – 1.20 (m, 4H), 0.81 (ddd, J = 
8.2, 6.3, 4.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 174.4, 158.2, 132.3, 129.5, 113.9, 60.5, 55.4, 
37.6, 23.4, 20.3, 15.3, 14.4. 
 
Ethyl (E)-3-methoxydec-4-enoate (5a) 
This compound was prepared from (E)-oct-2-enal using General Procedure B-
2. 1H NMR (400 MHz, CDCl3) δ 5.69 (dt, J = 15.4, 6.8 Hz, 1H), 5.28 (ddt, J = 
15.4, 8.3, 1.5 Hz, 1H), 4.14 (qd, J = 7.2, 0.8 Hz, 2H), 3.97 (td, J = 8.2, 5.5 Hz, 
1H), 3.25 (s, 3H), 2.59 (dd, J = 14.9, 8.1 Hz, 1H), 2.42 (dd, J = 14.9, 5.5 Hz, 1H), 
2.10 – 1.97 (m, 2H), 1.43 – 1.20 (m, 9H), 0.88 (t, J = 6.9 Hz, 3H). Spectral data are in agreement 
with that for the enzymatic product (see Section IX).   
 
Ethyl (E)-3-methoxyoct-4-enoate (5b) 
This compound was prepared from (E)-hex-2-enal using General Procedure 
B-2. 1H NMR (400 MHz, CDCl3) δ 5.69 (dt, J = 15.4, 6.8 Hz, 1H), 5.29 (ddt, 
J = 15.4, 8.2, 1.5 Hz, 1H), 4.14 (qd, J = 7.1, 0.8 Hz, 2H), 3.97 (td, J = 8.1, 5.5 
Hz, 1H), 3.25 (s, 3H), 2.59 (dd, J = 14.9, 8.1 Hz, 1H), 2.42 (dd, J = 14.9, 5.6 Hz, 1H), 2.06 – 1.99 
(m, 2H), 1.40 (sext, J = 7.3 Hz, 2H), 1.25 (t, J = 7.1 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 171.2, 135.3, 128.9, 79.0, 60.6, 56.2, 41.5, 34.3, 22.4, 14.4, 13.7. HRMS 
(FAB) m/z: 199.1320 [(M + H+)–H2]; calc. for C11H19O3: 199.1334. 
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Ethyl (E)-9-bromo-3-methoxynon-4-enoate (5c) 
This compound as prepared from (E)-7-bromohept-2-enal using General 
Procedure B-2. The synthesis of (E)-7-bromohept-2-enal was described in the 
synthesis of compound 4c in Section VI. 1H NMR (400 MHz, Chloroform-d) 
δ 5.67 (dt, J = 15.4, 6.7 Hz, 1H), 5.31 (dd, J = 15.4, 8.1 Hz, 1H), 4.13 (q, J = 
7.1 Hz, 2H), 3.97 (td, J = 8.0, 5.5 Hz, 1H), 3.40 (t, J = 6.7 Hz, 2H), 3.25 (s, 3H), 2.59 (dd, J = 15.0, 
8.0 Hz, 1H), 2.41 (dd, J = 15.0, 5.6 Hz, 1H), 2.08 (q, J = 7.2 Hz, 2H), 1.91 – 1.79 (m, 2H), 1.53 
(p, J = 7.5 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 171.1, 134.3, 129.5, 
78.8, 60.6, 56.3, 41.4, 33.7, 32.2, 31.4, 27.7, 14.4. HRMS (FAB) m/z: 293.0764 (M + H+); calc. 
for C12H22O379Br : 293.0752. 
 
Ethyl (E)-5-(4-methoxyphenyl)-3-methylpent-4-enoate (5d) 
To a 6 mL vial equipped with a stir bar was added Grubbs’ catalyst 2nd generation (10 mg, 
2 mol%). The vial was then evacuated and backfilled with argon for three times. Under argon, a 
dry CH2Cl2 solution (2 mL) containing 4-vinylanisole (100 mg, 0.75 mmol) and ethyl 3-
methylpent-4-enoate (503 mg, 3.75 mmol) was added to the vial via syringe. The mixture was 
stirred at 40 °C for 24 hours and then cooled to room temperature and filtered through a silica plug. 
The solvent was removed under reduced pressure and the crude product was purified using silica 
column chromatography with hexanes / ethyl acetate to give 5d (37 mg, 20% yield). 
1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (m, 2H), 6.84 (d, J = 8.8 Hz, 
2H), 6.34 (d, J = 15.9 Hz, 1H), 5.99 (dd, J = 15.9, 7.6 Hz, 1H), 4.12 (q, J 
= 7.1 Hz, 2H), 3.80 (s, 3H), 2.90 – 2.75 (m, 1H), 2.41 (dd, J = 14.7, 7.3 
Hz, 1H), 2.34 (dd, J = 14.7, 7.3 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), 1.14 (d, 
J = 6.7 Hz, 3H). Spectral data are in agreement with that for the enzymatic product (see Section 
IX).   
 
Ethyl 3-methoxydec-4-ynoate (5e) 
This compound was prepared from oct-2-ynal using General Procedure 
B-2. 1H NMR (400 MHz, CDCl3) δ 4.39 (ddt, J = 8.3, 5.4, 2.0 Hz, 1H), 
4.16 (qd, J = 7.2, 1.0 Hz, 2H), 3.39 (s, 3H), 2.73 (dd, J = 15.5, 8.4 Hz, 
1H), 2.63 (dd, J = 15.5, 5.4 Hz, 1H), 2.20 (td, J = 7.1, 2.0 Hz, 2H), 1.50 
(p, J = 7.2 Hz, 2H), 1.41 – 1.29 (m, 4H), 1.26 (t, J = 7.1 Hz, 3H), 0.89 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 170.4, 87.3, 67.7, 60.8, 56.6, 41.7, 31.1, 28.4, 22.3, 18.8, 14.3, 14.1 
(one carbon may be overlapping with the solvent peaks). HRMS (FAB) m/z: 227.1638 (M + H+); 
calc. for C13H23O3: 227.1647. 
 
Ethyl 2-(methoxymethyl)-3-pentylcycloprop-2-ene-1-carboxylate (5e’) 
This compound was prepared by rhodium-catalyzed cyclopropenation. To a dry 50 mL 
round bottom flask was added 1-methoxyoct-2-yne (4e) (280 mg, 2.0 mmol, 1.0 equiv.), 
Rh2(OAc)4 (9.0 mg, 1 mol%), and anhydrous dichloromethane (6 mL). The mixture was cooled to 
-78 °C, after which ethyl diazoacetate (87%, 525 mg, 4.0 mmol, 2.0 equiv.) in dichloromethane (5 
mL) was added dropwise to the solution over 6 hours. The reaction was allowed to slowly warm 
to room temperature and stirred for a total of 18 hours. The reaction mixture was concentrated 
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under reduced pressure. The crude product was purified by silica column chromatography using 
hexanes / ethyl acetate, followed by C18 column using methanol / water, to afford 5e’ (26 mg, 
0.11 mmol, 6% yield). 
1H NMR (400 MHz, CDCl3) δ 4.37 (t, J = 1.6 Hz, 2H), 4.12 (q, J = 7.1 
Hz, 2H), 3.39 (s, 3H), 2.47 (tt, J = 7.5, 1.6 Hz, 2H), 2.20 (s, 1H), 1.64 – 
1.52 (m, 2H), 1.37 – 1.28 (m, 4H), 1.24 (t, J = 7.1 Hz, 3H), 0.93 – 0.86 
(m, 3H). 13C NMR (101 MHz, CDCl3) δ 176.2, 110.3, 102.5, 65.8, 60.2, 58.6, 31.5, 26.7, 24.7, 
22.7, 22.5, 14.5, 14.1. HRMS (EI) m/z: 226.1573 (M+•); calc. for C13H22O3: 226.1569. 
 
Ethyl 3-(4-(dimethylamino)phenyl)propanoate (8a’) 
This compound was prepared from 4-(dimethylamino)benzaldehyde using 
General Procedure C. 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 8.7 Hz, 
2H), 6.70 (d, J = 8.7 Hz, 2H), 4.13 (q, J = 7.2 Hz, 2H), 2.92 (s, 6H), 2.89 
– 2.82 (m, 2H), 2.61 – 2.54 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 173.4, 149.4, 129.0, 128.8, 113.1, 60.4, 41.0, 36.6, 30.2, 14.4. HRMS (EI) 
m/z: 221.1430 (M+•); calc. for C13H19NO2: 221.1416. 
 
Ethyl 3-(4-(dimethylamino)phenyl)butanoate (8b’) 
This compound was prepared from 1-(4-(dimethylamino)phenyl)ethan-1-
one using General Procedure C. Spectral data are in agreement with 
literature report40. 1H NMR (400 MHz, CDCl3) δ 7.10 (d, J = 8.7 Hz, 2H), 
6.70 (d, J = 8.7 Hz, 2H), 4.08 (qd, J = 7.1, 1.1 Hz, 2H), 3.20 (dt, J = 8.4, 6.8 
Hz, 1H), 2.92 (s, 6H), 2.57 (dd, J = 14.8, 6.8 Hz, 1H), 2.49 (dd, J = 14.8, 8.4 
Hz, 1H), 1.27 (d, J = 7.0 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.8, 
149.4, 134.0, 127.4, 113.0, 60.3, 43.5, 41.0, 35.7, 22.0, 14.4. 
 
Ethyl 3-(3,4-dihydroquinolin-1(2H)-yl)propanoate (8f’) 
To a 100-mL round-bottom flask were added 1,2,3,4-tetrahydroquinoline (266.4 mg, 2.0 
mmol, 1.0 equiv.), ethyl 3-bromopropanoate (0.97 mL, 6.0 mmol, 3.0 equiv.), K2CO3 (0.552 g, 4.0 
mmol, 2.0 equiv.), KI (66.0 mg, 0.4 mmol, 0.2 equiv.) and N,N-dimethylformamide (30 mL). The 
reaction mixture was heated at 120 °C for 4 hours. After the reaction was cooled to room 
temperature and quenched by H2O (40 mL), the crude product was extracted by diethyl ether (20 
mL × 3). The combined organic layer was washed by H2O (40 mL) and brine (40 mL), and then 
dried over sodium sulfate and concentrated under reduced pressure. The crude product was 
purified by silica column chromatography with pentane / diethyl ether, followed by C18 column 
with methanol / water, to afford 8f’ (350 mg, 1.5 mmol, 75% yield). 
This compound is known in the literature41. 1H NMR (400 MHz, CDCl3) δ 7.11 
– 7.01 (m, 1H), 6.95 (dq, J = 7.1, 1.1 Hz, 1H), 6.66 – 6.54 (m, 2H), 4.14 (q, J = 
7.1 Hz, 2H), 3.65 – 3.57 (m, 2H), 3.33 – 3.25 (m, 2H), 2.75 (t, J = 6.4 Hz, 2H), 
2.64 – 2.54 (m, 2H), 1.99 – 1.89 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 172.6, 144.6, 129.5, 127.3, 122.8, 116.2, 110.7, 60.7, 49.5, 47.4, 
31.5, 28.1, 22.3, 14.4. 
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4-Methoxy-4-(4-methoxyphenyl)butan-2-one (10d) 
 This compound was prepared according to the procedure of Yadav et al42. Briefly, a 
mixture of 4-anisaldehyde (10 mmol), 2,2-dimethoxypropane (20 mmol) and iodine (0.2 mmol) in 
dry methylene chloride (20 mmol) was stirred under N2 for 30 min. After the reaction was complete 
as indicated by TLC, the reaction mixture was diluted with water and extracted with ethyl acetate 
(2 × 30 mL). The combined organic extracts were washed with sodium thiosulfate (aq., 15% w/v) 
and brine, and then dried over sodium sulfate and concentrated under reduced pressure. The crude 
product was purified by silica column chromatography with hexanes / ethyl acetate. 
1H NMR (300 MHz, CDCl3) δ 7.25 – 7.21 (m, 2H), 6.88 (d, J = 8.8 Hz, 2H), 
4.58 (dd, J = 8.8, 4.5 Hz, 1H), 3.79 (s, 3H), 3.16 (s, 3H), 3.05 – 2.88 (m, 1H), 
2.57 (dd, J = 15.8, 4.5 Hz, 1H), 2.14 (s, 3H). Spectral data are in agreement 
with that for the enzymatic product (see Section IX).   
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VIII. Small scale enzymatic reactions and product calibration curves 
Enzymatic reactions performed on analytical scale were conducted following the general 
procedure described below, also described in Section I (H) and Section I (I). Product formation 
was quantified by HPLC or GC based on the calibration curve of the corresponding racemic 
reference compound (Section VII). TTN is defined as the amount of product divided by total heme 
protein as measured by the hemochrome assay (Section I (G)). Analysis data presented in this 
section are for results shown in Fig. 3 and Fig. 4 of the main text.  
 
General procedure for biotransformations using whole E. coli cells  
Suspensions of E. coli expressing the appropriate heme protein variant in M9-N buffer 
(OD600 = 30, for data in Section VIII) were degassed by bubbling with argon in sealed vials for at 
least 40 minutes; the cells were kept on ice during this time. Separately, a solution of D-glucose 
(250 mM in M9-N) was degassed by sparging with argon for at least 30 minutes. All solutions 
were then transferred into an anaerobic chamber for reaction set up. To a 2 mL vial were added a 
GOX oxygen depletion solution (20 µL of stock solution containing 14,000 U/mL catalase and 
1,000 U/mL glucose oxidase in 0.1 M potassium phosphate buffer, pH 8.0), D-glucose (40 µL of 
250 mM stock solution in M9-N buffer), degassed suspension of E. coli expressing heme protein 
(OD600 = 30, 320 µL), alkane substrate (10 µL of 400 mM stock solution in EtOH), and ethyl 
diazoacetate (10 µL of 400 mM stock solution in EtOH) in the listed order. Final reaction volume 
was 400 µL; final concentrations were 10 mM alkane substrate, 10 mM ethyl diazoacetate, and 25 
mM D-glucose. Note: reaction performed with E. coli cells resuspended to OD600 = 30 indicates 
that 320 µL of OD600 = 30 cells were added, and likewise for other reaction OD600 descriptions. 
The vials were sealed, removed from the anaerobic chamber, and shaken at room temperature and 
500 rpm for 18 hours. The expression of heme protein was measured using the hemochrome assay 
(Section I (G)), and the concentration of heme protein in the biotransformation was calculated 
accordingly. 
Reaction workup for quantitative HPLC analysis. The reactions were quenched by addition 
of acetonitrile (400 µL) and internal standard (10 µL of 60 mM ethyl phenoxyacetate or 40 mM 
ethyl benzoate in acetonitrile, as appropriate). This mixture was then transferred to a 
microcentrifuge tube, vortexed (10 seconds, 3 times) and centrifuged (20,000 × g, 10 minutes). 
The supernatant was taken for HPLC analysis.  
Reaction workup for quantitative GC analysis. Internal standard 1,3,5-trimethoxybenzene 
(10 µL of 40 mM stock solution in cyclohexane) was added to the reaction vial followed by mixed 
solvent (cyclohexane / ethyl acetate = 1 : 1, 800 µL). The mixture was transferred to a 1.5 mL 
microcentrifuge tube, vortexed (10 seconds, 3 times), and centrifuged (20,000 × g, 5 minutes) to 
completely separate the organic and aqueous layers. The organic layer was taken for GC analysis. 
 
HPLC calibration curve preparation 
Stock solutions of chemically synthesized products at various concentrations (1 to 200 mM 
in EtOH) were prepared. To a 2 mL vial were added 380 µL water, 20 µL product stock solution, 
10 µL internal standard (60 mM ethyl phenoxyacetate or 40 mM ethyl benzoate in acetonitrile, as 
appropriate) and 400 µL acetonitrile. The mixture was vortexed and analyzed by HPLC. Data 
points represent the average of two runs. The standard curves plot product concentration in mM 
 
 
 
 
55 
(y-axis) against the ratio of product area to internal standard area on the HPLC (x-axis). 
GC calibration curve preparation  
Stock solutions of chemically synthesized products at various concentrations (0.2 to 200 
mM in EtOH) were prepared. To a microcentrifuge tube were added 380 µL M9-N buffer, 20 µL 
product stock solution, 10 µL internal standard (40 mM 1,3,5-trimethoxybenzene in cyclohexane), 
and 800 µL mixed solvent system (cyclohexane : ethyl acetate = 1:1). The mixture was vortexed 
(10 seconds, 3 times) then centrifuged (20,000 × g, 5 min) to completely separate the organic and 
aqueous layers. The organic layer was removed for GC analysis. All data points represent the 
average of at least two runs. The standard curves plot product concentration in mM (y-axis) against 
the ratio of product area to internal standard area on the GC (x-axis).  
 
Ethyl 3-methoxy-3-(4-methoxyphenyl)propanoate (3a) 
HPLC calibration curve with ethyl phenoxyacetate as internal standard (IS), at 220 nm 
 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1a (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3a-(1) 5457.7 1066.1 5.119 4.66 2.19 2133   
3a-(2) 5469.8 1137.5 4.809 4.38 2.19 2004   
3a-(3) 5740.7 1129.0 5.085 4.63 2.07 2238   
3a-(4) 5684.8 1133.4 5.016 4.57 2.07 2208 2150 100 
Notes: Pdt = product area, IS = internal standard area, [Pdt] = product concentration in reaction, 
[PC] = protein concentration in reaction, Avg. TTN = average total turnover number, SD TTN = 
standard deviation of TTN. These notes apply for the following tables. 
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Ethyl 3-methoxy-3-(p-tolyl)propanoate (3b) 
HPLC calibration curve with ethyl phenoxyacetate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1b (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3b-(1) 2719.0 2242.6 1.212 1.61 2.19 735   
3b-(2) 2760.9 2233.2 1.236 1.64 2.19 750   
3b-(3) 3257.6 2244.6 1.451 1.92 2.07 930   
3b-(4) 3275.5 2253.5 1.454 1.93 2.07 931 840 110 
 
Ethyl 3-(4-bromophenyl)-3-methoxypropanoate (3c) 
HPLC calibration curve with ethyl phenoxyacetate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1c (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3c-(1) 2433.4 2269.5 1.072 0.87 2.19 398   
3c-(2) 2583.9 2204.0 1.172 0.95 2.19 435   
3c-(3) 2728.2 2237.2 1.219 0.99 2.07 478   
3c-(4) 2024.0 2324.4 0.871 0.71 2.07 341 410 60 
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Ethyl 3-methoxy-3-(4-(trifluoromethyl)phenyl)propanoate (3d) 
HPLC calibration curve with ethyl phenoxyacetate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1d (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3d-(1) 1689.4 2249.3 0.751 1.28 2.19 584   
3d-(2) 1691.5 2250.5 0.752 1.28 2.19 585   
3d-(3) 1858.5 2192.0 0.848 1.44 2.07 697   
3d-(4) 1848.4 2229.5 0.829 1.41 2.07 681 640 60 
 
Ethyl 3-methoxy-3-(m-tolyl)propanoate (3e) 
HPLC calibration curve with ethyl phenoxyacetate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1e (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3e-(1) 853.7 2313.9 0.369 0.68 1.84 370   
3e-(2) 832.9 2311.4 0.360 0.66 1.84 361   
3e-(3) 1083.7 2335.0 0.464 0.85 2.06 416   
3e-(4) 1102.1 2327.5 0.474 0.87 2.06 424 390 30 
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Ethyl 2-(1,3-dihydroisobenzofuran-1-yl)acetate (3f) 
HPLC calibration curve with ethyl benzoate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1f (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3f-(1) 1548.2 2209.2 0.701 1.66 1.84 906   
3f-(2) 1530.2 2212.9 0.691 1.64 1.84 894   
3f-(3) 1737.5 2216.2 0.784 1.86 2.06 906   
3f-(4) 1716.1 2212.9 0.775 1.84 2.06 896 900 10 
 
Ethyl 2-(isochroman-1-yl)acetate (3g) 
HPLC calibration curve with ethyl phenoxyacetate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1g (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3g-(1) 2681.7 2293.4 1.169 2.13 1.84 1158   
3g-(2) 2646.0 2329.7 1.136 2.07 1.84 1125   
3g-(3) 3344.6 2355.0 1.420 2.58 2.06 1257   
3g-(4) 3388.4 2318.8 1.461 2.66 2.06 1293 1210 80 
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Ethyl 3-(4-(dimethylsilyl)phenyl)-3-methoxypropanoate (3h) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1h (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3h-(1) 2327.7 772.6 3.013 1.95 1.99 978   
3h-(2) 2193.5 729.1 3.009 1.95 1.99 977   
3h-(3) 2222.0 752.2 2.954 1.91 2.21 865   
3h-(4) 2288.8 755.6 3.029 1.96 2.21 887 930 60 
 
Ethyl 2-((4-(methoxymethyl)phenyl)dimethylsilyl)acetate (3h’) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
Analysis data for formation of 3h’ promoted by E. coli with P411-CHF (whole cells, room temp.):† 
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM 
Avg. 
[Pdt]/mM 
SD 
[Pdt]/mM 
3h’-(1) 2302.5 772.6 2.980 1.93 1.99   
3h’-(2) 2154.0 729.1 2.954 1.92 1.99   
3h’-(3) 2123.4 752.2 2.823 1.83 2.21   
3h’-(4) 2165.5 755.6 2.866 1.86 2.21 1.89 0.05 
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†Entries are from the same reactions as those used for analysis of 3h. TTN is not calculated. 
 
Analysis data for formation of 3h’ promoted by E. coli with P-I263F (whole cells, room temp.): 
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM 
Avg. 
[Pdt]/mM 
SD 
[Pdt]/mM 
3h’-(5) 5975.7 826.8 7.228 4.69 2.47   
3h’-(6) 6069.1 848.6 7.152 4.64 2.47   
3h’-(7) 5927.5 842.4 7.036 4.57 2.50   
3h’-(8) 5974.8 823 7.260 4.71 2.50 4.65 0.06 
 
Analysis data for formation of 3h’ promoted by vector control E. coli (whole cells, room temp.):†  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM
# Avg. [Pdt]/mM 
SD 
[Pdt]/mM 
3h’-(9) 2939.1 847.9 3.466 2.25 0.77   
3h’-(10) 2704.2 823.7 3.283 2.13 0.77   
3h’-(11) 2933.7 865.3 3.390 2.20 0.87   
3h’-(12) 2893.1 823.2 3.514 2.28 0.87 2.22 0.07 
Notes: †Vector control reactions employ E. coli cells that express a protein which does not contain 
a transition metal cofactor (halohydrin dehalogenase, UniProt ID: Q93D82). #[PC] refers to the 
concentration of heme b measured by the hemochrome assay. Since a heme protein is not over-
expressed in these cells, this is a measurement of free hemin and/or native heme b-containing 
proteins found in the E. coli.  
 
Ethyl 3-(4-methoxyphenyl)butanoate (3i) 
HPLC calibration curve with ethyl benzoate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1i (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3i-(1) 2267.1 2277.4 0.995 1.07 2.02 527   
3i-(2) 2224.4 2284.4 0.974 1.04 2.02 515   
3i-(3) 2533.9 2294.2 1.104 1.18 2.24 528   
3i-(4) 2592.3 2297.6 1.128 1.21 2.24 540 530 10 
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Ethyl 3-(4-methoxyphenyl)pentanoate (3j) 
HPLC calibration curve with ethyl phenoxyacetate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1j (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3j-(1) 192.6 2319.1 0.083 0.09 2.02 42   
3j-(2) 200.1 2285.5 0.088 0.09 2.02 44   
3j-(3) 236.0 2277.5 0.104 0.11 2.24 48   
3j-(4) 245.6 2308.5 0.106 0.11 2.24 49 46 3 
 
Ethyl 3-(4-ethylphenyl)butanoate (3k) 
HPLC calibration curve with ethyl benzoate as internal standard (IS), at 220 nm 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1k (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3k-(1) 970.6 2320.8 0.418 0.60 1.80 331   
3k-(2) 953.2 2327.4 0.410 0.58 1.80 324   
3k-(3) 1034.1 2412.6 0.429 0.61 1.78 343   
3k-(4) 1056.0 2426.4 0.435 0.62 1.78 348 340 10 
 
 
 
 
62 
Ethyl 3-(4-isopropylphenyl)butanoate (3l) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1l (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3l-(1) 354.6 765.1 0.463 0.28 1.99 140   
3l-(2) 369.9 755.0 0.490 0.30 1.99 148   
3l-(3) 414.3 761.5 0.544 0.33 2.21 149   
3l-(4) 392.5 767.8 0.511 0.31 2.21 140 140 5 
 
Ethyl 3-(4-methoxyphenyl)pent-4-enoate (3m) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 1m (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
3m-(1) 238.1 794.4 0.300 0.20 1.99 103   
3m-(2) 252.2 797.3 0.316 0.22 1.99 108   
3m-(3) 262.0 784.7 0.334 0.23 2.21 103   
3m-(4) 254.9 753.3 0.338 0.23 2.21 105 100 3 
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Ethyl 2-(4-methoxybenzyl)cyclopropane-1-carboxylate (3m’) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
 
Analysis data for P-I263F catalyzed cyclopropanation of 1m (whole cells, room temp.):  
Pdt- 
Entries 
Pdt 
(cis) 
Pdt 
(trans) IS 
[Pdt]/
mM* 
[PC]/
µM TTN d.r.
† Avg. TTN 
SD 
TTN 
3m’-(5) 556.9 359.4 887.9 0.702 2.47 284 59:41   
3m’-(6) 424.4 281.6 847.1 0.567 2.47 230 58:42   
3m’-(7) 590.1 379.0 826.2 0.798 2.50 319 59:41   
3m’-(8) 528.7 344.7 818.2 0.726 2.50 290 59:41 280 40 
Notes: *Refers to the total concentration of cyclopropane products (cis-3m’ + trans-3m’). 
†Diastereomeric ratio (d.r.) is given as cis : trans. 
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Ethyl (E)-3-methoxydec-4-enoate (5a) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 4a (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
5a-(1) 1710.3 200.0 8.552 8.52 2.25 3789   
5a-(2) 1765.1 217.4 8.119 8.09 2.25 3597   
5a-(3) 1623.6 215.6 7.531 7.51 1.94 3879   
5a-(4) 1482.7 204.9 7.236 7.21 1.94 3727 3750 120 
 
Ethyl (E)-3-methoxyoct-4-enoate (5b) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 4b (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
5b-(1) 2065.4 812.0 2.544 1.89 1.99 949   
5b-(2) 2036.8 795.5 2.560 1.90 1.99 955   
5b-(3) 2250.2 793.6 2.835 2.11 2.21 954   
5b-(4) 2217.2 790.8 2.804 2.08 2.21 944 950 5 
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Ethyl (E)-9-bromo-3-methoxynon-4-enoate (5c) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 4c (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
5c-(1) 1071.0 179.5 5.967 4.76 1.80 2645   
5c-(2) 1062.7 178.6 5.950 4.75 1.80 2637   
5c-(3) 1142.9 175.3 6.520 5.21 1.78 2917   
5c-(4) 1140.9 180.4 6.324 5.05 1.78 2829 2760 140 
 
Ethyl 3-methoxydec-4-ynoate (5e) 
GC calibration curve with 1,3,5-trimethoxybenzene as internal standard (IS) 
 
Analysis data for P411-CHF catalyzed C–H alkylation of 4e (whole cells, room temp.):  
Pdt- 
Entries Pdt IS Pdt/IS [Pdt]/mM [PC]/µM TTN 
Avg. 
TTN 
SD 
TTN 
5e-(1) 405.4 903.5 0.449 0.33 1.80 183   
5e-(2) 370.3 856.6 0.432 0.32 1.80 176   
5e-(3) 388.3 843.5 0.460 0.34 1.78 189   
5e-(4) 407.2 828.8 0.491 0.36 1.78 202 190 10 
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IX. Enzymatic C–H alkylation reactions on preparative scale 
Preparation of E. coli cells expressing P411 variants for preparative-scale reactions  
HBamp (480 mL) in a 1 L flask was inoculated with an overnight culture (20 mL, LBamp) of 
E. coli (E. cloni BL21(DE3)) cells containing a pET22b(+) plasmid encoding the desired P411 
variant. The culture was shaken at 37 °C and 220 rpm (no humidity control) for 2.5 hours. The 
culture was placed on ice for 40 minutes, and 5-aminolevulinic acid (1.0 mM final concentration) 
and IPTG (0.5 mM final concentration) were added. The incubator temperature was reduced to 20 
°C, and the culture was allowed to shake for 16–18 hours at 130 rpm. When greater amounts of 
cells were required, additional E. coli cultures were prepared in this manner. Cells were pelleted 
by centrifugation (3,000 × g, 5 min, 4 °C), resuspended in M9-N buffer and adjusted to OD600 ≈ 
60. An aliquot of cells at OD600 ≈ 60 (3 mL) was taken for the hemochrome assay (see Section I 
(G)) to determine protein concentration. When applicable, the cell suspension was diluted with 
M9-N buffer to achieve the OD600 which was used for the reaction. Cell suspensions in M9-N 
buffer were kept on ice until use.  
 
General Procedure D:  Enzymatic C–H alkylation reactions on preparative scale  
Procedure D-I (alkane substrate is limiting reagent). To an Erlenmeyer flask equipped with 
a screw cap (reaction vessel, Chemglass CG-1543: 250 mL, 500 mL, or 1000 mL) was added a 
suspension of E. coli expressing the indicated P411 variant (generally OD600 = 30). The headspace 
of the reaction vessel was degassed with argon (at least 1 hour for volumes less than 200 mL, at 
least 2 hours for volumes greater than 200 mL) while kept on ice. To degas the headspace of a 
flask containing E. coli cells, the flask is covered with aluminum foil and a stream of argon is 
flowed through the flask just above the cell suspension. Separately, a solution of D-glucose (250 
mM in M9-N) was bubbled with argon and the headspace of a flask containing GOX oxygen 
depletion system (a solution of 14,000 U/mL catalase and 1,000 U/mL glucose oxidase, kept on 
ice) was degassed for at least 1 hour. In an anaerobic chamber, GOX, D-glucose, alkane substrate 
(1.0 equiv.), and diazo compound (1.0 equiv.) were added to the reaction vessel in this order.  The 
vessel was capped, sealed with parafilm, and shaken (150–200 rpm) at room temperature. After 
one hour, the reaction vessel was transferred again to the anaerobic chamber where a second 
portion of E. coli cells expressing the P411 variant (the headspace of the flask containing these 
cells was degassed with argon following same procedure) and additional diazo compound (1.0 
equiv.) were added. The vessel was capped, sealed with parafilm, and shaken (150–200 rpm) at 
room temperature for 14–17 additional hours. Final conditions were E. coli expressing P411 
variant, alkane substrate (0.2–0.5 mmol, 1.0 equiv., larger scales for 3a, 5a, and 8f, see Section 
X), diazo compound (2.0 equiv.), D-glucose (25 mM), GOX oxygen depletion system (700 U/mL 
catalase, 50 U/mL glucose oxidase), 2 vol% EtOH in M9-N buffer under anaerobic conditions; 
total reaction time 15–18 hours.  
Procedure D-II (diazo compound is limiting reagent). To an Erlenmeyer flask equipped with 
a screw cap (reaction vessel, Chemglass CG-1543: 250 mL, 500 mL, or 1000 mL) was added a 
suspension of E. coli expressing the indicated P411 variant. The headspace of the reaction vessel 
was degassed with argon (at least 1 hour) while kept on ice. To degas the headspace of a flask 
containing E. coli cells, the flask is covered with aluminum foil and a stream of argon is flowed 
through the flask just above the cell suspension. Separately, a solution of D-glucose (250 mM in 
M9-N) was bubbled with argon. In an anaerobic chamber, D-glucose, alkane substrate (2.0 equiv.), 
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and diazo compound (1.0 equiv.) were added to the reaction vessel in this order.  The vessel was 
capped, sealed with parafilm, and shaken (150–200 rpm) at room temperature. Final conditions 
were E. coli expressing P411 variant, alkane substrate (1.0 mmol, 2.0 equiv.), diazo compound 
(0.5 mmol, 1.0 equiv.), D-glucose (25 mM), 2 vol% EtOH in M9-N buffer under anaerobic 
conditions; total reaction time 15–18 hours.  
Workup Procedure D-i. Every 35 mL portion of the preparative scale reaction mixture was 
transferred to a 50 mL Eppendorf conical tube (catalog no. 0030122178). To the reaction mixture 
in every tube was added 15 mL mixed organic solvent (1 : 1 hexanes : ethyl acetate); the solution 
was shaken vigorously and centrifuged (10,000 × g, 5 minutes, Beckman-Coulter Avanti J-25 
centrifuge equipped with JA-12 rotor) to separate the organic and aqueous layers. The organic 
layer was collected and the aqueous layer was subject to three additional rounds of extraction. The 
organic layers were combined, dried over Na2SO4, and concentrated under reduced pressure. 
Purification was performed by silica column chromatography with either hexanes / ethyl acetate 
or hexanes / dichloromethane / diethyl ether as eluent systems to afford the desired product. 
Additional purification by reverse phase chromatography (Biotage Isolera equipped with Biotage 
SNAP Ultra C18 column, water / methanol eluent system) was utilized if necessary. TTNs were 
calculated based on measured protein concentration and the isolated yield of the product. 
Workup Procedure D-ii. Every ~100–125 mL portion of preparative scale reaction mixture 
was transferred to a centrifuge bottle. To the reaction mixture in every bottle was added equal 
volume ethyl acetate; the solution was shaken vigorously and centrifuged (14,000 × g, 10 minutes, 
Beckman-Coulter Avanti J-25 centrifuge equipped with JA-10 rotor) to separate the organic and 
aqueous layers. The organic layer was collected and the aqueous layer was subject to three 
additional rounds of extraction. The combined organics were dried over Na2SO4, and concentrated 
under reduced pressure. Purification was performed by silica column chromatography with either 
hexanes / ethyl acetate or hexanes / dichloromethane / diethyl ether as eluent systems to afford the 
desired product. Additional purification by reverse phase chromatography (Biotage Isolera 
equipped with Biotage SNAP Ultra C18 column, water / methanol eluent system) was utilized if 
necessary. TTNs were calculated based on measured protein concentration and the isolated yield 
of the product. 
 
Ethyl 3-methoxy-3-(4-methoxyphenyl)propanoate (3a) 
This compound was prepared using a modified version of General Procedure D-I carried 
out at 4 °C. The reaction mixture was kept on ice during the addition of all reagents and shaken in 
an incubator set to 4 °C and 150 rpm. In addition, a solution of Na2S2O4 (5 mL, 40 mM in M9-N, 
bubbled with argon for 1 hour) was added following the second addition of E. coli cells expressing 
P411-CHF. Final conditions were E. coli expressing P411-CHF (resuspended to OD600 = 44), 
alkane substrate (1.0 mmol, 1.0 equiv.), ethyl diazoacetate (2.0 mmol, 2.0 equiv.), D-glucose (25 
mM), GOX oxygen depletion system (700 U/mL catalase, 50 U/mL glucose oxidase), Na2S2O4 (1 
mM), 2 vol% EtOH in M9-N buffer under anaerobic conditions at 4 °C; total reaction time 18 
hours.  
The reaction was quenched with the addition of 100 mL acetonitrile. The crude reaction 
mixture was transferred to a centrifuge tube, shaken vigorously, and centrifuged to pellet the cells 
(14,000 × g, 10 minutes). The supernatant was decanted and the acetonitrile was removed under 
reduced pressure. Following, the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The 
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cell pellet was resuspended in H2O and this suspension was also extracted using ethyl acetate (3 × 
20 mL; centrifugation (3,000 × g, 5 min) was used to help separate the organic and aqueous layers. 
The combined organics were dried over Na2SO4 and concentrated under reduced pressure. 
Purification by reverse phase preparative HPLC (column: Eclipse XDB-C8, 5 um, 9.4 × 250 mm) 
using water / acetonitrile eluent system afforded 3a.  
E. coli suspension in M9-N  
(variant: P411-CHF, OD600 = 44, 4 °C) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
110.0 51.0* 4.77 0.768 10.0 20.0 
Alkane substrate (1a) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.50 2.0 1.0 1.0 1.0; 1.0 2.0 
Purification eluent Product 
1: water / MeCN (reverse phase 
preparative HPLC) 
 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
194.7 0.817 82% 1060 
*A solution of Na2S2O4 (5 mL, 40 mM in M9-N, bubbled with argon for 1 hour) was added 
following the second addition of E. coli cells expressing P411-CHF. Final concentration of 
Na2S2O4 in the reaction is 1 mM. 
Notes: [PC] = protein concentration in original cell suspension, n_pro = amount of protein in the 
reaction, n_1 = amount of alkane substrate in the reaction, n_2 = total amount of diazo compound 
in the reaction, add. = addition, m[Pdt] = mass of product isolated, n[Pdt] = amount of product. a 
GOX oxygen depletion system is 14,000 U/mL catalase and 1,000 U/ mL glucose oxidase in 0.1 
M potassium phosphate buffer (pH=8.0); the final reaction mixture contains 700 U/mL catalase 
and 50 U/mL glucose oxidase. bD-glucose stock solution is 250 mM in M9-N buffer; final 
concentration of D-glucose in the reaction is 25 mM. These notes apply for all tables in this section. 
 
 1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.8 Hz, 
2H), 4.58 (dd, J = 9.0, 4.9 Hz, 1H), 4.14 (qd, J = 7.1, 1.2 Hz, 2H), 3.81 (s, 
3H), 3.19 (s, 3H), 2.80 (dd, J = 15.2, 9.0 Hz, 1H), 2.55 (dd, J = 15.2, 4.9 Hz, 
1H), 1.23 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 171.2, 159.5, 
132.7, 128.0, 114.0, 79.7, 60.7, 56.7, 55.4, 43.7, 14.3. HRMS (EI) m/z: 238.1213 (M+˙); calc. for 
C13H18O4: 238.1205. [α]23D = –46.354 ± 0.411° (c 0.5, CHCl3). SFC Chiralpak AD-H column 
(3% i-PrOH in supercritical CO2, 2.5 mL/min, 40 °C), tr = 9.02 min (major), 10.50 min (minor), 
98.0 : 2.0 e.r. 
  
OMe
MeO
CO2Et
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Ethyl 3-(4-methoxyphenyl)butanoate (3i) 
This compound was prepared using General Procedure D-I and Workup Procedure D-i.  
E. coli suspension in M9-N  
(variant: P411-CHF, OD600 = 29) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
110.0 56.0 2.25 0.374 10.0 20.0 
Alkane substrate (1i) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.10 2.0 0.2 0.20 1.0; 1.0 0.4 
Purification eluent Product 
1: Hex / EtOAc (normal phase) 
2: water / MeOH  
(reverse phase) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
21.3 0.096 48% 260 
 
Spectral data is in agreement with literature report40. 1H NMR (500 MHz, 
CDCl3) δ 7.14 (d, J = 8.5 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 4.08 (qd, J = 7.2, 
1.2 Hz, 2H), 3.79 (s, 3H), 3.24 (h, J = 7.1 Hz, 1H), 2.57 (dd, J = 14.9, 7.2 Hz, 
1H), 2.51 (dd, J = 14.9, 8.0 Hz, 1H), 1.28 (d, J = 7.0 Hz, 3H), 1.19 (t, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.6, 158.2, 138.0, 127.8, 113.9, 60.4, 55.4, 43.4, 35.9, 
22.1, 14.3. [α]23D = +26.334 ± 0.676° (c 0.5, CHCl3). SFC Chiralcel OB-H column (supercritical 
CO2, 2.5 mL/min, 40 °C), tr = 5.50 min (minor), 6.24 min (major), 97.9 : 2.1 e.r. 
 
Ethyl (E)-5-(4-methoxyphenyl)-3-methylpent-4-enoate (5d) 
This compound was prepared using General Procedure D-I and Workup Procedure D-ii.  
E. coli suspension in M9-N 
(variant: P411-CHF, OD600 = 32) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
137.5 70.0 2.59 0.536 12.5 25.0 
Alkane substrate (4d) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.10 2.5 0.25 0.20 1.25; 1.25 0.50 
Purification eluent Product 
Hex / (4 : 1 DCM : Et2O) (normal 
phase) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
9.7 0.039 15.6% 70 
 
  
Me
MeO
CO2Et
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1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (m, 2H), 6.84 (d, J = 8.8 Hz, 
2H), 6.34 (d, J = 15.9 Hz, 1H), 5.99 (dd, J = 15.9, 7.6 Hz, 1H), 4.12 (q, J 
= 7.1 Hz, 2H), 3.80 (s, 3H), 2.90 – 2.75 (m, 1H), 2.41 (dd, J = 14.7, 7.3 
Hz, 1H), 2.34 (dd, J = 14.7, 7.3 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), 1.14 (d, 
J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.6, 159.0, 132.3, 130.4, 128.3, 127.3, 114.0, 
60.4, 55.4, 42.1, 34.3, 20.5, 14.5. HRMS (FAB) m/z: 248.1417 (M+˙); calc. for C15H20O3: 
248.1413.  SFC Chiralcel OB-H column (3% i-PrOH in supercritical CO2, 2.5 mL/min, 40 °C), 
tr = 6.62 min (minor), 7.66 min (major), 97.0 : 3.0 e.r. 
 
Ethyl 3-(methyl(p-tolyl)amino)propanoate (8a) 
This compound was prepared using General Procedure D-I and Workup Procedure D-i.  
E. coli suspension in M9-N 
(variant: P411-CHF, OD600 = 29) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
55.0 28.0 2.13 0.177 5.0 10.0 
Alkane substrate (7a) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.50 1.0 0.50 1.00 0.50; 0.50 1.0 
Purification eluent Product 
1: Hex / EtOAc (normal phase) m[Pdt]/mg n[Pdt]/mmol yield TTN 91.2 0.412 82% 2330 
 
Spectral data is in agreement with literature report43. 1H NMR (400 MHz, 
CDCl3) δ 7.05 (d, J = 8.3 Hz, 2H), 6.67 (d, J = 8.6 Hz, 2H), 4.12 (q, J = 
7.1 Hz, 2H), 3.64 (t, J = 7.2 Hz, 2H), 2.90 (s, 3H), 2.54 (t, J = 7.2 Hz, 2H), 
2.25 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
172.6, 146.8, 129.9, 126.3, 113.1, 60.7, 49.1, 38.5, 31.8, 20.4, 14.3. 
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Ethyl 3-((4-ethylphenyl)(methyl)amino)propanoate (8b) 
This compound was prepared using General Procedure D-I and Workup Procedure D-ii.  
E. coli suspension in M9-N 
(variant: P411-CHF, OD600 = 30) 
GOX 
solutiona 
D-glucose 
in M9-Na 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
55.0 28.0 2.02 0.168 5.0 10.0 
Alkane substrate (7b) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.50 1.0 0.50 1.00 0.50; 0.50 1.0 
Purification eluent Product 
1: Hex / (4 : 1 DCM : Et2O) 
(normal phase) 
2: water / MeOH 
(reverse phase) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
88.0 0.374 75% 2230 
 
1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 8.7 Hz, 2H), 6.69 (d, J = 8.8 
Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 3.65 (t, J = 7.2 Hz, 2H), 2.91 (s, 3H), 
2.60 – 2.51 (m, 4H), 1.25 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.6, 146.9, 132.8, 128.7, 113.0, 60.7, 
49.1, 38.5, 31.9, 27.9, 16.1, 14.3. HRMS (ESI-TOF) m/z: 236.1673 (M + H+); calc. for 
C14H22NO2: 236.1651.  
 
Ethyl 2-(1-phenylpyrrolidin-2-yl)acetate (8c) 
This compound was prepared using General Procedure D-I and Workup Procedure D-ii.  
E. coli suspension in M9-N  
(variant: P411-CHF, OD600 = 31) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
55.0 28.0 2.65 0.220 5.0 10.0 
Alkane substrate (7c) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.50 1.0 0.50 1.00 0.50; 0.50 1.0 
Purification eluent Product 
1: Hex / (4 : 1 DCM : Et2O) 
(normal phase) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
104.1 0.446 89% 2030 
 
  
N
Me
Me
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1H NMR (400 MHz, CDCl3) δ 7.29 – 7.20 (m, 2H), 6.69 (tt, J = 7.2, 1.1 Hz, 1H), 
6.62 (d, J = 7.9 Hz, 2H), 4.21 – 4.14 (m, 3H), 3.48 – 3.37 (m, 1H), 3.23 – 3.14 
(m, 1H), 2.79 (dd, J = 15.0, 2.9 Hz, 1H), 2.22 (dd, J = 15.0, 10.5 Hz, 1H), 2.12 – 
1.98 (m, 3H), 1.97 – 1.82 (m, 1H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 172.2, 146.6, 129.5, 116.0, 112.0, 60.6, 55.5, 48.0, 37.8, 31.1, 23.1, 
14.4. HRMS (ESI-TOF) m/z: 234.1491 (M + H+); calc. for C14H20NO2: 234.1494. [α]23D = +2.056 
± 0.834° (c 0.5, CHCl3). HPLC Chiralcel OD-H column (6% i-PrOH in n-hexane, 1.0 mL/min, 
room temperature), tr = 6.20 min (minor), 8.58 min (major), 82.8 : 17.2 e.r. 
 
Ethyl 2-(1-(4-methoxyphenyl)pyrrolidin-2-yl)acetate (8d) 
This compound was prepared using General Procedure D-I and Workup Procedure D-i.  
E. coli suspension in M9-N 
(variant: P411-CHF, OD600 = 31) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
55.0 28.0 2.17 0.180 5.0 10.0 
Alkane substrate (7d) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.50 1.0 0.50 1.0 0.50; 0.50 1.0 
Purification eluent Product 
1: Hex / EtOAc (normal phase) 
2: water / MeOH  
(reverse phase) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
102.1 0.388 78% 2150 
 
1H NMR (400 MHz, CDCl3) δ 6.86 (d, J = 9.1 Hz, 2H), 6.58 (d, J = 9.1 Hz, 2H), 
4.16 (q, J = 7.2 Hz, 2H), 4.13 – 4.05 (m, 1H), 3.76 (s, 3H), 3.42 – 3.35 (m, 1H), 
3.17 – 3.09 (m, 1H), 2.76 (dd, J = 14.9, 3.0 Hz, 1H), 2.20 (dd, J = 14.9, 10.4 Hz, 
1H), 2.13 – 1.96 (m, 3H), 1.92 – 1.82 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H).  13C 
NMR (101 MHz, CDCl3) δ 172.3, 151.1, 141.5, 115.3, 112.9, 60.6, 56.1, 56.0, 
48.6, 38.1, 31.1, 23.3, 14.4. HRMS (FAB) m/z: 263.1518 (M+˙); calc. for 
C15H21NO3: 263.1521. [α]23D = +7.310 ± 0.478° (c 0.5, CHCl3). HPLC Chiralcel OD-H column 
(6% i-PrOH in n-hexane, 1.0 mL/min, room temperature), tr = 7.25 min (minor), 8.12 min (major), 
83.7 : 16.3 e.r. 
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Ethyl 2-(1-(3-chlorophenyl)pyrrolidin-2-yl)acetate (8e) 
This compound was prepared using General Procedure D-I and Workup Procedure D-i.  
E. coli suspension in M9-N 
(variant: P411-CHF, OD600 = 29) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
137.5 70.0 3.24 0.673 12.5 25.0 
Alkane substrate (7e) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.20 2.5 0.50 0.40 1.25; 1.25 1.0 
Purification eluent Product 
1: Hex / EtOAc (normal phase) 
2: water / MeOH  
(reverse phase) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
89.6 0.335 67% 500 
 
1H NMR (500 MHz, CDCl3) δ 7.13 (t, J = 8.1 Hz, 1H), 6.65 (dd, J = 7.9, 1.8 Hz, 
1H), 6.57 (t, J = 2.2 Hz, 1H), 6.48 (dd, J = 8.3, 2.3 Hz, 1H), 4.23 – 4.12 (m, 3H), 
3.44 – 3.36 (m, 1H), 3.22 – 3.12 (m, 1H), 2.74 (dd, J = 15.1, 3.0 Hz, 1H), 2.23 
(dd, J = 15.1, 10.4 Hz, 1H), 2.13 – 2.01 (m, 3H), 1.97 – 1.85 (m, 1H), 1.30 (t, J 
= 7.1 Hz, 3H).  13C NMR (126 MHz, CDCl3) δ 171.9, 147.6, 135.3, 130.4, 115.9, 
111.9, 110.2, 60.7, 55.5, 48.1, 37.7, 31.1, 23.0, 14.4. HRMS (ESI-TOF) m/z: 268.1094 (M + H+); 
calc. for C14H19NO235Cl: 268.1104. [α]23D = +7.144 ± 0.875° (c 0.5, CHCl3). HPLC Chiralcel 
OD-H column (6% i-PrOH in n-hexane, 1.0 mL/min, room temperature), tr = 6.29 min (minor), 
6.87 min (major), 90.3 : 9.7 e.r. 
 
(–)-Ethyl (R)-2-(1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)acetate ((–)-8f) 
This compound was prepared using General Procedure D-I and Workup Procedure D-i.  
E. coli suspension in M9-N  
(variant: P411-CHF, OD600 = 31) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
55.0 28.0 2.40 0.199 5.0 10.0 
Alkane substrate (7f) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.50 1.0 0.50 1.00 0.50; 0.50 1.0 
Purification eluent Product 
1: Hex / (4 : 1 DCM : Et2O) 
(normal phase) 
2: water / acetonitrile (reverse 
phase preparative HPLC) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
48.9c 0.210 42% 1050d 
c Regiomeric ratio 9 : 1 for 8f : 8f’ determined by 1H NMR. 
d Reported for the sum of regioisomers 8f and 8f’. 
N
CO2Et
Cl
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1H NMR (400 MHz, CDCl3) δ 7.14 – 7.02 (m, 1H, both 
isomers), 6.99 (d, J = 7.3 Hz, 0.9H, isomer 8f), 6.97 – 6.93 
(m, 0.1H, isomer 8f’), 6.68 – 6.51 (m, 2H, both isomers), 
4.15 (q, J = 7.1 Hz, 2H, both isomers), 3.86 – 3.78 (m, 0.9H, 
isomer 8f), 3.65 – 3.57 (m, 0.2H, isomer 8f’), 3.32 – 3.25 
(m, 0.2H, isomer 8f’), 2.93 (s, 2.7H, isomer 8f), 2.91 – 2.79 (m, 0.9H, isomer 8f), 2.77 – 2.67 (m, 
1.1H, both isomers), 2.65 – 2.54 (m, 1.1H, both isomers), 2.39 (dd, J = 14.7, 8.6 Hz, 0.9H, isomer 
8f), 2.08 – 1.84 (m, 2H, both isomers), 1.30 – 1.24 (m, 3H, both isomers). 13C NMR (101 MHz, 
CDCl3) δ 172.6, 172.3, 144.8, 144.6, 129.5, 129.0, 127.3, 127.3, 122.8, 121.6, 116.2, 116.2, 111.0, 
110.7, 60.7, 60.7, 56.1, 49.6, 47.3, 37.8, 36.7, 31.5, 28.2, 25.5, 23.3, 22.3, 14.4. With variant P411-
CHF: [α]23D =  –2.980 ± 0.898° (c 1.0, CHCl3). With variant P411-CHF: SFC Chiralcel OB-H 
column (3% i-PrOH supercritical CO2, 2.5 mL/min, 40 °C), tr = 6.47 min (major), 7.38 min 
(minor), 73.0 : 27.0 e.r. 
 
Benzyl 3-(methyl(p-tolyl)amino)propanoate (10a) 
This compound was prepared using General Procedure D-I and Workup Procedure D-i.  
E. coli suspension in M9-N  
(variant: P411-CHF, OD600 = 30) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
55.0 28.0 2.04 0.170 5.0 10.0 
Alkane substrate (7a) stock in EtOH Diazo (9a) stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.50 1.0 0.50 1.00 0.50; 0.50 1.0 
Purification eluent Product 
1: Hex / EtOAc (normal phase) m[Pdt]/mg n[Pdt]/mmol yield TTN 19.0c 0.061d 12%d 360d 
c Isolated with 10% diazo dimer.  
d Corrected for diazo dimer.  
 
This compound is known in the literature.44 1H NMR (400 MHz, CDCl3) 
δ 7.39 – 7.31 (m, 5H), 7.04 (d, J = 8.7 Hz, 2H), 6.66 (d, J = 8.8 Hz, 2H), 
5.11 (s, 2H), 3.66 (t, J = 7.2 Hz, 2H), 2.87 (s, 3H), 2.61 (t, J = 7.2 Hz, 2H), 
2.25 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 172.4, 146.7, 135.9, 133.9, 
129.9, 128.7, 128.4, 126.3, 113.2, 66.5, 49.1, 38.5, 31.8, 20.4. HRMS 
(ESI-TOF) m/z: 284.1635 (M + H+); calc. for C18H22NO2: 284.1651. 
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3-((Methyl(p-tolyl)amino)methyl)dihydrofuran-2(3H)-one (10b) 
This compound was prepared using General Procedure D-II and Workup Procedure D-i.  
E. coli suspension in M9-N  
(variant: P411-IY (T327I), OD600 = 55) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Volume/ mL [PC]/µM n_pro/µmol volume/mL volume/mL 
88.0 6.77 0.595 0.0 10.0 
Alkane substrate (7a) stock in EtOH Diazo (9b) stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
1.0 1.0 1.0 0.50 1.0 0.50 
Purification eluent Product 
1: Hex / EtOAc (normal phase) m[Pdt]/mg n[Pdt]/mmol yield TTN 37.2 0.170 34% 280 
 
1H NMR (400 MHz, CDCl3) δ 7.07 (d, J = 8.3 Hz, 2H), 6.68 (d, J = 8.6 Hz, 
2H), 4.35 (td, J = 8.8, 2.6 Hz, 1H), 4.15 (ddd, J = 10.0, 9.1, 6.6 Hz, 1H), 3.94 
(dd, J = 15.1, 4.5 Hz, 1H), 3.43 (dd, J = 15.1, 8.0 Hz, 1H), 2.96 (s, 3H), 2.91 
(dddd, J = 10.6, 8.6, 8.0, 4.5 Hz, 1H), 2.34 (dddd, J = 12.7, 8.9, 6.6, 2.6 Hz, 
1H), 2.26 (s, 3H), 2.11 (dtd, J = 12.8, 10.2, 8.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 178.5, 
146.8, 130.0, 126.7, 113.1, 66.7, 53.3, 39.6, 38.7, 28.1, 20.4. HRMS (FAB) m/z: 218.1172 ([(M 
+ H+)–H2); calc. for C13H16NO2: 218.1181. With variant P411-IY T327I: HPLC Chiralcel OD-H 
column (6% i-PrOH in n-hexane, 1.0 mL/min, 32 °C), tr = 22.826 min (major), 24.286 min 
(minor), 78.0 : 22.0 e.r. 
 
N-Methoxy-N-methyl-3-(methyl(p-tolyl)amino)propanamide (10c) 
This compound was prepared using General Procedure D-II and Workup Procedure D-i.  
E. coli suspension in M9-N  
(variant: P411-IY (T327I), OD600 = 55) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Volume/ mL [PC]/µM n_pro/µmol volume/mL volume/mL 
88.0 7.00 0.616 0.0 10.0 
Alkane substrate (7a) stock in EtOH Diazo (9c) stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
1.0 1.0 1.0 0.50 1.0 0.50 
Purification eluent Product 
1: Hex / EtOAc (normal phase) m[Pdt]/mg n[Pdt]/mmol yield TTN 72.3 0.306 61% 500 
 
1H NMR (400 MHz, CDCl3) δ 7.04 (d, J = 8.2 Hz, 2H), 6.68 (d, J = 8.7 
Hz, 2H), 3.70 – 3.64 (m, 2H), 3.62 (s, 3H), 3.17 (s, 3H), 2.92 (s, 3H), 
2.66 (t, J = 7.2 Hz, 2H), 2.25 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
173.2, 146.8, 129.9, 125.9, 112.8, 61.5, 48.8, 38.6, 32.2, 29.0, 20.4. 
HRMS (ESI-TOF) m/z: 237.1616 (M + H+); calc. for C13H21N2O2: 237.1603. 
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4-Methoxy-4-(4-methoxyphenyl)butan-2-one (10d) 
This compound was prepared using General Procedure D-II and Workup Procedure D-i. 
E. coli suspension in M9-N  
(variant: P411-CHF, OD600 = 60) c 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Volume/ mL [PC]/µM n_pro/µmol volume/mL volume/mL 
88.0 8.17 0.719 0.0 10.0 
Alkane substrate (1a) stock in EtOH Diazo (9d) stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
1.0 1.0 1.0 0.50 1.0 0.50 
Purification eluent Product 
1: Hex / EtOAc (normal phase) m[Pdt]/mg n[Pdt]/mmol yield TTN 21.8 0.105 21% 150 
c Enzyme was expressed using a modified procedure. After addition of 5-aminolevulinic acid (1.0 
mM final concentration) and IPTG (0.5 mM final concentration), the incubator temperature was 
set to 24 °C, and the culture was allowed to shake for 20 hours at 140 rpm. Product formation was 
also observed when cultures were expressed following the typical protocol. 
 
 1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 
2H), 4.58 (dd, J = 8.8, 4.5 Hz, 1H), 3.81 (s, 3H), 3.17 (s, 3H), 2.97 (dd, J = 
15.8, 8.8 Hz, 1H), 2.58 (dd, J = 15.8, 4.5 Hz, 1H), 2.15 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 206.9, 159.4, 133.0, 127.9, 114.1, 79.3, 56.6, 55.4, 52.0, 31.2. 
HRMS (ESI-TOF) m/z: 231.0999 (M + Na+); calc. for C12H16O3Na: 231.0997. 
HPLC Chiralcel OJ-H column (6% i-PrOH in n-hexane, 1.0 mL/min, 28 °C), tr = 20.152 min 
(major), 21.760 min (minor), 71.0 : 29.0 e.r. 
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X. Syntheses of (+)-lyngbic acid and (+)-cuspareine 
 Experimental details for the formal synthesis of (R)-(+)-lyngbic acid and the total synthesis 
of (R)-(+)-cuspareine can be found below. Enzymatic C–H alkylation is the key stereo-defining 
step in the routes to both molecules.  
 
Supplementary Fig. 14. Detailed scheme for the formal synthesis of (+)-lyngbic acid. 
 
(+)-Ethyl (E)-3-methoxydec-4-enoate ((+)-5a) 
Prepared following General Procedure D-I and Workup Procedure D-ii (see Section IX).  
E. coli suspension in M9-N  
(variant: P411-CHF, OD600 = 29) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
220.0 112.0 2.21 0.734 20.0 40.0 
Alkane substrate (4a) stock in EtOH Ethyl diazoacetate (2) stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.60 4.0 2.4 1.2 2.0; 2.0 4.8 
Purification eluent Product 
1: Hex / (4 : 1 DCM : Et2O) 
(normal phase) 
2: water / MeOH 
(reverse phase) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
470.6 2.061 86% 2810 
Notes: [PC] = protein concentration in original cell suspension, n_pro = amount of protein in the 
reaction, n_1 = amount of alkane substrate in the reaction, n_2 = total amount of diazo compound 
in the reaction, add. = addition, m[Pdt] = mass of product isolated, n[Pdt] = amount of product. a 
GOX oxygen depletion system is 14,000 U/mL catalase and 1,000 U/ mL glucose oxidase in 0.1 
M potassium phosphate buffer (pH=8.0); the final reaction mixture contains 700 U/mL catalase 
and 50 U/mL glucose oxidase. bD-glucose stock solution is 250 mM; final concentration of D-
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glucose in the reaction is 25 mM. These notes apply for all tables in this section.  
1H NMR (400 MHz, CDCl3) δ 5.69 (dt, J = 15.4, 6.8 Hz, 1H), 5.28 (ddt, J = 
15.4, 8.3, 1.5 Hz, 1H), 4.14 (qd, J = 7.2, 0.8 Hz, 2H), 3.97 (td, J = 8.2, 5.5 Hz, 
1H), 3.25 (s, 3H), 2.59 (dd, J = 14.9, 8.1 Hz, 1H), 2.42 (dd, J = 14.9, 5.5 Hz, 
1H), 2.10 – 1.97 (m, 2H), 1.43 – 1.20 (m, 9H), 0.88 (t, J = 6.9 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 171.2, 135.6, 128.7, 79.0, 60.6, 56.2, 41.5, 32.3, 31.5, 28.9, 22.6, 14.4, 
14.2. HRMS (EI) m/z: 228.1717 (M+˙); calc. for C13H24O3: 228.1726.  [α]23D = +7.504 ± 0.733° 
(c 0.5, CHCl3). GC CycloSil–B column (110 °C), tr = 53.72 min (minor), 55.35 min (major), 94.7 
: 5.3 e.r. Absolute stereochemistry was assigned after elaboration to (+)-6. 
 
(+)-Ethyl 3-methoxydecanoate ((+)-6s) 
To a solution of (+)-ethyl (E)-3-methoxydec-4-enoate ((+)-5a, 114.2 mg, 0.5 mmol, 1.0 
equiv.) in MeOH (5 mL) was added Pd/C (10% Pd on activated charcoal, 13.3 mg, 2.5 mol%). H2 
was bubbled through the solution for ~30 minutes. The reaction was stirred at room temperature 
under 1 atm H2 for 16 hours. The crude product was filtered through a pad of Celite and 
concentrated under reduced pressure. Purification by silica column chromatography with hexanes 
/ ethyl acetate afforded (+)-6s (116.9 mg, 0.5 mmol, quantitative yield). 
1H NMR (400 MHz, CDCl3) δ 4.15 (q, J = 7.1 Hz, 2H), 3.63 (ddt, J = 7.3, 6.3, 
5.5 Hz, 1H), 3.35 (s, 3H), 2.52 (dd, J = 15.0, 7.3 Hz, 1H), 2.39 (dd, J = 15.0, 5.4 
Hz, 1H), 1.57 – 1.41 (m, 2H), 1.40 – 1.20 (m, 13H), 0.88 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 172.0, 78.0, 60.5, 57.1, 39.7, 34.1, 31.9, 29.8, 29.4, 
25.2, 22.8, 14.4, 14.2. HRMS (FAB) m/z: 231.1965 (M + H+); calc. for C13H27O3: 231.1960. [α]23D 
= +4.293 ± 0.136° (c 1.0, MeOH). Absolute stereochemistry was assigned after derivatization to 
(+)-6. 
 
(+)-3-Methoxydecanoic acid ((+)-6) 
To a solution of (+)-ethyl 3-methoxydecanoate ((+)-6s, 46.1 mg, 0.2 mmol, 1.0 equiv.) in 
MeOH (2 mL) was added NaOH (aq., 15%, 2 mL). The reaction mixture was stirred at room 
temperature for 1 hour and then slowly acidified with HCl (aq., 1 M) at 0 °C until pH 2‒3. 
Extraction by dichloromethane (15 mL × 3), drying over magnesium sulfate, followed by 
concentration under reduced pressure afforded product 6 (40.8 mg, 0.2 mmol, quantitative yield) 
without further purification. 
This compound is known in the literature46. 1H NMR (400 MHz, CDCl3) δ 3.63 
(p, J = 6.0 Hz, 1H), 3.39 (s, 3H), 2.55 (dd, J = 15.5, 6.9 Hz, 1H), 2.50 (dd, J = 
15.5, 5.3 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.55 – 1.42 (m, 1H), 1.38 – 1.20 (m, 10H), 
0.88 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.2, 77.7, 57.1, 39.1, 
33.6, 31.9, 29.7, 29.4, 25.1, 22.8, 14.2. [α]23D = +4.021 ± 1.649° (c 1.0, MeOH). The absolute 
configuration of (+)-6 was assigned to be (R) by comparing the measured optical rotation value 
with the literature reported value for (R)-(+)-6 (lit. [α]27D = +3.0°, c 0.67, MeOH)46. HRMS (EI) 
m/z: 202.1598 (M•+); calc. for C11H22O3: 202.1569. 
OMe
Me
CO2Et
OMe
CO2Et
Me
OMe
CO2H
Me
 
 
 
 
79 
 
Supplementary Fig. 15. Detailed scheme for the synthesis of (+)-cuspareine. 
 
(+)-Ethyl (S)-2-(1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)acetate ((+)-8f) 
Prepared following General Procedure D-I and Workup Procedure D-ii (see Section IX).  
E. coli suspension in M9-N  
(variant: P411-gen5, OD600 = 31) 
GOX 
solutiona 
D-glucose 
in M9-Nb 
Addition 1, 
volume/ mL 
Addition 2, 
volume/mL [PC]/µM n_pro/µmol volume/mL volume/mL 
275.0 140.0 4.67 1.938 25.0 50.0 
Alkane substrate (7f) stock in EtOH Ethyl diazoacetate stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL add. 1; add. 2 n_2/mmol 
0.60 5.0 3.0 1.20 2.5; 2.5 6.0 
Purification eluent Product 
1: Hex / (4 : 1 DCM : Et2O)  
2: water / MeOH 
(reverse phase) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
594.1c 2.546 85% 1310 
c Regiomeric ratio > 50 : 1 for 8f : 8f’ determined by 1H NMR.  
 
1H NMR (400 MHz, CDCl3) δ 7.14 – 7.04 (m, 1H), 6.99 (d, J = 7.3 Hz, 1H), 
6.63 (td, J = 7.3, 1.1 Hz, 1H), 6.55 (d, J = 8.2 Hz, 1H), 4.15 (q, J = 7.1 Hz, 
2H), 3.86 – 3.78 (m, 1H), 2.93 (s, 3H), 2.91 – 2.79 (m, 1H), 2.71 (ddd, J = 
16.6, 5.5, 2.8 Hz, 1H), 2.60 (ddd, J = 14.7, 5.4, 0.8 Hz, 1H), 2.39 (dd, J = 14.7, 
8.6 Hz, 1H), 2.07 – 1.95 (m, 1H), 1.89 (ddt, J = 13.4, 5.8, 2.9 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.3, 144.8, 129.0, 127.3, 121.6, 116.2, 111.0, 60.7, 56.1, 37.8, 
36.6, 25.5, 23.3, 14.4. HRMS (FAB) m/z: 233.1405 (M+˙); calc. for C14H19NO2: 233.1416. With 
variant P411-gen5: [α]23D = +9.440 ± 0.292° (c 0.5, CHCl3). With variant P411-gen5: SFC 
Chiralcel OB-H column (supercritical CO2/isopropanol = 97:3, 2.5 mL/min, 40 °C), tr = 6.44 min 
(minor), 7.25 min (major), 91.1 : 8.9 e.r. Absolute stereochemistry was assigned after elaboration 
(+)-8fb
CO2EtN2
E. coli harboring
P411-gen5
85% yield
594 mg at 
3.0 mmol scale
quantitative
(+)-8f: 
1310 TTN
> 50 : 1 r.r. (C2 : C1)
91.1 : 8.9 e.r.
LiBH4, MeOH
2
90% yield
MsCl, TEA
then LiBr
M9-N buffer
(—)-8fa
N
Me
7f
2
1
N
Me
CO2Et N
Me
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N
Me
(+)-cuspareine
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to (+)-cuspareine.  
 
(–)-2-(1-Methyl-1,2,3,4-tetrahydroquinolin-2-yl)ethan-1-ol ((–)-8fa) 
To a solution of (+)-ethyl 2-(1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)acetate ((+)-8f, 
233.3 mg, 1.0 mmol, 1.0 equiv.) and MeOH (60.8 µL, 1.5 mmol, 1.5 equiv.) in dry diethyl ether 
(20 mL) was added LiBH4 (2 M in THF, 1.0 mL, 2.0 mmol, 2.0 equiv.) dropwise. The reaction 
mixture was heated to reflux (~45 °C) for 4 hours (monitored by TLC). Upon completion, the 
reaction was quenched by ethyl acetate (2 mL) and stirred for 30 min at room temperature, 
quenched by MeOH (2 mL) and stirred for another 20 min at 0 °C, and finally quenched by NH4Cl 
(sat. aq., 5 mL) at 0 °C. The crude product was then extracted by diethyl ether (30 mL × 3). The 
combined organic layer was washed by brine (30 mL), dried over sodium sulfate and concentrated 
under reduced pressure. Purification by silica column chromatography with hexanes / ethyl acetate 
afforded 8fa (192.1 mg, 1.0 mmol, quantitative yield). 
This compound is known in the literature47. 1H NMR (400 MHz, CDCl3) δ 
7.12 – 7.06 (m, 1H), 7.01 – 6.96 (m, 1H), 6.62 (td, J = 7.3, 1.2 Hz, 1H), 6.59 
(dd, J = 8.2, 1.1 Hz, 1H), 3.82 – 3.71 (m, 2H), 3.51 – 3.44 (m, 1H), 2.97 (s, 
3H), 2.88 – 2.76 (m, 1H), 2.70 (ddd, J = 16.4, 5.3, 3.4 Hz, 1H), 2.00 – 1.81 
(m, 3H), 1.72 – 1.61 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 145.4, 129.0, 127.3, 122.2, 116.2, 
112.0, 60.6, 56.2, 39.1, 34.6, 24.8, 23.8. [α]23D = –28.096 ± 2.416° (c 0.5, CHCl3). Absolute 
stereochemistry was assigned after derivatization to (+)-cuspareine.  
 
(+)-2-(2-Bromoethyl)-1-methyl-1,2,3,4-tetrahydroquinoline ((+)-8fb) 
To a solution of (–)-2-(1-Methyl-1,2,3,4-tetrahydroquinolin-2-yl)ethan-1-ol ((–)-8fa, 
114.8 mg, 0.6 mmol, 1.0 equiv.) and triethylamine (133.8 µL, 0.96 mmol, 1.6 equiv.) in dry THF 
(12 mL) at 0 °C was added methanesulfonyl chloride (MsCl, 70 µL, 1.5 equiv.). The reaction 
mixture was warmed to room temperature over 30 min and stirred for additional 30 min. Upon 
completion, the reaction was quenched by NaHCO3 (sat. aq., 10 mL) and H2O (10 mL). The 
mesylated product was then extracted by diethyl ether (30 mL × 3). The combined organic layer 
was washed by brine (30 mL), dried over sodium sulfate and concentrated under reduced pressure. 
The mesylated product was then dissolved in DMF (6 mL) and LiBr (259.5 mg, 3.0 mmol, 5.0 
equiv.) was added. The reaction was heated to 70 °C and stirred for 2 hours. Upon completion, the 
reaction was quenched by H2O (30 mL). The crude product was then extracted by diethyl ether 
(30 mL × 3). The combined organic layer was washed by H2O (30 mL) and brine (30 mL), dried 
over sodium sulfate and concentrated under reduced pressure. Purification by silica column 
chromatography with hexanes / ethyl acetate afforded 8fb (136.8 mg, 0.54 mmol, 90% yield). 
1H NMR (400 MHz, CDCl3) δ 7.12 – 7.06 (m, 1H), 7.01 – 6.95 (m, 1H), 6.61 
(td, J = 7.3, 1.2 Hz, 1H), 6.56 (dd, J = 8.2, 1.1 Hz, 1H), 3.58 – 3.47 (m, 2H), 
3.43 (ddd, J = 10.1, 7.7, 6.3 Hz, 1H), 2.99 (s, 3H), 2.84 – 2.66 (m, 2H), 2.22 – 
2.11 (m, 1H), 2.01 – 1.90 (m, 2H), 1.90 – 1.81 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 145.1, 129.0, 127.4, 121.5, 116.0, 111.2, 57.0, 38.7, 34.9, 31.0, 24.3, 23.6. HRMS (FAB) 
m/z: 254.0548 (M + H+); calc. for C12H1779BrN: 254.0544. [α]23D = +33.638 ± 2.022° (c 0.5, 
CHCl3). Absolute stereochemistry was assigned after derivatization to (+)-cuspareine.  
 
N
Me
OH
N
Me
Br
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(+)-Cuspareine 
(+)-Cuspareine was synthesized through Suzuki-Miyaura cross-coupling between an alkyl 
bromide and an aryl boronic acid. The reaction conditions for this cross-coupling are derived from 
those described by Fu et al.48. 
To a 50-mL resealable Schlenk tube were added Pd(OAc)2 (4.04 mg, 0.018 mmol, 15 
mol%), di-tert-butyl(methyl)phosphonium tetrafluoroborate (tBu2PMe·HBF4, 8.93 mg, 0.036 
mmol, 30 mol%), KOtBu (40.4 mg, 0.36 mmol, 3.0 equiv.) and tAmyl-OH (0.6 mL). The tube was 
charged with Ar and sealed. The mixture was stirred at 60 °C for 20 min until the color of mixture 
turned pale yellow. After the mixture was cooled to room temperature, (3,4-
dimethoxyphenyl)boronic acid (54.6 mg, 0.30 mmol, 2.5 equiv.) and a solution of (+)-2-(2-
bromoethyl)-1-methyl-1,2,3,4-tetrahydroquinoline ((+)-8fb, 30.5 mg, 0.12 mmol, 1.0 equiv.) in 
tAmyl-OH (0.6 mL) were added to the tube. Another portion of tAmyl-OH (0.8 mL) was used to 
wash the solution residue of (+)-8fb and then transferred to the tube. The tube was charged with 
Ar and sealed again. After the reaction mixture was stirred at 60 °C for 15 hours, it was then cooled 
to room temperature, diluted with diethyl ether (6 mL), filtrated through a pad of Celite, washed 
by diethyl ether (30 mL) and concentrated under reduced pressure. Purification by silica column 
chromatography with hexanes / ethyl acetate afforded (+)-cuspareine (20.8 mg, 0.067 mmol, 56% 
yield). 
Spectral data is in agreement with literature report49. 1H NMR (400 
MHz, CDCl3) δ 7.09 (td, J = 7.6, 1.4 Hz, 1H), 6.99 (d, J = 7.0 Hz, 1H), 
6.80 (d, J = 8.0 Hz, 1H), 6.75 – 6.70 (m, 2H), 6.60 (td, J = 7.3, 1.1 Hz, 
1H), 6.54 (d, J = 8.2 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.33 – 3.26 (m, 
1H), 2.92 (s, 3H), 2.91 – 2.80 (m, 1H), 2.74 – 2.63 (m, 2H), 2.54 (ddd, J = 13.9, 10.1, 6.4 Hz, 1H), 
2.01 – 1.87 (m, 3H), 1.74 (dddd, J = 13.6, 10.1, 8.8, 5.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
149.0, 147.3, 145.4, 134.8, 128.8, 127.2, 121.8, 120.2, 115.5, 111.7, 111.4, 110.7, 58.5, 56.1, 56.0, 
38.2, 33.2, 32.1, 24.5, 23.7. [α]23D = +23.404 ± 0.723° (c 0.5, CHCl3). The absolute configuration 
of (+)-cuspareine was assigned to be (R) by comparing the measured optical rotation value with 
the literature reported value for (R)-(+)-cuspareine (lit. [α]27D = +23.516°, c 0.8, CHCl3)49.  
N
Me
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XI. Determination of enantioselectivity  
 Enantioselectivity of enzymatic C–H alkylation products were determined by chiral HPLC, 
chiral SFC, or chiral GC analysis. Representative traces, and their conditions, are shown below.  
The absolute configuration of P411-CHF synthesized 3i was assigned to be (S) by 
comparing the chiral HPLC separation of rac-3i and P411-CHF synthesized 3i with that reported 
in the literature50. The absolute configuration was further confirmed by comparing the optical 
rotation values for P411-CHF synthesized 3i and (S)-(+)-3i as reported in the literature50. The 
absolute configurations of 3a–3h and 3j–3m were inferred by analogy, assuming the selectivity 
with P411-CHF remains the same in the enzymatic syntheses of those compounds.  
 The absolute configuration of P411-CHF synthesized (+)-5a was determined to be (S) after 
elaboration to (+)-6 (see Section X for more details). The absolute configurations of 5b–5e were 
inferred by analogy, assuming the selectivity with P411-CHF remains the same in the enzymatic 
syntheses of those compounds. 
The absolute configuration of P411-gen5 synthesized (+)-8f was determined to be (S) after 
elaboration to (+)-cuspareine (see Section X for more details). As P411-CHF shows the opposite 
selectivity for the synthesis of (–)-8f, P411-CHF produces (R)-8f in excess.  
 
Ethyl 3-methoxy-3-(4-methoxyphenyl)propanoate (3a) 
SFC (Chiralpak AD-H column): 3% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 235 nm. 
 
 
 
rac-3a 
OMe
MeO
CO2Et
3a
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rac-3a with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
9.262 2752.2 49.91 9.119 4039.8 96.67 
10.404 2761.9 50.09 10.524 139.3 3.33 
Total 5514.1 100.00 Total 4179.1 100.00 
with P411-CHF, 1.0 mmol scale, 4 °C 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
9.016 5572.2 98.01 
10.501 112.9 1.99 
Total 5685.1 100.00 
 
  
with P411-CHF  
with P411-CHF 
1.0 mmol scale 
4 °C  
 
 
 
 
84 
Ethyl 3-methoxy-3-(p-tolyl)propanoate (3b) 
SFC (Chiralpak AD-H column): 2% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 210 nm.  
 
 
 
 
rac-3b with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
5.712 5526.8 49.93 5.705 868.8 7.14 
7.342 5543.1 50.07 7.205 11295.1 92.86 
Total 11069.9 100.00 Total 12163.9 100.00 
 
  
rac-3b 
with P411-CHF  
OMe
Me
CO2Et
3b
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Ethyl 3-(4-bromophenyl)-3-methoxypropanoate (3c) 
SFC (Chiralpak AD-H column): 3% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 210 nm. 
 
 
 
 
rac-3c with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
8.037 7344.4 50.12 8.181 328.3 3.55 
9.256 7310.0 49.88 9.306 8922.5 96.45 
Total 14654.4 100.00 Total 9250.8 100.00 
 
  
rac-3c 
with P411-CHF  
3c
OMe
Br
CO2Et
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Ethyl 3-methoxy-3-(4-(trifluoromethyl)phenyl)propanoate (3d) 
GC (Chiraldex G-TA column): 110 °C 
 
 
 
 
rac-3d with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
36.373 1713.4 50.01 36.449 2670.1 98.62 
37.640 1712.8 49.99 37.569 37.4 1.38 
Total 3426.2 100.00 Total 2707.5 100.00 
 
  
rac-3d 
with P411-CHF  
3d
OMe
F3C
CO2Et
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Ethyl 3-methoxy-3-(m-tolyl)propanoate (3e) 
HPLC (Chiralpak IC column): 4% i-PrOH in hexane, 1.5 mL/min, 23 °C,  
210 nm 
 
 
 
 
 
rac-3e with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
5.678 11965.5 49.39 5.692 2696.8 86.35 
6.792 12262.0 50.61 6.801 426.1 13.65 
Total 24227.5 100.00 Total 3122.9 100.00 
 
  
rac-3e 
with P411-CHF  
OMe
Me
CO2Et
3e
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Ethyl 2-(1,3-dihydroisobenzofuran-1-yl)acetate (3f) 
SFC (Chiralpak AD-H column): 3% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 210 nm 
 
 
 
 
 
 
rac-3f with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
8.511 7248.1 49.80 8.604 1486.5 11.05 
10.392 7305.1 50.20 10.294 11970.1 88.95 
Total 14553.2 100.00 Total 13456.6 100.00 
 
  
rac-3f 
with P411-CHF  
O
CO2Et
3f
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Ethyl 2-(isochroman-1-yl)acetate (3g) 
SFC (Chiralcel OJ-H column): 0.2% i-PrOH in supercritical CO2, 2.5 mL/min, 
40 °C, 210 nm 
 
 
 
rac-3g with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
5.301 5667.0 49.86 5.309 7040.0 31.01 
5.987 5698.9 50.14 5.951 15664.4 68.99 
Total 11365.9 100.00 Total 22704.4 100.00 
 
  
rac-3g 
with P411-CHF  
O
CO2Et
3g
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Ethyl 3-(4-(dimethylsilyl)phenyl)-3-methoxypropanoate (3h) 
SFC (Chiralcel OD-H column): 2% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 210 nm 
 
 
 
rac-3h with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
3.332 3189.7 49.96 3.309 4027.1 97.94 
3.998 3195.4 50.04 3.997 84.6 2.06 
Total 6385.1 100.00 Total 4111.7 100.00 
 
  
rac-3h 
with P411-CHF  
OMe
Si
H
Me Me
CO2Et
3h
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Ethyl 3-(4-methoxyphenyl)butanoate (3i) 
SFC (Chiralcel OB-H column): supercritical CO2, 2.5 mL/min, 40 °C, 
210 nm.  
 
 
 
 
rac-3i with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
5.478 4668.2 49.73 5.496 69.8 2.09 
6.417 4719.7 50.27 6.240 3264.5 97.91 
Total 9387.9 100.00 Total 3334.3 100.00 
 
The absolute configuration of P411-CHF synthesized 3i was determined to be (S) by 
comparing the chiral HPLC separation (Chiralcel OJ-H column, 1% i-PrOH in hexanes, traces not 
shown) of rac-3i and P411-CHF synthesized 3i with that reported in the literature50. The absolute 
configuration was further confirmed by comparing the optical rotation value for P411-CHF 
synthesized 3i, [α]23D = +26.3° (c 0.5, CHCl3, see Section XI), and (S)-(+)-3i as reported in the 
literature ([α]23D = +26.2°, c 0.59, CHCl3)50. 
  
rac-3i 
with P411-CHF  
Me
MeO
CO2Et
3i
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Ethyl 3-(4-methoxyphenyl)pentanoate (3j) 
SFC (Chiralcel OB-H column): 1% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 210 nm.  
 
 
 
 
 
rac-3j with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
3.778 4842.1 49.90 3.788 n. d.   -  
4.609 4860.8 50.10 4.595 1777.2 100.00 
Total 9702.9 100.00 Total 1777.2 100.00 
 
  
with P411-CHF  
MeO
CO2Et
3j
Me
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Ethyl 3-(4-ethylphenyl)butanoate (3k) 
HPLC (Chiralcel OD-H column): 3% i-PrOH in hexane, 1.0 mL/min, 32 
°C, 210 nm. 
 
 
 
 
 
rac-3k with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
6.150 5082.3 49.78 6.220 771.4  3.88 
6.603 5126.4 50.22 6.635 19124.9 96.12 
Total 10208.7 100.00 Total 19896.3 100.00 
 
  
with P411-CHF  
Me
CO2Et
3k
Me
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Ethyl 3-(4-isopropylphenyl)butanoate (3l) 
SFC (Chiralpak IC column): 0.5% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 210 nm. 
 
 
 
rac-3l with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
7.850 3335.0 50.09 7.970 49.8  2.64 
8.707 3323.1 49.91 8.836 1839.3 97.36 
Total 6658.1 100.00 Total 1889.1 100.00 
 
  
with P411-CHF  
Me
CO2Et
3l
Me
Me
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Ethyl 3-(4-methoxyphenyl)pent-4-enoate (3m) 
SFC (Chiralpak AD-H column): 1% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 210 nm. 
 
 
 
 
 
rac-3m with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
6.694 1126.7 49.97 6.591 2658.4 100.00 
7.472 1128.2 50.03 7.472 n. d. -  
Total 2254.9 100.00 Total 2658.4 100.00 
 
  
with P411-CHF  
MeO
CO2Et
3m
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Ethyl (E)-3-methoxydec-4-enoate (5a) 
 GC (CycloSil–B column): 110 °C  
 
 
 
 
 
 
 
rac-5a with P411-CHF  
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
53.578 550.4 49.42 54.236 40.6 6.45 
55.382 563.3 50.58 55.912 588.9 93.55 
Total 1113.7 100.00 Total 629.5 100.00 
with P411-CHF, 2.4 mmol scale 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
53.722 39.4 5.31 
55.353 702.4 94.69 
Total 741.8 100.00 
The absolute configuration of P411-CHF synthesized 5a was determined to be (S) after 
derivatization to (+)-6 (see Section X for more details). 
rac-5a 
with P411-CHF  
with P411-CHF 
 2.4 mmol scale 
OMe
5a
Me
CO2Et
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Ethyl (E)-3-methoxyoct-4-enoate (5b) 
GC (CycloSil–B column): 90 °C 
 
 
rac-5b with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
45.564 415.3 50.72 45.740 62.0 5.31 
48.340 403.5 49.28 48.184 1105.8 94.69 
Total 818.8 100.00 Total 1167.8 100.00 
 
  
rac-5b 
with P411-CHF  
OMe
5b
Me
CO2Et
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Ethyl (E)-9-bromo-3-methoxynon-4-enoate (5c) 
GC (CycloSil–B column): 130 °C 
 
 
 
rac-5c with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
108.58 293.1 48.24 108.81 19.90 3.70 
110.65 314.5 51.76 110.54 518.30 96.30 
Total 607.6 100.00 Total 538.2 100.00 
 
  
rac-5c 
with P411-CHF  
OMe
5c
Br
CO2Et
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Ethyl (E)-5-(4-methoxyphenyl)-3-methylpent-4-enoate (5d) 
SFC (Chiralcel OB-H column): 3% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 254 nm. 
 
 
 
 
 
rac-5d with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
6.571 2158.1 49.86 6.624 99.0 3.00 
7.605 2170.0 50.14 7.655 3202.5 97.00 
Total 4328.1 100.00 Total 3301.5 100.00 
 
  
Me
MeO
CO2Et
5d
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Ethyl 3-methoxydec-4-ynoate (5e) 
GC (CycloSil–B column): 110 °C for 50 min., ramp 1 °C per minute 
for 10 min. (to 120 °C), 120 °C for 10 min. 
 
 
 
 
 
rac-5e with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
64.08 262.0 50.61 64.19 13.5 1.04 
65.26 255.7 49.39 65.08 1289.9 98.96 
Total 517.7 100.00 Total 1303.4 100.00 
 
 
  
rac-5e 
with P411-CHF  
OMe
5e
Me
CO2Et
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Ethyl 2-(1-phenylpyrrolidin-2-yl)acetate (8c) 
HPLC (Chiralcel OD-H column): 6% i-PrOH in hexane, 1.0 mL/min, room 
temperature, 235 nm. 
 
 
 
8c with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
6.201 1130.5 17.20 
8.578 5443.7 82.80 
Total 6574.2 100.00 
 
GC-MS traces for separated enantiomers (tr = 6.2 min, tr = 8.6 min) individually analyzed 
and the original sample (combined): 
 
GC-MS conditions (HP-5ms column): 90 °C, isothermal for 2.0 min; 90 °C to 250 °C, 12 °C/min 
gradient; 250 °C, isothermal for 2.0 min; 250 °C to 300 °C, 30 °C/min gradient; 300 °C, isothermal 
for 1.0 min. 
  
with P411-CHF  
Black trace: tr=6.2 min 
Red trace: tr=8.6 min 
Blue trace: combined 
N
CO2Et
8c
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Ethyl 2-(1-(4-methoxyphenyl)pyrrolidin-2-yl)acetate (8d) 
HPLC (Chiralcel OD-H column): 6% i-PrOH in hexane, 1.0 mL/min, room 
temperature, 235 nm. 
 
 
 
8d with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
7.249 305.6 16.30 
8.119 1568.8 83.70 
Total 1874.4 100.00 
 
GC-MS traces for separated enantiomers (tr = 7.2 min, tr = 8.1 min) individually analyzed 
and the original sample (combined): 
 
GC-MS conditions (HP-5ms column): 90 °C, isothermal for 2.0 min; 90 °C to 250 °C, 12 °C/min 
gradient; 250 °C, isothermal for 2.0 min; 250 °C to 300 °C, 30 °C/min gradient; 300 °C, isothermal 
for 1.0 min. 
  
with P411-CHF  
Black trace: tr=7.2 min 
Red trace: tr=8.1 min 
Blue trace: combined 
N
CO2Et
8d
OMe
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Ethyl 2-(1-(3-chlorophenyl)pyrrolidin-2-yl)acetate (8e) 
HPLC (Chiralcel OD-H column): 6% i-PrOH in hexane, 1.0 mL/min, room 
temperature, 235 nm. 
 
 
 
8e with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
6.285 454.4 9.69 
6.865 4233.3 90.31 
Total 4687.7 100.00 
 
GC-MS traces for separated enantiomers (tr = 6.3 min, tr = 6.9 min) individually analyzed 
and the original sample (combined): 
 
GC-MS conditions (HP-5ms column): 90 °C, isothermal for 2.0 min; 90 °C to 250 °C, 12 °C/min 
gradient; 250 °C, isothermal for 2.0 min; 250 °C to 300 °C, 30 °C/min gradient; 300 °C, isothermal 
for 1.0 min. 
  
with P411-CHF  
Black trace: tr=6.3 min 
Red trace: tr=6.9 min 
Blue trace: combined 
N
CO2Et
8e
Cl
 
 
 
 
104 
Ethyl 2-(1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)acetate (8f) 
SFC (Chiralcel OB-H column): 3% i-PrOH in supercritical CO2, 2.5 
mL/min, 40 °C, 235 nm. 
 
   
 
 
 
8f with P411-CHF 8f with P411-gen5 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
6.473 1317.7 72.95 6.437 330.7 8.86 
7.384 488.7 27.05 7.246 3399.2 91.14 
Total 1806.4 100.00 Total 3729.9 100.00 
 
The absolute configuration of P411-gen5 synthesized (+)-8f was determined to be (S) after 
derivatization to (+)-cuspareine (see Section X for more details). As P411-CHF shows the opposite 
selectivity for the synthesis of (–)-8f, P411-CHF produces (R)-8f in excess. 
  
8f’ 
with P411-CHF  
with P411-gen5  
N
Me
CO2Et
8f
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 3-((Methyl(p-tolyl)amino)methyl)dihydrofuran-2(3H)-one (10b) 
HPLC (Chiralcel OD-H column): 6% i-PrOH in hexane, 1.0 mL/min, 32 °C, 
254 nm. 
 
 
 
10b with P411-IY (T327I) 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
22.826 10966.9 78.05 
24.286 3084.7 21.95 
Total 14051.6 100.00 
 
GC-MS traces for separated enantiomers (tr = 22.8 min, tr = 24.3 min) individually analyzed 
and the original sample (combined): 
 
GC-MS conditions (HP-5ms column): 90 °C, isothermal for 2.0 min; 90 °C to 250 °C, 12 °C/min gradient; 
250 °C, isothermal for 2.0 min; 250 °C to 300 °C, 30 °C/min gradient; 300 °C, isothermal for 1.0 min. 
with P411-IY (T327I)  
Black trace: tr=22.8 min 
Red trace: tr=24.3 min 
Blue trace: combined 
10b
N
Me
Me
O
O
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4-Methoxy-4-(4-methoxyphenyl)butan-2-one (10d) 
 
HPLC (Chiralcel OJ-H column): 6% i-PrOH in hexane, 1.0 mL/min, 28 
°C, 220 nm. 
 
 
 
rac-10d with P411-CHF 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
Retention 
Time (min) 
Area 
(mAU*s) Area % 
20.217 8495.99 49.99 20.152 12329.7 70.98 
21.713 8499.17 50.01 21.760 5040.6 29.02 
Total 16995.16 100.00 Total 17370.3 100.00 
 
  
rac-10d 
with P411-CHF  
MeO
OMe
Me
O
10d
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XII. 1H and 13C NMR Spectra 
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